<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Eliciting adverse effects data from participants in clinical trials - Allen, EN - 2018 | Cochrane Library</title> <meta content="Eliciting adverse effects data from participants in clinical trials - Allen, EN - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.MR000039.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Eliciting adverse effects data from participants in clinical trials - Allen, EN - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.MR000039.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.MR000039.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Eliciting adverse effects data from participants in clinical trials" name="citation_title"/> <meta content="Elizabeth N Allen" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="elizabeth.allen@uct.ac.za" name="citation_author_email"/> <meta content="Clare IR Chandler" name="citation_author"/> <meta content="London School of Hygiene and Tropical Medicine" name="citation_author_institution"/> <meta content="Nyaradzo Mandimika" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="Cordelia Leisegang" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="Karen Barnes" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.MR000039.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/01/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.MR000039.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.MR000039.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.MR000039.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Checklist; *Clinical Trials as Topic; *Drug‐Related Side Effects and Adverse Reactions; *Research Subjects" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.MR000039.pub2&amp;doi=10.1002/14651858.MR000039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="JmNqPX1V";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eMR000039\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eMR000039\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eMR000039\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eMR000039\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ja","pt","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.MR000039.pub2",title:"Eliciting adverse effects data from participants in clinical trials",firstPublishedDate:"Jan 16, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Methodology Review Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=JmNqPX1V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.MR000039.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.MR000039.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.MR000039.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.MR000039.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.MR000039.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="MR000039.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.MR000039.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="MR000039.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.MR000039.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.MR000039.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5468 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.MR000039.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-sec-0100"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-sec-0029"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-sec-0034"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-sec-0035"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-sec-0058"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-sec-0094"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/appendices#MR000039-sec-0103"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Methodology</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Eliciting adverse effects data from participants in clinical trials</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/information#MR000039-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Elizabeth N Allen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/information#MR000039-cr-0003">Clare IR Chandler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/information#MR000039-cr-0004">Nyaradzo Mandimika</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/information#MR000039-cr-0005">Cordelia Leisegang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.MR000039.pub2/information#MR000039-cr-0006">Karen Barnes</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/information/en#MR000039-sec-0106">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 January 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.MR000039.pub2">https://doi.org/10.1002/14651858.MR000039.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="MR000039-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#MR000039-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#MR000039-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#MR000039-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pt#MR000039-abs-0004">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#MR000039-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="MR000039-abs-0001" lang="en"> <section id="MR000039-sec-0001"> <h3 class="title" id="MR000039-sec-0001">Background</h3> <p>Analysis of drug safety in clinical trials involves assessing adverse events (AEs) individually or by aggregate statistical synthesis to provide evidence of likely adverse drug reactions (ADR). While some AEs may be ascertained from physical examinations or tests, there is great reliance on reports from participants to detect subjective symptoms, where he/she is often the only source of information. There is no consensus on how these reports should be elicited, although it is known that questioning methods influence the extent and nature of data detected. This leaves room for measurement error and undermines comparisons between studies and pooled analyses. This review investigated comparisons of methods used in trials to elicit participant‐reported AEs. This should contribute to knowledge about the methodological challenges and possible solutions for achieving better, or more consistent, AE ascertainment in trials. </p> </section> <section id="MR000039-sec-0002"> <h3 class="title" id="MR000039-sec-0002">Objectives</h3> <p>To systematically review the research that has compared methods used within clinical drug trials (or methods that would be specific for such trials) to elicit information about AEs defined in the protocol or in the planning for the trial. </p> </section> <section id="MR000039-sec-0003"> <h3 class="title" id="MR000039-sec-0003">Search methods</h3> <p>Databases (searched to March 2015 unless indicated otherwise) included: Embase; MEDLINE; MEDLINE in Process and Other Non‐Indexed Citations; Cochrane Methodology Register (July 2012); Cochrane Central Register of Controlled Trials (February 2015); Cochrane Database of Systematic Reviews; Database of Abstracts of Reviews of Effects (January 2015); Health Technology Assessment database (January 2015); CINAHL; CAB Abstracts; BIOSIS (July 2013); Science Citation Index; Social Science Citation Index; Conference Proceedings Citation Index – Science. The search used thesaurus headings and synonyms for the following concepts: (A): Adverse events AND measurement; (B): Participants AND elicitation (also other synonyms for extraction of information about adverse effects from people); (C): Participants AND checklists (also other synonyms as for B). Pragmatic ways were used to limit the results whilst trying to maintain sensitivity. There were no date or sample size restrictions but only reports published in English were included fully, because of resource constraints as regards translation. </p> </section> <section id="MR000039-sec-0004"> <h3 class="title" id="MR000039-sec-0004">Selection criteria</h3> <p>Two types of studies were included: drug trials comparing two or more methods within‐ or between‐participants to elicit participant‐reported AEs, and research studies performed outside the context of a trial to compare methods which could be used in trials (evidenced by reference to such applicability). Primary outcome data included AEs elicited from participants taking part in any such clinical trial. We included any participant‐reported data relevant for an assessment of drug‐related harm, using the original authors' terminology (and definition, where available), with comment on whether the data were likely to be treatment‐emergent AEs or not. </p> </section> <section id="MR000039-sec-0005"> <h3 class="title" id="MR000039-sec-0005">Data collection and analysis</h3> <p>Titles and abstracts were independently reviewed for eligibility. Full texts of potentially eligible citations were independently reviewed for final eligibility. Relevant data were extracted and subjected to a 100% check. Disagreements were resolved by discussion, involving a third author. The risk of bias was independently assessed by two authors. The Cochrane 'Risk of bias' tool was used for reports comparing outcomes between participants, while for within‐participant comparisons, each study was critically evaluated in terms of potential impact of the design and conduct on findings using the framework of selection, performance, detection, attrition, reporting, and other biases. An attempt was made to contact authors to retrieve protocols or specific relevant missing information. Reports were not excluded on the basis of quality unless data for outcomes were impossible to compare (e.g. where denominators differed). A narrative synthesis was conducted because differences in study design and presentation meant that a quantitative meta‐analysis was not possible. </p> </section> <section id="MR000039-sec-0006"> <h3 class="title" id="MR000039-sec-0006">Main results</h3> <p>The 33 eligible studies largely compared open questions with checklist‐type questions or rating scales. Two included participant interviews. Despite different designs, populations and details of questioning methods, the narrative review showed that more specific questioning of participants led to more AEs detected compared to a more general enquiry. A subset of six studies suggested that more severe, bothersome, or otherwise clinically relevant AEs were reported when an initial open enquiry was used, while some less severe, bothersome, or clinically relevant AEs were only reported with a subsequent specific enquiry. However, two studies showed that quite severe or debilitating AEs were only detected by an interview, while other studies did not find a difference in the nature of AEs between elicitation methods. No conclusions could be made regarding the impact of question method on the ability to detect a statistically significant difference between study groups. There was no common statistical rubric, but we were able to represent some effect measures as a risk ratio of the proportion of participants with at least one AE. This showed a lower level of reporting for open questions (O) compared to checklists (CL), with a range for the risk ratios of 0.12 to 0.64. </p> </section> <section id="MR000039-sec-0007"> <h3 class="title" id="MR000039-sec-0007">Authors' conclusions</h3> <p>This review supports concerns that methods to elicit participant‐reported AEs influence the detection of these data. There was a risk for under‐detection of AEs in studies using a more general elicitation method compared to those using a comprehensive method. These AEs may be important from a clinical perspective or for patients. This under‐detection could compromise ability to pool AE data. However, the impact on the nature of the AE detected by different methods is unclear. The wide variety and low quality of methods to compare elicitation strategies limited this review. Future studies would be improved by using and reporting clear definitions and terminology for AEs (and other important variables), frequency and time period over which they were ascertained, how they were graded, assessed for a relationship to the study drug, coded, and tabulated/reported. While the many potential AE endpoints in a trial may preclude the development of general AE patient‐reported outcome measurement instruments, much could also be learnt from how these employ both quantitative and qualitative methods to better understand data elicited. Any chosen questioning method needs to be feasible for use by both staff and participants. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="MR000039-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#MR000039-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#MR000039-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#MR000039-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#MR000039-abs-0003">日本語</a> </li> <li class="section-language"> <a class="" href="full/pt#MR000039-abs-0005">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#MR000039-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="MR000039-abs-0002" lang="en"> <h3>Questioning clinical trial participants about their health in order to collect information on adverse effects of drugs </h3> <p>Clinical drug trials or studies are usually conducted to assess how well the drug works but also whether it causes any harm (side effects or adverse effects). Adverse effects can be detected by the trial doctor examining participants or taking some blood samples or doing other kinds of tests. The trial staff can also ask participants about how they are feeling after taking the trial drug. However, the way participants are asked about their health can vary from trial to trial, or even within a trial. In some trials, participants may be asked a simple open question such as 'how have you been feeling?', while in other trials, participants may be asked about whether they have had any of a long list of possible symptoms (such as 'have you had a headache, stomach ache, or sore muscles?'). There has been concern that these different kinds of questions and how they are phrased will impact on what participants report about their health during a trial. This might then affect the trial's results and what we know about the side effects of drugs. </p> <p>We did this review to look at studies that compared different types of participant questioning methods in order to investigate these issues. We found 33 studies comparing mainly open questions with checklist‐type questions, but also some ratings scales and participant interviews. While the studies were all very different in terms of the types of disease, drugs, and patients studied, we found in general that, as would be expected, when a more specific type of question was asked (like a checklist), participants reported more symptoms. What is interesting is that, in those studies that looked more closely at the types of symptoms reported, it seems that an open question picks up the more severe or bothersome symptoms compared to a checklist‐type question. However, some studies found that even quite severe or bothersome symptoms were not reported when a participant is asked an open question and these severe symptoms will only be reported with the more specific question. This makes it difficult to say whether one method is better than any other and the different questioning methods may, in fact, be complementary and therefore should be used together. It is also difficult to say what a specific question should include, as it might take too long for a participant to have to answer a very long list. While more research is needed to resolve the remaining uncertainties, it is very important for trials to be clear about which kind of questioning was used when they publish their results. This will help readers understand the trial's findings about the side effects and make it easier to make accurate comparisons between trials. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="MR000039-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="MR000039-sec-0100"></div> <h3 class="title" id="MR000039-sec-0101">Implication for methodological research</h3> <section id="MR000039-sec-0101"> <p>The wide variety and inherent low quality of methods used to compare elicitation strategies in clinical drug trials limited this review. Although we recognise that this is a complicated area, future studies would be improved by using and reporting clear definitions and terminology for AEs (and other important variables), the frequency and time period over which they were ascertained, and how they were graded, assessed for a relationship to the study drug, coded, and tabulated/reported. As is the case with similar work conducted in other areas of pharmacoepidemiology, this research is hampered by the lack of a true gold standard against which to assess the data reported by participants. This means that measures are likely to be concordant rather than valid (<a href="./references#MR000039-bbs2-0101" title="WestSL , StromBL , PollC . Validity of pharmacoepidemiologic drug and diagnosis data. In: StromBL editor(s). Pharmacoepidemiology. 4. Chichester (UK): John Wiley &amp; Sons, 2005:709‐65. ">West 2005</a>). However, improving record linkages, using blood samples for pharmacokinetic analysis of commonly used medications to detect non‐study medicines, and comparing new strategies against existing ones are options to explore. While the many potential AE endpoints in any given trial may preclude the development of general AE PRO measurement instruments, much could also be learnt from how these employ both quantitative and qualitative methods to understand data elicited (<a href="./references#MR000039-bbs2-0085" title="USFood , DrugAdministration . Guidance for Industry: patient‐reported outcome measures: use in medical product development to support labeling claims.. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf (accessed prior to 14 September 2017). ">FDA 2009</a>). </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="MR000039-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="MR000039-sec-0029"></div> <section id="MR000039-sec-0030"> <h3 class="title" id="MR000039-sec-0030">Description of the problem or issue</h3> <p>Manufacturers must demonstrate safety, efficacy, and quality of their investigational drug by way of clinical trials in order to achieve registration with regulatory authorities. Thereafter, they, and other stakeholders, continue to evaluate the product’s risk profile in subsequent trials, particularly in under‐studied population groups (<a href="./references#MR000039-bbs2-0093" title="International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Pharmacovigilance planning: notice for guidance on planning pharmacovigilance activities (Topic E2E). www.ich.org/products/guidelines/efficacy/article/efficacy‐guidelines.html. (accessed prior to 14 September 2017). ">ICH 2004</a>). Safety analyses in clinical trials largely involve identifying untoward medical occurrences after exposure. These endpoints, which are not necessarily causally related, are called adverse events (or sometimes adverse effects) (AEs) (<a href="./references#MR000039-bbs2-0092" title="International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guideline for Good Clinical Practice (Topic E6/R1). www.ich.org/products/guidelines/efficacy/article/efficacy‐guidelines.html. (accessed prior to 14 September 2017). ">ICH 1996</a>). AEs are assessed either on an individual case basis or by aggregate statistical synthesis to provide evidence of likely adverse drug reactions (ADRs), which are those AEs that have a reasonable possibility of being caused by the trial drug (<a href="./references#MR000039-bbs2-0081" title="Council for International Organizations of Medical Sciences. Management of Safety Information from Clinical Trials. Report of CIOMS Working Group VI. Geneva: CIOMS, 2005. ">CIOMS 2005</a>). </p> <p>The processes involved in collecting, recording, analysing, and reporting AEs are generally considered more complex than those involved in evaluating the potential benefits of a drug, and methods are relatively less developed (<a href="./references#MR000039-bbs2-0091" title="HuangHY , AndrewsE , JonesJ , SkovenML , TilsonH . Pitfalls in meta‐analyses on adverse events reported form clinical trials. Pharmacoepidemiology and Drug Safety2011;20(10):1014‐20. ">Huang 2011</a>). While some AEs may be ascertained from physical examinations or tests, there is a great reliance on reports from the participants to detect subjective symptoms, where the participant is the only source of information. There is no consensus on how these reports should be elicited from participants, although it is well known that methods involving direct questioning influence the extent and nature of the data detected (<a href="./references#MR000039-bbs2-0084" title="USFood , DrugAdministration . Reviewer guidance: Conducting a clinical safety review of a new product application and preparing a report on the review. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation /Guidances/ucm072974.pdf (accessed prior to 14 September 2017). ">FDA 2005</a>). For instance, studies have found that giving participants a checklist of potential AEs yields more reports than posing a general enquiry about change in health (<a href="./references#MR000039-bbs2-0005" title="BentS , PadulaA , AvinsAL . Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Annals of Internal Medicine2006;144(4):257‐61. ">Bent 2006</a>). However, it is uncertain whether one way of questioning over another is better for detecting ADRs (<a href="./references#MR000039-bbs2-0032" title="WernickeJF , FariesD , MiltonD , WeyrauchK . Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Safety2005;28(11):1057‐63. ">Wernicke 2005</a>). Should methods to elicit AEs be less than optimal, there is a margin for measurement error which will undermine individual trial results and meta‐analyses of multiple trials. This problem will also occur if trials use disparate methods. This restricts the ability to detect rare ADRs and to explore factors influencing the assessment of risk (<a href="./references#MR000039-bbs2-0084" title="USFood , DrugAdministration . Reviewer guidance: Conducting a clinical safety review of a new product application and preparing a report on the review. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation /Guidances/ucm072974.pdf (accessed prior to 14 September 2017). ">FDA 2005</a>; <a href="./references#MR000039-bbs2-0091" title="HuangHY , AndrewsE , JonesJ , SkovenML , TilsonH . Pitfalls in meta‐analyses on adverse events reported form clinical trials. Pharmacoepidemiology and Drug Safety2011;20(10):1014‐20. ">Huang 2011</a>). This situation is compounded by generally poor reporting in subsequent publications about which methods were used to determine participant‐reported AEs (<a href="./references#MR000039-bbs2-0094" title="IoannidisJP , EvansSJ , GøtzschePC , O'NeillRT , AltmanDG , SchulzK , et al. CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine2004;141(10):781‐8. ">Ioannidis 2004</a>). </p> </section> <section id="MR000039-sec-0031"> <h3 class="title" id="MR000039-sec-0031">Description of the methods being investigated</h3> <p>This review investigated any method used in a clinical trial to elicit participant‐reported AEs, such as a general enquiry, checklist, diary, memory aid etc, whether applied face‐to‐face or otherwise. Due to the lack of consensus, as described above, the details of all methods studied were only known once the review was ongoing. Studies that included a comparison of methods used to elicit information on other participant‐reported variables (e.g. concomitant medications or medical histories) were also included in the review. </p> </section> <section id="MR000039-sec-0032"> <h3 class="title" id="MR000039-sec-0032">How these methods might work</h3> <p>Little is known specifically about how different methods of AE elicitation work, although this is likely to be similar to questions about other topics, in that response to questioning involves comprehension, judgement, recall from memory, and communication of the response (<a href="./references#MR000039-bbs2-0100" title="TourangeauR . Cognitive sciences and survey methods. In: JabineT , StrafM , TanurJ , TourangeauR editor(s). Cognitive aspects of survey methodology: building a bridge between disciplines. Washington D.C.: National Academy Press, 1984. ">Tourangeau 1984</a>). Our earlier qualitative study of barriers to accurate and complete reporting of harms data suggests that questioning detail and terminology influences participants’ recognition of health issues and treatments. Moreover, we suggested that the perceived relative importance of health issues and treatments to the participant may be a factor (<a href="./references#MR000039-bbs2-0078" title="AllenEN , BarnesKI , MushiAM , MassaweI , StaedkeSG , MehtaU , et al. Eliciting harms data from trial participants: how perceptions of illness and treatment mediate recognition of relevant information to report. Trials2011;12(Suppl 1):A10. ">Allen 2011</a>). </p> </section> <section id="MR000039-sec-0033"> <h3 class="title" id="MR000039-sec-0033">Why it is important to do this review</h3> <p>Current heterogeneity in, and uncertainty about, the best practices for participant‐reported AE elicitation in clinical trials leaves regulatory authorities, policy makers, healthcare professionals, patients, and the public unsure about how far results are accurate and comparable. It would therefore be useful to synthesise research that compares elicitation methods. This should contribute to knowledge about the methodological challenges, and possible solutions, for achieving better, or harmonised, AE ascertainment in clinical trials. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="MR000039-sec-0034" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="MR000039-sec-0034"></div> <p>To systematically review the research that has compared the methods used within clinical drug trials (or that would be specific for such trials) to elicit information about the AEs that were defined in the protocol or in the planning for the trial. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="MR000039-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="MR000039-sec-0035"></div> <section id="MR000039-sec-0036"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="MR000039-sec-0037"> <h4 class="title">Types of studies</h4> <p> <ul id="MR000039-list-0001"> <li> <p>Clinical drug trials that include a comparison of two or more methods to elicit participant‐reported AEs; </p> </li> <li> <p>Research studies that have been performed outside the context of a clinical drug trial to compare two or more methods to elicit participant‐reported AEs but which could be used in clinical trials (evidenced by reference to such applicability). </p> </li> </ul> </p> </section> <section id="MR000039-sec-0038"> <h4 class="title">Types of data</h4> <p>AEs elicited from participants taking part in a clinical trial. For the purposes of this review, AEs are defined as those outcomes that were prespecified as potential AEs to be investigated in the trial (including expected or unexpected AEs, the latter which will not be known, but are intended to be detected during the trial), recognizing that the trial itself might reveal that these are not actually increased in an intervention group compared with a control group. Concomitant medication and medical history data were also included in this review if the eligible study also included a comparison of methods used to elicit those. This is because these variables also impact on the assessment of whether an AE is likely to be an ADR. It became apparent during the review that terminology and definitions used for AEs were unclear or inconsistent. This is partly due to changing perspectives on this topic over time and partly because we included research studies outside the context of a clinical drug trial. Thus, we included studies that reported participant‐reported data relevant for an assessment of drug‐related tolerability or harm, using the original authors' terminology (and definition, where available) with comment on whether the AEs were likely to be treatment‐emergent or not. </p> </section> <section id="MR000039-sec-0039"> <h4 class="title">Types of methods</h4> <p>Any combination of elicitation methods compared within or between participants. This included, but was not limited to, unstructured or structured enquiries, checklists, or questionnaires (e.g. by body system, symptom etc.), diaries, and memory aids. </p> </section> <section id="MR000039-sec-0040"> <h4 class="title">Types of outcome measures</h4> <section id="MR000039-sec-0041"> <h5 class="title">Primary outcomes</h5> <p> <ul id="MR000039-list-0002"> <li> <p>The effect measure (or number, proportion) and/or nature (e.g. characteristics, severity, causality assessment) of AEs identified by the method of elicitation, as defined by the original authors. </p> </li> </ul> </p> </section> <section id="MR000039-sec-0042"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="MR000039-list-0003"> <li> <p>If relevant, the effect measure (or number, proportion) and/or nature (e.g. characteristics, severity, causality assessment) of AEs identified by the method of elicitation by the relevant trial interventions; </p> </li> <li> <p>If relevant, the effect measure (or number, proportion) and/or nature (e.g. medication class) of concomitant medications and/or medical histories identified by the method of elicitation, as defined by the original authors; </p> </li> <li> <p>If relevant, summary results of qualitative methods used;</p> </li> <li> <p>If relevant, results of inherent elicitation method validation studies.</p> </li> </ul> </p> </section> </section> </section> <section id="MR000039-sec-0043"> <h3 class="title">Search methods for identification of studies</h3> <p>There was no date or sample size restrictions in the searches, but only reports published in English were searched for and included in the review, because of resource constraints as regards translation. </p> <section id="MR000039-sec-0044"> <h4 class="title">Electronic searches</h4> <p>The searches were designed and conducted with the assistance of an experienced information professional. A list of databases and search strategies was finalised prior to starting the search, with subsequent iterations fully documented. The following databases were searched: Embase (OVID) 1980 to 2015 week 11; MEDLINE (OVID) 1946 to March week 2 2015; MEDLINE in Process and Other Non‐Indexed Citations, March 16<sup>th</sup> 2015; Cochrane Methodology Register (Wiley Online) Issue 3 of 4, July 2012 (no longer updated); Cochrane Central Register of Controlled Trials (Wiley Online) Issue 2 of 12, February 2015; Cochrane Database of Systematic Reviews (Wiley Online) Issue 3 of 12, March 2015; Database of Abstracts of Reviews of Effects (Wiley Online) Issue 1 of 4, January 2015; Health Technology Assessment database (Wiley Online) Issue 1 of 4, January 2015; CINAHL (EBSCO) 1981 to March 2015; CAB Abstracts (OVID) 1973 to 2015 Week 10; BIOSIS (Web of Knowledge) 1969 to July 2013 (can no longer access); Science Citation Index (Web of Knowledge) 1970 to March 2015; Social Science Citation Index (Web of Knowledge) 1970 to March 2015; Conference Proceedings Citation Index – Science (Web of Knowledge) 1990 to March 2015. </p> <p>The search was designed using thesaurus headings and synonyms for each of the following concepts: (A): Adverse events AND measurement; (B): Participants AND elicitation (also other synonyms for the extraction of information about adverse effects from people); (C): Participants AND checklists (also other synonyms for the methods used to extract information about adverse effects from people). </p> <p>Ideally, the search would have been run using the following search string: A AND (B OR C). Unfortunately, this produced an unmanageablely large number of results, mainly because it was impossible for the search to differentiate between (i) studies aiming to compare two different methods for eliciting adverse effects data (i.e. the eligible studies for this review); and (ii) studies which mentioned in their abstract that they collected data from participants about adverse effects (i.e. thousands of studies that would not be eligible for this review). </p> <p>The information specialist, with help from information colleagues, used pragmatic methods to limit the search results whilst trying to maintain sensitivity in the search. Each of these were used separately and then combined with OR: </p> <p> <ul id="MR000039-list-0004"> <li> <p>Frequency searching: retrieving only those records which contained certain adverse effect‐related terms at least three times in the abstract, the rationale being that if the study is based on the collection of adverse effects data, then associated terms would be used at least three times in the abstract. This part of the strategy was tested with different proximities (i.e. two times or four times) by comparing a sample of results from each to see what was being lost as the number increased; </p> </li> </ul> <ul id="MR000039-list-0005"> <li> <p>Title field: one part of the search retrieved only those records with adverse effects terms in the title, the rationale being that if the study is focused on collection of adverse effects data then associated terms would be in the title. This could only be used in the databases accessed through OVID because other databases do not provide this functionality. Some of the other databases provided manageable numbers of results without these techniques; with others, the title field technique was used. </p> </li> </ul> </p> <p>There were no date limits on the electronic searches, but the searches were limited to the English language. </p> <p>See <a href="./appendices#MR000039-sec-0104">Appendix 1</a> for the search strategies used in each database (presented with the results). We used Endnote X3 to collect, de‐duplicate, screen titles/abstracts, and record decisions on inclusion of papers. </p> </section> <section id="MR000039-sec-0045"> <h4 class="title">Searching other resources</h4> <p>We supplemented the electronic searches by checking reference lists of included reports, some excluded reports that were relevant to the topic, and other reports known to the authors who are familiar with the research area (<a href="./references#MR000039-bbs2-0090" title="HorsleyT , DingwallO , SampsonM . Checking reference lists to find additional studies for systematic reviews. Cochrane Database of Systematic Reviews2011, Issue 8. [DOI: 10.1002/14651858.MR000026.pub2] ">Horsley 2011</a>), handsearching recent relevant topic‐area conference abstracts (International Conference on Pharmacoepidemiology and Therapeutic Risk Management, International Society of Pharmacovigilance annual meeting) (<a href="./references#MR000039-bbs2-0097" title="SchererRW , LangenbergP , VonElmE . Full publication of results initially presented in abstracts. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.MR000005.pub3] ">Scherer 2007</a>), and searching online libraries of theses/dissertations. </p> </section> </section> <section id="MR000039-sec-0046"> <h3 class="title" id="MR000039-sec-0046">Data collection and analysis</h3> <section id="MR000039-sec-0047"> <h4 class="title">Selection of studies</h4> <p>The first author (EA) examined titles and, where available, abstracts of identified citations in order to remove obviously irrelevant reports (e.g. non‐human studies). Thereafter, two authors (EA and NM or CL) independently reviewed the remaining titles and abstracts for eligibility according to the <a href="#MR000039-sec-0036">Criteria for considering studies for this review</a>, as described in the protocol for this review (<a href="./references#MR000039-bbs2-0103" title="AllenEN , ChandlerCIR , MandimikaN , BarnesK . Eliciting adverse effects data from participants in clinical trials. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.MR000039] ">Allen 2013b</a>). The full texts for all reports that appeared relevant were sought, as well as those for which the title and abstract was insufficient to determine eligibility. Reports from the same piece of research were linked together. The same review authors independently assessed final eligibility, with disagreements resolved by discussion, involving a third author (KB), as necessary). While the review authors were blinded to each other's assessments, they were not blinded to any information in the titles, abstracts, or full texts. All documents relating to this search and selection process were recorded along with the primary reason for non‐inclusion. </p> </section> <section id="MR000039-sec-0048"> <h4 class="title">Data extraction and management</h4> <p>One review author (EA) extracted data onto a data extraction form according to a prespecified list, with a second review author (CL) checking 100% of fields. Disagreements were resolved by consensus, with, if necessary, a third author (KB) consulted to resolve disagreements. The original planned list was pre‐tested with two reports and modified before being finalised as: </p> <p> <ul id="MR000039-list-0006"> <li> <p>Authors;</p> </li> <li> <p>Date published;</p> </li> <li> <p>Summary of study methods including any drug(s), indications/inclusion criteria, assessments(s), and duration of follow‐up; </p> </li> <li> <p>Data (AE or equivalent with original authors' terminology and definition, where available; medications and medical histories if these were also outcomes of the comparison) </p> </li> <li> <p>Comparisons (within or between participants);</p> </li> <li> <p>Elicitation methods, including (if available) description of their development and application methods. Also training/experience of staff, how AEs were described, whether verbatim reports were captured, and language; </p> </li> <li> <p>Outcomes and results:</p> <ul id="MR000039-list-0007"> <li> <p>The relative effect estimates derived from one method of ascertainment versus the other, by study group, if relevant; </p> </li> <li> <p>The number/proportion and/or nature of AEs as defined by the original authors of the trial, by study group, if relevant: </p> </li> <li> <p>If relevant, the relative effect estimates/number/proportion and/or nature of concomitant medications and/or medical histories; </p> </li> <li> <p>If relevant, summary of qualitative results;</p> </li> <li> <p>if relevant, statistical test results (including those from validation studies);</p> </li> </ul> </li> <li> <p>References to animal or human toxicology, pharmacovigilance databases, participants, or patient/consumer experiences (including explanations for differential reporting, such as qualitative results, and underlying conceptual theories or orientations); </p> </li> <li> <p>Key conclusions and limitations as reported by the original authors or as determined by us, as the reviewers. </p> </li> </ul> </p> </section> <section id="MR000039-sec-0049"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The risk of bias was independently assessed by two review authors (EA and KB), according to the Cochrane 'Risk of bias' tool, as far as was feasible in terms of the actual study design encountered (<a href="./references#MR000039-bbs2-0082" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Vol. 5.1.0, Chichester (UK): John Wiley &amp; Sons, 2011. ">Cochrane 2011</a>). Where this was not feasible due to the study methodology (e.g. for reports that compared outcomes within participants), the studies were critically evaluated in terms of the potential impact of the study’s design and conduct on its findings regarding selection, performance, detection, attrition, and reporting biases, and any other biases that we considered important. </p> <p>It is acknowledged that a 'risk of bias' assessment is dependent on the completeness and quality of the original study report and we attempted to contact the original authors whose email addresses were available to retrieve protocols or specific relevant missing information (<a href="./references#MR000039-bbs2-0102" title="YoungT , HopewellS . Methods for obtaining unpublished data. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.MR000027.pub2] ">Young 2011</a>). We did not exclude reports from this review on the basis of quality, unless insufficient data for the comparison were reported. </p> </section> <section id="MR000039-sec-0050"> <h4 class="title">Measures of the effect of the methods</h4> <p>Effect measures from different methods were compared, where possible, by assessing an overlap in 95% confidence intervals (<a href="./references#MR000039-bbs2-0087" title="GolderS , LokeYK , BlandM . Meta‐analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLOS Medicine2011;8(5):e1001026. [PUBMED: 21559325] ">Golder 2011</a>). </p> </section> <section id="MR000039-sec-0051"> <h4 class="title">Unit of analysis issues</h4> <p>The units of analysis were only known once the review was ongoing. The way that studies presented their data varied from absolute numbers of AEs, to means, medians, the proportion of participants with AEs and some study‐specific scores. This precluded quantitative pooling of data to generate pooled estimates. However, wherever possible, data were transformed into a common quantitative rubric. </p> </section> <section id="MR000039-sec-0052"> <h4 class="title">Dealing with missing data</h4> <p>We sought to minimize the amount of missing data through contact with original authors, as mentioned above (<a href="./references#MR000039-bbs2-0102" title="YoungT , HopewellS . Methods for obtaining unpublished data. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.MR000027.pub2] ">Young 2011</a>). Thereafter, any assumptions made about missing data, any statistical methods used to impute them, and the potential impact of these methods on the findings of the review, were reported. </p> </section> <section id="MR000039-sec-0053"> <h4 class="title">Assessment of heterogeneity</h4> <p>As noted above, pooled estimates could not be calculated, so we did not follow our plan to assess heterogeneity using the Chi<sup>2</sup> test and I<sup>2</sup> statistic (<a href="./references#MR000039-bbs2-0089" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21:1539‐58. ">Higgins 2002</a>). </p> </section> <section id="MR000039-sec-0054"> <h4 class="title">Assessment of reporting biases</h4> <p>As noted above, we could not calculate pooled estimates and so we could not follow our plan to assess reporting bias using a funnel plot (<a href="./references#MR000039-bbs2-0099" title="SterneJAC , EggerM . Funnel plots for detecting bias in meta‐analysis: guidelines on choice of axis. Journal of Clinical Epidemiology2001;54(10):1046‐55. ">Sterne 2001</a>). </p> </section> <section id="MR000039-sec-0055"> <h4 class="title">Data synthesis</h4> <p>As a meta‐analysis of included studies was not possible, given differences in study designs, interventions, and presentation, we conducted a narrative synthesis using recommendations by <a href="./references#MR000039-bbs2-0096" title="PopayJ , RobertsH , SowdenA , PetticrewM , AraiL , RodgersM , et al. Guidance on the conduct of narrative synthesis in systematic reviews. Results of an ESRC funded research project (as supplied prior to 14 September 2017). Data on file2006. ">Popay 2006</a>. One author (EA) first examined the included studies for any a priori theoretical basis for how elicitation methods could differ, in case this could contribute to the interpretation and applicability of the review findings. We developed a narrative summary of the scope of the study designs in order to look at aspects of study design across studies, and the <a href="./references#MR000039-sec-0113" title="">Characteristics of included studies</a> table was used as the starting point for organising studies for synthesis. For the latter, we tabulated brief key study characteristics and the results within two broad categories of whether outcomes were compared between or within participants. Where studies had not calculated an effect, we did this using raw or summary data, where possible, in order to develop common quantitative rubrics. We examined the tabulation for relationships within and between the studies, with the aim of identifying variables that potentially moderated the effects. We followed the same process, where relevant, for items relating to the impact of different elicitation methods on the between‐drug effects, the nature of AEs detected, and previous or concomitant medication and medical history data reported. </p> </section> <section id="MR000039-sec-0056"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not conduct any meta‐analyses and so no quantitative subgroup analyses or investigations of heterogeneity were done. </p> </section> <section id="MR000039-sec-0057"> <h4 class="title">Sensitivity analysis</h4> <p>Likewise, because we did not conduct any meta‐analyses, no sensitivity analyses were performed. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="MR000039-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="MR000039-sec-0058"></div> <section id="MR000039-sec-0059"> <h3 class="title">Description of studies</h3> <p>See the <a href="./references#MR000039-sec-0113" title="">Characteristics of included studies</a>, <a href="./references#MR000039-sec-0114" title="">Characteristics of excluded studies</a> and <a href="./references#MR000039-sec-0115" title="">Characteristics of studies awaiting classification</a> tables. </p> <section id="MR000039-sec-0060"> <h4 class="title">Results of the search</h4> <p>See <a href="#MR000039-fig-0001">Figure 1</a> for a flow diagram of the search metrics and <a href="./appendices#MR000039-sec-0104">Appendix 1</a> for the electronic search results. Our electronic search identified 13,903 papers, decreasing to 9663 after de‐duplication. An additional 35 papers were identified for inspection from non‐electronic methods after reviewing the references lists of included and some relevant excluded reports and handsearches. We sought the full text for 203 articles, of which 33 were eligible for inclusion. In total, 168 articles were excluded after checking the full text; 25 were further duplicates or variations on reports already assessed that did not add any relevant data, 10 were not in English or had been retracted, 98 did not include a comparison of methods for eliciting AE data, or the comparison was not possible due to the way data were collected or presented, 23 did not report any methods of relevance for clinical trials, seven only included an objectively measured AE (e.g. observation by a healthcare worker or laboratory report), or otherwise ineligible assessment, and five were conference abstracts without an associated paper. A further two articles are awaiting classification. See the <a href="./references#MR000039-sec-0114" title="">Characteristics of excluded studies</a> for details of articles which some readers may expect to be included. Nineteen included studies were found from the electronic search and 14 through non‐electronic means. </p> <div class="figure" id="MR000039-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="MR000039-fig-0001" src="/cdsr/doi/10.1002/14651858.MR000039.pub2/media/CDSR/MR000039/image_n/nMR000039-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="MR000039-sec-0061"> <h4 class="title">Included studies</h4> <p>Of the 33 eligible studies, 32 were published in full and one was a letter to the editor (<a href="./references#MR000039-bbs2-0016" title="KruftB , NelsonLA , StewartJA , StewartWC . Adverse event reporting. Ophthalmology2007;114(7):1420. ">Kruft 2007</a>). </p> <section id="MR000039-sec-0062"> <h5 class="title">Theoretical basis for elicitation methods</h5> <p>The reports of the included studies were largely not explicit, or were unclear, about the theoretical basis for the work. Often, the expectation was simply that data were likely to be underreported if participants were not questioned in detail and that more specific questioning would be likely to increase the number of AE reports although it might have missed AEs that were not explicitly shown on the list or tool. One study, however, asserted that a theoretical advantage of a general enquiry was the absence of suggestion, but also hypothesised that response styles (like stoicism) are more likely to influence open‐ended questioning than checklist methods of elicitation (<a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a>). <a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a> postulated that participants allowed to volunteer information may conceal or fail to recognise symptoms, while suggestible participants may report symptoms when questioned even though there is little objective evidence of the symptom being present. <a href="./references#MR000039-bbs2-0026" title="RosenthalJ , BahrmannH , BenkertK , BaumgartP , BönnerG , KleinG , et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta‐blocker. Cardiology1996;87(5):409‐14. ">Rosenthal 1996</a> stated that 'connotation of words, among many other factors' could influence AE responses. Some authors hypothesised that the nature of AEs detected by the different methods would be informative. This included the consideration that extra AEs reported through more specific questioning methods, like a checklist, were less likely to be clinically relevant, severe/bothersome or caused by the intervention than those reported spontaneously or in response to what some call 'non‐leading' open enquiries (<a href="./references#MR000039-bbs2-0003" title="BarberBL , SantanelloNC . Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. International Journal of Clinical Pharmacology and Therapeutics1995;33(11):598‐604. ">Barber 1995</a>, <a href="./references#MR000039-bbs2-0011" title="DowningRW , RickelsK , MeyersF . Side reactions in neurotics. I. A comparison of two methods of assessment. Journal of Clinical Pharmacology and the Journal of New Drugs1970;10(5):289‐97. ">Downing 1970</a>, <a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a>). Where hypotheses were mentioned, they were largely based on a study or studies that we cited in this review, which may or may not be supported by the evidence. Studies that compared methods as part of a validation exercise for a new elicitation tool aimed to measure concordance (<a href="./references#MR000039-bbs2-0009" title="DeVriesST , MolPG , DeZeeuwD , Haaijer‐RuskampFM , DenigP . Development and initial validation of a patient‐reported adverse drug event questionnaire. Drug Safety2013;36(9):765‐77. ">De Vries 2013</a>; <a href="./references#MR000039-bbs2-0010" title="DeVriesST , Haaijer‐RuskampFM , DeZeeuwD , DenigP . The validity of a patient‐reported adverse drug event questionnaire using different recall periods. Quality of Life Research2014;23(9):2439‐45. ">De Vries 2014</a>). One study was explicit that it was conducted retrospectively with data already collected by different elicitation methods (<a href="./references#MR000039-bbs2-0016" title="KruftB , NelsonLA , StewartJA , StewartWC . Adverse event reporting. Ophthalmology2007;114(7):1420. ">Kruft 2007</a>). Two were natural experiments, in that the method for eliciting AE data changed during a trial (<a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a>; <a href="./references#MR000039-bbs2-0019" title="MonteiroWO , NoshirvaniHF , MarksIM , LelliottPT . Anorgasmia from clomipramine in obsessive‐compulsive disorder. A controlled trial. British Journal of Psychiatry1987;151:107‐12. ">Monteiro 1987</a>). For other studies, it was unclear whether the comparison was an a priori objective (<a href="./references#MR000039-bbs2-0013" title="HermansL , DeblanderA , DeKeyserP , ScheysI , LesaffreE , WestelinckKJ . At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild‐to‐moderate hypertension: a double‐blind, randomized, parallel‐group study. British Journal of Clinical Pharmacology1994;38(4):335‐40. ">Hermans 1994</a>; <a href="./references#MR000039-bbs2-0020" title="NichollsDP , HusainiMH , BulpittCJ , StephensMD , ButlerAG . Comparison of labetalol and propranolol in hypertension. British Journal of Clinical Pharmacology1980;9(3):233‐7. ">Nicholls 1980</a>; <a href="./references#MR000039-bbs2-0021" title="O'ConnellK , DavisAR , KernsJ . Oral contraceptives: side effects and depression in adolescent girls. Contraception2007;75(4):299‐304. ">O'Connell 2007</a>; <a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a>; <a href="./references#MR000039-bbs2-0032" title="WernickeJF , FariesD , MiltonD , WeyrauchK . Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Safety2005;28(11):1057‐63. ">Wernicke 2005</a>; <a href="./references#MR000039-bbs2-0033" title="YeoWW , MacleanD , RichardsonPJ , RamsayLE . Cough and enalapril: assessment by spontaneous reporting and visual analogue scale under double‐blind conditions. British Journal Clinical Pharmacology1991;31(3):356‐9. ">Yeo 1991</a>). </p> </section> <section id="MR000039-sec-0063"> <h5 class="title">Scope of study designs and presentations</h5> <section id="MR000039-sec-0064"> <h6 class="title">Methods</h6> <p>Included studies were conducted within a wide range of therapeutic areas (and therefore with various participants and drug interventions), including cardiology (<a href="./references#MR000039-bbs2-0006" title="BorghiC , PallaviniG , ComiD , GrilloM , LombardoM , ManteroO , et al. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy. International Journal of Clinical Pharmacology, Therapy and Toxicology1984;22(6):324‐8. ">Borghi 1984</a>, <a href="./references#MR000039-bbs2-0013" title="HermansL , DeblanderA , DeKeyserP , ScheysI , LesaffreE , WestelinckKJ . At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild‐to‐moderate hypertension: a double‐blind, randomized, parallel‐group study. British Journal of Clinical Pharmacology1994;38(4):335‐40. ">Hermans 1994</a>, <a href="./references#MR000039-bbs2-0020" title="NichollsDP , HusainiMH , BulpittCJ , StephensMD , ButlerAG . Comparison of labetalol and propranolol in hypertension. British Journal of Clinical Pharmacology1980;9(3):233‐7. ">Nicholls 1980</a>, <a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a>, <a href="./references#MR000039-bbs2-0025" title="ReillyMC , ZbrozekAS . Assessing the responsiveness of a quality‐of‐life instrument and the measurement of symptom severity in essential hypertension. Pharmacoeconomics1992;2(1):54‐66. ">Reilly 1992</a>, <a href="./references#MR000039-bbs2-0026" title="RosenthalJ , BahrmannH , BenkertK , BaumgartP , BönnerG , KleinG , et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta‐blocker. Cardiology1996;87(5):409‐14. ">Rosenthal 1996</a>, <a href="./references#MR000039-bbs2-0029" title="TörökE , KósaE , SzontaghM , JuvanczP , EggenhoferJ , BorvendégJ . Comparison of methods to detect side‐effect on clinical application of chloranolol, a beta‐adrenergic receptor inhibitor. European Journal of Clinical Pharmacology1984;26(5):555‐62. ">Török 1984</a>, <a href="./references#MR000039-bbs2-0030" title="WallanderMA , DimenäsE , SvärdsuddK , WiklundI . Evaluation of three methods of symptom reporting in a clinical trial of felodipine. European Journal of Clinical Pharmacology1991;41(3):187‐96. ">Wallander 1991</a>, <a href="./references#MR000039-bbs2-0033" title="YeoWW , MacleanD , RichardsonPJ , RamsayLE . Cough and enalapril: assessment by spontaneous reporting and visual analogue scale under double‐blind conditions. British Journal Clinical Pharmacology1991;31(3):356‐9. ">Yeo 1991</a>), psychiatry (<a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a>, <a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a>, <a href="./references#MR000039-bbs2-0011" title="DowningRW , RickelsK , MeyersF . Side reactions in neurotics. I. A comparison of two methods of assessment. Journal of Clinical Pharmacology and the Journal of New Drugs1970;10(5):289‐97. ">Downing 1970,</a><a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a>, <a href="./references#MR000039-bbs2-0015" title="JacobsonAF , GoldsteinBJ , DominguezRA , SteinbookRM . Interrater agreement and reliability measures of SAFTEE: general inquiry vs. systematic inquiry. Psychopharmacology Bulletin1987;23(1):97‐101. ">Jacobson 1987</a>, <a href="./references#MR000039-bbs2-0017" title="LandénM , HögbergP , ThaseME . Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Journal of Clinical Psychiatry2005;66(1):100‐6. ">Landén 2005</a>, <a href="./references#MR000039-bbs2-0019" title="MonteiroWO , NoshirvaniHF , MarksIM , LelliottPT . Anorgasmia from clomipramine in obsessive‐compulsive disorder. A controlled trial. British Journal of Psychiatry1987;151:107‐12. ">Monteiro 1987</a>, <a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a>), ophthalmology (<a href="./references#MR000039-bbs2-0003" title="BarberBL , SantanelloNC . Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. International Journal of Clinical Pharmacology and Therapeutics1995;33(11):598‐604. ">Barber 1995</a>, <a href="./references#MR000039-bbs2-0016" title="KruftB , NelsonLA , StewartJA , StewartWC . Adverse event reporting. Ophthalmology2007;114(7):1420. ">Kruft 2007</a>), diabetes (<a href="./references#MR000039-bbs2-0009" title="DeVriesST , MolPG , DeZeeuwD , Haaijer‐RuskampFM , DenigP . Development and initial validation of a patient‐reported adverse drug event questionnaire. Drug Safety2013;36(9):765‐77. ">De Vries 2013</a>, <a href="./references#MR000039-bbs2-0010" title="DeVriesST , Haaijer‐RuskampFM , DeZeeuwD , DenigP . The validity of a patient‐reported adverse drug event questionnaire using different recall periods. Quality of Life Research2014;23(9):2439‐45. ">De Vries 2014</a>), dysmenorrhoea (<a href="./references#MR000039-bbs2-0021" title="O'ConnellK , DavisAR , KernsJ . Oral contraceptives: side effects and depression in adolescent girls. Contraception2007;75(4):299‐304. ">O'Connell 2007</a>), gastrointestinal diseases (<a href="./references#MR000039-bbs2-0004" title="BarrowmanJA , HerxheimerA , KitsTP . Unwanted effects of pentagastrin. Clinical Pharmacology and Therapeutics1970;11(6):862‐8. ">Barrowman 1970</a>), gonorrhoea (<a href="./references#MR000039-bbs2-0031" title="WallinJ , SjövallJ . Detection of adverse drug reactions in a clinical trial using two types of questioning. Clinical Therapeutics1981;3(6):450‐2. ">Wallin 1981</a>), malaria (<a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a>) (a study conducted by the authors of this review), migraine (<a href="./references#MR000039-bbs2-0027" title="SheftellFD , FeleppaM , TepperSJ , RapoportAM , CiannellaL , BigalM . Assessment of adverse events associated with triptans ‐ methods of assessment influence the results. Headache2004;44(10):978‐82. ">Sheftell 2004</a>), Parkinson's disease (<a href="./references#MR000039-bbs2-0023" title="Perez‐LloretS , ReyMV , FabreN , OryF , SpampinatoU , MontastrucJL , et al. Do Parkinson's disease patients disclose their adverse events spontaneously?. European Journal of Clinical Pharmacology2012;68(5):857‐65. ">Perez‐Lloret 2012</a>), prostatic hyperplasia (<a href="./references#MR000039-bbs2-0005" title="BentS , PadulaA , AvinsAL . Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Annals of Internal Medicine2006;144(4):257‐61. ">Bent 2006</a>), rheumatology (<a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a>), and an unspecified indication for antihistamines (<a href="./references#MR000039-bbs2-0018" title="LundbergPK . Assessment of drugs' side effects: Visual Analogue Scale versus check‐list format. Perceptual and Motor Skills1980;50(3):1067‐73. ">Lundberg 1980</a>). Three studies were not related to any specific therapeutic area (<a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a>, <a href="./references#MR000039-bbs2-0028" title="SpilkerAV , KesslerJM . Comparison of symptoms elicited by checklist and fill‐in‐the‐blank questionnaires. Pharmacoepidemiology News1987;22:272‐7. ">Spilker 1987</a>) or the therapeutic area was not specified (<a href="./references#MR000039-bbs2-0032" title="WernickeJF , FariesD , MiltonD , WeyrauchK . Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Safety2005;28(11):1057‐63. ">Wernicke 2005</a>). </p> <p>Five studies involved healthy volunteers, students or employees (<a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a>, <a href="./references#MR000039-bbs2-0004" title="BarrowmanJA , HerxheimerA , KitsTP . Unwanted effects of pentagastrin. Clinical Pharmacology and Therapeutics1970;11(6):862‐8. ">Barrowman 1970</a>, <a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a>, <a href="./references#MR000039-bbs2-0018" title="LundbergPK . Assessment of drugs' side effects: Visual Analogue Scale versus check‐list format. Perceptual and Motor Skills1980;50(3):1067‐73. ">Lundberg 1980</a>, <a href="./references#MR000039-bbs2-0028" title="SpilkerAV , KesslerJM . Comparison of symptoms elicited by checklist and fill‐in‐the‐blank questionnaires. Pharmacoepidemiology News1987;22:272‐7. ">Spilker 1987</a>). The remainder were conducted with patients. <a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a> was treating children and therefore included caregivers in the elicitation process, some of whom received a reimbursement fee for taking part in the study. Two other studies were conducted in adolescents (<a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a>, <a href="./references#MR000039-bbs2-0021" title="O'ConnellK , DavisAR , KernsJ . Oral contraceptives: side effects and depression in adolescent girls. Contraception2007;75(4):299‐304. ">O'Connell 2007</a>), one in children and adults (<a href="./references#MR000039-bbs2-0032" title="WernickeJF , FariesD , MiltonD , WeyrauchK . Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Safety2005;28(11):1057‐63. ">Wernicke 2005</a>) and the remainder were conducted in adults (or we assumed them to be in adults when age was not explicit). However, because age ranges were missing from several papers, we did not include age in the <a href="./references#MR000039-sec-0113" title="">Characteristics of included studies</a> table. </p> <p>Most studies were conducted in Europe (N = 17) or the United States (N = 12). Two other studies were multinational (<a href="./references#MR000039-bbs2-0016" title="KruftB , NelsonLA , StewartJA , StewartWC . Adverse event reporting. Ophthalmology2007;114(7):1420. ">Kruft 2007</a>, <a href="./references#MR000039-bbs2-0027" title="SheftellFD , FeleppaM , TepperSJ , RapoportAM , CiannellaL , BigalM . Assessment of adverse events associated with triptans ‐ methods of assessment influence the results. Headache2004;44(10):978‐82. ">Sheftell 2004</a>), one African (<a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a>) and the location of one was not reported (<a href="./references#MR000039-bbs2-0032" title="WernickeJF , FariesD , MiltonD , WeyrauchK . Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Safety2005;28(11):1057‐63. ">Wernicke 2005</a>). </p> <p>Seven studies were conducted outside of a clinical trial (<a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a>, <a href="./references#MR000039-bbs2-0009" title="DeVriesST , MolPG , DeZeeuwD , Haaijer‐RuskampFM , DenigP . Development and initial validation of a patient‐reported adverse drug event questionnaire. Drug Safety2013;36(9):765‐77. ">De Vries 2013</a>, <a href="./references#MR000039-bbs2-0010" title="DeVriesST , Haaijer‐RuskampFM , DeZeeuwD , DenigP . The validity of a patient‐reported adverse drug event questionnaire using different recall periods. Quality of Life Research2014;23(9):2439‐45. ">De Vries 2014</a>, <a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a>, <a href="./references#MR000039-bbs2-0023" title="Perez‐LloretS , ReyMV , FabreN , OryF , SpampinatoU , MontastrucJL , et al. Do Parkinson's disease patients disclose their adverse events spontaneously?. European Journal of Clinical Pharmacology2012;68(5):857‐65. ">Perez‐Lloret 2012</a>, <a href="./references#MR000039-bbs2-0027" title="SheftellFD , FeleppaM , TepperSJ , RapoportAM , CiannellaL , BigalM . Assessment of adverse events associated with triptans ‐ methods of assessment influence the results. Headache2004;44(10):978‐82. ">Sheftell 2004</a>, <a href="./references#MR000039-bbs2-0028" title="SpilkerAV , KesslerJM . Comparison of symptoms elicited by checklist and fill‐in‐the‐blank questionnaires. Pharmacoepidemiology News1987;22:272‐7. ">Spilker 1987</a>). The remainder were nested within, or integral to, a trial. This latter group were all randomised trials, with either a reference drug or placebo, except for <a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a>; and <a href="./references#MR000039-bbs2-0031" title="WallinJ , SjövallJ . Detection of adverse drug reactions in a clinical trial using two types of questioning. Clinical Therapeutics1981;3(6):450‐2. ">Wallin 1981</a>, which used single‐arm designs, and <a href="./references#MR000039-bbs2-0029" title="TörökE , KósaE , SzontaghM , JuvanczP , EggenhoferJ , BorvendégJ . Comparison of methods to detect side‐effect on clinical application of chloranolol, a beta‐adrenergic receptor inhibitor. European Journal of Clinical Pharmacology1984;26(5):555‐62. ">Török 1984</a>, which used a mixture of randomised and single‐arm trials. Four studies were conducted as part of validating two new tools for eliciting AEs: <a href="./references#MR000039-bbs2-0009" title="DeVriesST , MolPG , DeZeeuwD , Haaijer‐RuskampFM , DenigP . Development and initial validation of a patient‐reported adverse drug event questionnaire. Drug Safety2013;36(9):765‐77. ">De Vries 2013</a> and <a href="./references#MR000039-bbs2-0010" title="DeVriesST , Haaijer‐RuskampFM , DeZeeuwD , DenigP . The validity of a patient‐reported adverse drug event questionnaire using different recall periods. Quality of Life Research2014;23(9):2439‐45. ">De Vries 2014</a> (outside of a trial) and <a href="./references#MR000039-bbs2-0015" title="JacobsonAF , GoldsteinBJ , DominguezRA , SteinbookRM . Interrater agreement and reliability measures of SAFTEE: general inquiry vs. systematic inquiry. Psychopharmacology Bulletin1987;23(1):97‐101. ">Jacobson 1987</a> and <a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a> (within a trial). </p> </section> <section id="MR000039-sec-0065"> <h6 class="title">Data</h6> <p>Most studies sought to elicit any AE, while others focused on a specific AE or specific AEs of special interest. The studies of specific AEs included occular‐related abnormalities (<a href="./references#MR000039-bbs2-0016" title="KruftB , NelsonLA , StewartJA , StewartWC . Adverse event reporting. Ophthalmology2007;114(7):1420. ">Kruft 2007</a>), sexual dysfunction (<a href="./references#MR000039-bbs2-0017" title="LandénM , HögbergP , ThaseME . Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Journal of Clinical Psychiatry2005;66(1):100‐6. ">Landén 2005</a>, <a href="./references#MR000039-bbs2-0019" title="MonteiroWO , NoshirvaniHF , MarksIM , LelliottPT . Anorgasmia from clomipramine in obsessive‐compulsive disorder. A controlled trial. British Journal of Psychiatry1987;151:107‐12. ">Monteiro 1987</a>), depression (<a href="./references#MR000039-bbs2-0021" title="O'ConnellK , DavisAR , KernsJ . Oral contraceptives: side effects and depression in adolescent girls. Contraception2007;75(4):299‐304. ">O'Connell 2007</a>), cough (<a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a>, <a href="./references#MR000039-bbs2-0033" title="YeoWW , MacleanD , RichardsonPJ , RamsayLE . Cough and enalapril: assessment by spontaneous reporting and visual analogue scale under double‐blind conditions. British Journal Clinical Pharmacology1991;31(3):356‐9. ">Yeo 1991</a>), and self‐harm (<a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a>). However, there were significant variations in terminology and definitions for the data being collected, which made our analysis challenging. It was largely older studies that used the terms 'side‐effect' (<a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a>, <a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a>, <a href="./references#MR000039-bbs2-0018" title="LundbergPK . Assessment of drugs' side effects: Visual Analogue Scale versus check‐list format. Perceptual and Motor Skills1980;50(3):1067‐73. ">Lundberg 1980</a>, <a href="./references#MR000039-bbs2-0020" title="NichollsDP , HusainiMH , BulpittCJ , StephensMD , ButlerAG . Comparison of labetalol and propranolol in hypertension. British Journal of Clinical Pharmacology1980;9(3):233‐7. ">Nicholls 1980</a>, <a href="./references#MR000039-bbs2-0021" title="O'ConnellK , DavisAR , KernsJ . Oral contraceptives: side effects and depression in adolescent girls. Contraception2007;75(4):299‐304. ">O'Connell 2007</a>, <a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a>, <a href="./references#MR000039-bbs2-0029" title="TörökE , KósaE , SzontaghM , JuvanczP , EggenhoferJ , BorvendégJ . Comparison of methods to detect side‐effect on clinical application of chloranolol, a beta‐adrenergic receptor inhibitor. European Journal of Clinical Pharmacology1984;26(5):555‐62. ">Török 1984</a>), 'side reaction' (<a href="./references#MR000039-bbs2-0011" title="DowningRW , RickelsK , MeyersF . Side reactions in neurotics. I. A comparison of two methods of assessment. Journal of Clinical Pharmacology and the Journal of New Drugs1970;10(5):289‐97. ">Downing 1970</a>), 'unwanted effect' (<a href="./references#MR000039-bbs2-0006" title="BorghiC , PallaviniG , ComiD , GrilloM , LombardoM , ManteroO , et al. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy. International Journal of Clinical Pharmacology, Therapy and Toxicology1984;22(6):324‐8. ">Borghi 1984</a>), and 'adverse reaction' (<a href="./references#MR000039-bbs2-0031" title="WallinJ , SjövallJ . Detection of adverse drug reactions in a clinical trial using two types of questioning. Clinical Therapeutics1981;3(6):450‐2. ">Wallin 1981</a>) to describe the data collected, regardless of whether it was treatment‐emergent or not, or whether a causality assessment had been performed. More recent studies used 'adverse experience' (<a href="./references#MR000039-bbs2-0003" title="BarberBL , SantanelloNC . Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. International Journal of Clinical Pharmacology and Therapeutics1995;33(11):598‐604. ">Barber 1995</a>), 'adverse health event' (<a href="./references#MR000039-bbs2-0015" title="JacobsonAF , GoldsteinBJ , DominguezRA , SteinbookRM . Interrater agreement and reliability measures of SAFTEE: general inquiry vs. systematic inquiry. Psychopharmacology Bulletin1987;23(1):97‐101. ">Jacobson 1987</a>), 'adverse event', 'adverse drug event' or just 'event' (<a href="./references#MR000039-bbs2-0005" title="BentS , PadulaA , AvinsAL . Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Annals of Internal Medicine2006;144(4):257‐61. ">Bent 2006</a>, <a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a>, <a href="./references#MR000039-bbs2-0009" title="DeVriesST , MolPG , DeZeeuwD , Haaijer‐RuskampFM , DenigP . Development and initial validation of a patient‐reported adverse drug event questionnaire. Drug Safety2013;36(9):765‐77. ">De Vries 2013</a>, <a href="./references#MR000039-bbs2-0010" title="DeVriesST , Haaijer‐RuskampFM , DeZeeuwD , DenigP . The validity of a patient‐reported adverse drug event questionnaire using different recall periods. Quality of Life Research2014;23(9):2439‐45. ">De Vries 2014</a>, <a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a>, <a href="./references#MR000039-bbs2-0013" title="HermansL , DeblanderA , DeKeyserP , ScheysI , LesaffreE , WestelinckKJ . At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild‐to‐moderate hypertension: a double‐blind, randomized, parallel‐group study. British Journal of Clinical Pharmacology1994;38(4):335‐40. ">Hermans 1994</a>, <a href="./references#MR000039-bbs2-0016" title="KruftB , NelsonLA , StewartJA , StewartWC . Adverse event reporting. Ophthalmology2007;114(7):1420. ">Kruft 2007</a>, <a href="./references#MR000039-bbs2-0017" title="LandénM , HögbergP , ThaseME . Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Journal of Clinical Psychiatry2005;66(1):100‐6. ">Landén 2005</a>, <a href="./references#MR000039-bbs2-0023" title="Perez‐LloretS , ReyMV , FabreN , OryF , SpampinatoU , MontastrucJL , et al. Do Parkinson's disease patients disclose their adverse events spontaneously?. European Journal of Clinical Pharmacology2012;68(5):857‐65. ">Perez‐Lloret 2012</a>, <a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a>, <a href="./references#MR000039-bbs2-0026" title="RosenthalJ , BahrmannH , BenkertK , BaumgartP , BönnerG , KleinG , et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta‐blocker. Cardiology1996;87(5):409‐14. ">Rosenthal 1996</a>, <a href="./references#MR000039-bbs2-0027" title="SheftellFD , FeleppaM , TepperSJ , RapoportAM , CiannellaL , BigalM . Assessment of adverse events associated with triptans ‐ methods of assessment influence the results. Headache2004;44(10):978‐82. ">Sheftell 2004</a>, <a href="./references#MR000039-bbs2-0030" title="WallanderMA , DimenäsE , SvärdsuddK , WiklundI . Evaluation of three methods of symptom reporting in a clinical trial of felodipine. European Journal of Clinical Pharmacology1991;41(3):187‐96. ">Wallander 1991</a>, <a href="./references#MR000039-bbs2-0032" title="WernickeJF , FariesD , MiltonD , WeyrauchK . Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Safety2005;28(11):1057‐63. ">Wernicke 2005</a>). </p> <p>As our protocol (<a href="./references#MR000039-bbs2-0103" title="AllenEN , ChandlerCIR , MandimikaN , BarnesK . Eliciting adverse effects data from participants in clinical trials. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.MR000039] ">Allen 2013b</a>) allowed for the inclusion of methods' studies conducted outside of a clinical trial, we expected that not all studies would collect or report AEs according to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) definition ('any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment'). However, of the 26 comparisons nested within or integral to clinical trials, only six could confidently be considered as reporting treatment‐emergent AEs ‐ i.e. taking baseline symptoms or medical history into account when interpreting data collected as a new event or worsening of a previous event (<a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a>, <a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a>, <a href="./references#MR000039-bbs2-0013" title="HermansL , DeblanderA , DeKeyserP , ScheysI , LesaffreE , WestelinckKJ . At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild‐to‐moderate hypertension: a double‐blind, randomized, parallel‐group study. British Journal of Clinical Pharmacology1994;38(4):335‐40. ">Hermans 1994</a>, <a href="./references#MR000039-bbs2-0017" title="LandénM , HögbergP , ThaseME . Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Journal of Clinical Psychiatry2005;66(1):100‐6. ">Landén 2005</a>, <a href="./references#MR000039-bbs2-0019" title="MonteiroWO , NoshirvaniHF , MarksIM , LelliottPT . Anorgasmia from clomipramine in obsessive‐compulsive disorder. A controlled trial. British Journal of Psychiatry1987;151:107‐12. ">Monteiro 1987</a>, <a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a>, <a href="./references#MR000039-bbs2-0032" title="WernickeJF , FariesD , MiltonD , WeyrauchK . Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Safety2005;28(11):1057‐63. ">Wernicke 2005</a>). The reports of four other studies were clear that they were collecting symptoms that were not necessarily treatment‐emergent (<a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a>, <a href="./references#MR000039-bbs2-0025" title="ReillyMC , ZbrozekAS . Assessing the responsiveness of a quality‐of‐life instrument and the measurement of symptom severity in essential hypertension. Pharmacoeconomics1992;2(1):54‐66. ">Reilly 1992</a>, <a href="./references#MR000039-bbs2-0028" title="SpilkerAV , KesslerJM . Comparison of symptoms elicited by checklist and fill‐in‐the‐blank questionnaires. Pharmacoepidemiology News1987;22:272‐7. ">Spilker 1987</a>; and <a href="./references#MR000039-bbs2-0029" title="TörökE , KósaE , SzontaghM , JuvanczP , EggenhoferJ , BorvendégJ . Comparison of methods to detect side‐effect on clinical application of chloranolol, a beta‐adrenergic receptor inhibitor. European Journal of Clinical Pharmacology1984;26(5):555‐62. ">Török 1984</a>). The remaining studies were unclear about this. For simplicity, we used AE as the default term hereafter. <a href="./references#MR000039-bbs2-0026" title="RosenthalJ , BahrmannH , BenkertK , BaumgartP , BönnerG , KleinG , et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta‐blocker. Cardiology1996;87(5):409‐14. ">Rosenthal 1996</a> only reported on AEs that matched those on the checklist. </p> <p>Some studies looked at the nature of the AEs elicited, although the way this was done varied. <a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a> included a global statement of the investigator's assessment of severity and causality of all AEs collected. Other authors reported individual assessments of severity, clinical relevance, clinical action taken, seriousness, discomfort and/or bother. Assessments were either performed by investigators (<a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a>, <a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a>, <a href="./references#MR000039-bbs2-0013" title="HermansL , DeblanderA , DeKeyserP , ScheysI , LesaffreE , WestelinckKJ . At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild‐to‐moderate hypertension: a double‐blind, randomized, parallel‐group study. British Journal of Clinical Pharmacology1994;38(4):335‐40. ">Hermans 1994</a>, <a href="./references#MR000039-bbs2-0015" title="JacobsonAF , GoldsteinBJ , DominguezRA , SteinbookRM . Interrater agreement and reliability measures of SAFTEE: general inquiry vs. systematic inquiry. Psychopharmacology Bulletin1987;23(1):97‐101. ">Jacobson 1987</a>, <a href="./references#MR000039-bbs2-0023" title="Perez‐LloretS , ReyMV , FabreN , OryF , SpampinatoU , MontastrucJL , et al. Do Parkinson's disease patients disclose their adverse events spontaneously?. European Journal of Clinical Pharmacology2012;68(5):857‐65. ">Perez‐Lloret 2012</a>, <a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a>) or participants (<a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a>, <a href="./references#MR000039-bbs2-0003" title="BarberBL , SantanelloNC . Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. International Journal of Clinical Pharmacology and Therapeutics1995;33(11):598‐604. ">Barber 1995</a>, <a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a>, <a href="./references#MR000039-bbs2-0011" title="DowningRW , RickelsK , MeyersF . Side reactions in neurotics. I. A comparison of two methods of assessment. Journal of Clinical Pharmacology and the Journal of New Drugs1970;10(5):289‐97. ">Downing 1970</a>, <a href="./references#MR000039-bbs2-0025" title="ReillyMC , ZbrozekAS . Assessing the responsiveness of a quality‐of‐life instrument and the measurement of symptom severity in essential hypertension. Pharmacoeconomics1992;2(1):54‐66. ">Reilly 1992</a>, <a href="./references#MR000039-bbs2-0027" title="SheftellFD , FeleppaM , TepperSJ , RapoportAM , CiannellaL , BigalM . Assessment of adverse events associated with triptans ‐ methods of assessment influence the results. Headache2004;44(10):978‐82. ">Sheftell 2004</a>, <a href="./references#MR000039-bbs2-0028" title="SpilkerAV , KesslerJM . Comparison of symptoms elicited by checklist and fill‐in‐the‐blank questionnaires. Pharmacoepidemiology News1987;22:272‐7. ">Spilker 1987</a>) using tools such as investigator‐grading schemes (mild, moderate, severe etc.) and participant‐reported rating scales. It was not clear for <a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a> or <a href="./references#MR000039-bbs2-0031" title="WallinJ , SjövallJ . Detection of adverse drug reactions in a clinical trial using two types of questioning. Clinical Therapeutics1981;3(6):450‐2. ">Wallin 1981</a> who assessed severity. </p> <p>Other relevant results related to the feasibility (<a href="./references#MR000039-bbs2-0009" title="DeVriesST , MolPG , DeZeeuwD , Haaijer‐RuskampFM , DenigP . Development and initial validation of a patient‐reported adverse drug event questionnaire. Drug Safety2013;36(9):765‐77. ">De Vries 2013</a>) and acceptability (<a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a>) of different questioning methods, and <a href="./references#MR000039-bbs2-0010" title="DeVriesST , Haaijer‐RuskampFM , DeZeeuwD , DenigP . The validity of a patient‐reported adverse drug event questionnaire using different recall periods. Quality of Life Research2014;23(9):2439‐45. ">De Vries 2014</a> measured differing recall periods. <a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a> collected qualitative data from in‐depth interviews with selected participants to explore reasons for differential reporting between elicitation methods, and captured medical history and non‐study drug data in the same way as the AEs. <a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a>; <a href="./references#MR000039-bbs2-0013" title="HermansL , DeblanderA , DeKeyserP , ScheysI , LesaffreE , WestelinckKJ . At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild‐to‐moderate hypertension: a double‐blind, randomized, parallel‐group study. British Journal of Clinical Pharmacology1994;38(4):335‐40. ">Hermans 1994</a>; <a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a> and <a href="./references#MR000039-bbs2-0025" title="ReillyMC , ZbrozekAS . Assessing the responsiveness of a quality‐of‐life instrument and the measurement of symptom severity in essential hypertension. Pharmacoeconomics1992;2(1):54‐66. ">Reilly 1992</a> also elicited baseline AE or symptom data, but there was not enough information to clarify whether measures of effect after baseline were treatment‐emergent or not. </p> <p>While we generally excluded studies that involved an objective assessment of AEs (e.g. through laboratory tests or physical examinations), it was possible to identify some participant‐reported AE data in two of these justifying their inclusion in this review (<a href="./references#MR000039-bbs2-0029" title="TörökE , KósaE , SzontaghM , JuvanczP , EggenhoferJ , BorvendégJ . Comparison of methods to detect side‐effect on clinical application of chloranolol, a beta‐adrenergic receptor inhibitor. European Journal of Clinical Pharmacology1984;26(5):555‐62. ">Török 1984</a>, <a href="./references#MR000039-bbs2-0030" title="WallanderMA , DimenäsE , SvärdsuddK , WiklundI . Evaluation of three methods of symptom reporting in a clinical trial of felodipine. European Journal of Clinical Pharmacology1991;41(3):187‐96. ">Wallander 1991</a>). For another study (<a href="./references#MR000039-bbs2-0006" title="BorghiC , PallaviniG , ComiD , GrilloM , LombardoM , ManteroO , et al. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy. International Journal of Clinical Pharmacology, Therapy and Toxicology1984;22(6):324‐8. ">Borghi 1984</a>), it was possible that one of the methods involved a doctor 'filtering' participant reports (i.e. just reporting those he or she considered ADRs). This study was also included in the review by restricting the comparison to the other two methods that reflected participant‐reported data. </p> </section> <section id="MR000039-sec-0066"> <h6 class="title">Comparisons</h6> <p>Most (N = 25) studies compared data within participants. That is, each participant was asked about AEs by two or more elicitation methods. The remainder of the studies allocated groups of participants to different methods for eliciting AEs. <a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a>, <a href="./references#MR000039-bbs2-0005" title="BentS , PadulaA , AvinsAL . Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Annals of Internal Medicine2006;144(4):257‐61. ">Bent 2006</a>, <a href="./references#MR000039-bbs2-0006" title="BorghiC , PallaviniG , ComiD , GrilloM , LombardoM , ManteroO , et al. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy. International Journal of Clinical Pharmacology, Therapy and Toxicology1984;22(6):324‐8. ">Borghi 1984</a>, <a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a>, and <a href="./references#MR000039-bbs2-0028" title="SpilkerAV , KesslerJM . Comparison of symptoms elicited by checklist and fill‐in‐the‐blank questionnaires. Pharmacoepidemiology News1987;22:272‐7. ">Spilker 1987</a> allocated methods randomly while <a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a>, <a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a> and <a href="./references#MR000039-bbs2-0029" title="TörökE , KósaE , SzontaghM , JuvanczP , EggenhoferJ , BorvendégJ . Comparison of methods to detect side‐effect on clinical application of chloranolol, a beta‐adrenergic receptor inhibitor. European Journal of Clinical Pharmacology1984;26(5):555‐62. ">Török 1984</a> used non‐random allocation. Four of the between‐participant comparisons involved comparing one method with that method plus another one (<a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a>, <a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a>, <a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a> and <a href="./references#MR000039-bbs2-0029" title="TörökE , KósaE , SzontaghM , JuvanczP , EggenhoferJ , BorvendégJ . Comparison of methods to detect side‐effect on clinical application of chloranolol, a beta‐adrenergic receptor inhibitor. European Journal of Clinical Pharmacology1984;26(5):555‐62. ">Török 1984</a>). </p> <p>Most comparisons were of participant responses to open questions (O) (and/or occasionally a completely spontaneous report, i.e. where no question was asked) and responses to what can be summarised as a checklist or questionnaire pick‐list of potential AEs (CL). Two of these studies involved answers to an open question written on a blank (B) form <a href="./references#MR000039-bbs2-0027" title="SheftellFD , FeleppaM , TepperSJ , RapoportAM , CiannellaL , BigalM . Assessment of adverse events associated with triptans ‐ methods of assessment influence the results. Headache2004;44(10):978‐82. ">Sheftell 2004</a>, <a href="./references#MR000039-bbs2-0028" title="SpilkerAV , KesslerJM . Comparison of symptoms elicited by checklist and fill‐in‐the‐blank questionnaires. Pharmacoepidemiology News1987;22:272‐7. ">Spilker 1987</a>) and one an open question on a daily diary (D) as a gold standard (<a href="./references#MR000039-bbs2-0010" title="DeVriesST , Haaijer‐RuskampFM , DeZeeuwD , DenigP . The validity of a patient‐reported adverse drug event questionnaire using different recall periods. Quality of Life Research2014;23(9):2439‐45. ">De Vries 2014</a>). Other comparisons involved rating scales (R), such as visual analogue scales (VAS), that used a particular change over time to determine the incidence of an AE (e.g. the Brief Suicide Severity Rating Scale used by <a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a>) or was simply reported as a mm change (e.g. <a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a>). Two studies conducted interviews (INT) with participants (<a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a>, <a href="./references#MR000039-bbs2-0019" title="MonteiroWO , NoshirvaniHF , MarksIM , LelliottPT . Anorgasmia from clomipramine in obsessive‐compulsive disorder. A controlled trial. British Journal of Psychiatry1987;151:107‐12. ">Monteiro 1987</a>). The comparisons other than O/B/D versus CL were: O versus R (<a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a>, <a href="./references#MR000039-bbs2-0016" title="KruftB , NelsonLA , StewartJA , StewartWC . Adverse event reporting. Ophthalmology2007;114(7):1420. ">Kruft 2007</a>, <a href="./references#MR000039-bbs2-0017" title="LandénM , HögbergP , ThaseME . Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Journal of Clinical Psychiatry2005;66(1):100‐6. ">Landén 2005</a>, <a href="./references#MR000039-bbs2-0033" title="YeoWW , MacleanD , RichardsonPJ , RamsayLE . Cough and enalapril: assessment by spontaneous reporting and visual analogue scale under double‐blind conditions. British Journal Clinical Pharmacology1991;31(3):356‐9. ">Yeo 1991</a>), CL versus another CL (<a href="./references#MR000039-bbs2-0009" title="DeVriesST , MolPG , DeZeeuwD , Haaijer‐RuskampFM , DenigP . Development and initial validation of a patient‐reported adverse drug event questionnaire. Drug Safety2013;36(9):765‐77. ">De Vries 2013</a>, specifically the impact of using body categories on reporting), CL versus R (<a href="./references#MR000039-bbs2-0018" title="LundbergPK . Assessment of drugs' side effects: Visual Analogue Scale versus check‐list format. Perceptual and Motor Skills1980;50(3):1067‐73. ">Lundberg 1980</a>, <a href="./references#MR000039-bbs2-0030" title="WallanderMA , DimenäsE , SvärdsuddK , WiklundI . Evaluation of three methods of symptom reporting in a clinical trial of felodipine. European Journal of Clinical Pharmacology1991;41(3):187‐96. ">Wallander 1991</a>), O versus CL versus another CL (<a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a>), O versus CL versus R (<a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a>), O versus another type of O versus CL (<a href="./references#MR000039-bbs2-0005" title="BentS , PadulaA , AvinsAL . Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Annals of Internal Medicine2006;144(4):257‐61. ">Bent 2006</a>), O versus CL versus INT (<a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a> [in a subset of participants only], <a href="./references#MR000039-bbs2-0019" title="MonteiroWO , NoshirvaniHF , MarksIM , LelliottPT . Anorgasmia from clomipramine in obsessive‐compulsive disorder. A controlled trial. British Journal of Psychiatry1987;151:107‐12. ">Monteiro 1987</a>)), and B versus B versus CL (<a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a>). </p> <p>The detail of questioning (e.g. phraseology of O, the number and type of specific symptoms or body systems asked about in CL), and how methods were developed and applied (e.g. verbal, written, or electronic) varied widely within these comparisons. See <a href="#MR000039-tbl-0001">Table 1</a> for more information. </p> <div class="table" id="MR000039-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of questioning methods</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Description</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Development</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Open questions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Questions about health and medicine use without reference to particular conditions, body systems, or treatments. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal. Answers probed according to common clinical practice in eliciting a medical and treatment history. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have you noticed any change in bodily function or had any physical complaints in the past week?". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0003" title="BarberBL , SantanelloNC . Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. International Journal of Clinical Pharmacology and Therapeutics1995;33(11):598‐604. ">Barber 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants instructed to call if they experienced AE and asked at visits if they had experienced AE. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Passive and verbal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0004" title="BarrowmanJA , HerxheimerA , KitsTP . Unwanted effects of pentagastrin. Clinical Pharmacology and Therapeutics1970;11(6):862‐8. ">Barrowman 1970</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asked to describe any unusual sensation.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0005" title="BentS , PadulaA , AvinsAL . Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Annals of Internal Medicine2006;144(4):257‐61. ">Bent 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>“Did you have any significant medical problem since the last study visit?”). If “yes”, asked to identify. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐administered, recorded by study assistant on checklist.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0005" title="BentS , PadulaA , AvinsAL . Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Annals of Internal Medicine2006;144(4):257‐61. ">Bent 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>“Since the last study visit, have you limited your usual daily activities for more than 1 day because of a medical problem?”). If “yes”, asked to identify. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐administered, recorded by study assistant on checklist.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0006" title="BorghiC , PallaviniG , ComiD , GrilloM , LombardoM , ManteroO , et al. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy. International Journal of Clinical Pharmacology, Therapy and Toxicology1984;22(6):324‐8. ">Borghi 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No detail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No detail</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spontaneous reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0011" title="DowningRW , RickelsK , MeyersF . Side reactions in neurotics. I. A comparison of two methods of assessment. Journal of Clinical Pharmacology and the Journal of New Drugs1970;10(5):289‐97. ">Downing 1970</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"How are you feeling?". If no reference to drug‐related symptomology: "How else are you feeling?" then "How does the drug make you feel?". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Has ____ had any physical or health problems since….? I'm talking about something that started to become a problem during this time or an old problem that got much worse.", "Have there been activities that ____ didn't do as often or that he/she didn't do at all because of not feeling well since _____?", "Since ____, has ____ said that his/her body feels funny... or that he/she has any aches or pains... or that some part of him/her hurts or doesn't feel well?" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Constructed from an existing instrument (SAFTEE) as a scripted interview, with instructions, demographic queries and a glossary of preferred AE terms. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0013" title="HermansL , DeblanderA , DeKeyserP , ScheysI , LesaffreE , WestelinckKJ . At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild‐to‐moderate hypertension: a double‐blind, randomized, parallel‐group study. British Journal of Clinical Pharmacology1994;38(4):335‐40. ">Hermans 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"How have you felt since your last visit?"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have you noticed any new symptoms which might be related to the treatment?"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0015" title="JacobsonAF , GoldsteinBJ , DominguezRA , SteinbookRM . Interrater agreement and reliability measures of SAFTEE: general inquiry vs. systematic inquiry. Psychopharmacology Bulletin1987;23(1):97‐101. ">Jacobson 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have you had any physical or health problems during the past week (or specified assessment interval)? Have you noticed any changes in your physical appearance during the past week (or specified assessment interval)? Have you cut down on the things you usually do because of not feeling well physically during the past week (or specified assessment interval)?" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal structured interview</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAFTEE developed by the National Institute of Mental Health. This study part of validation exercise. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0016" title="KruftB , NelsonLA , StewartJA , StewartWC . Adverse event reporting. Ophthalmology2007;114(7):1420. ">Kruft 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"How are you doing since your last visit?".</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0017" title="LandénM , HögbergP , ThaseME . Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Journal of Clinical Psychiatry2005;66(1):100‐6. ">Landén 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐leading question such as: "Have you felt different in any way since you started the new treatment?" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0019" title="MonteiroWO , NoshirvaniHF , MarksIM , LelliottPT . Anorgasmia from clomipramine in obsessive‐compulsive disorder. A controlled trial. British Journal of Psychiatry1987;151:107‐12. ">Monteiro 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spontaneous reports.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0020" title="NichollsDP , HusainiMH , BulpittCJ , StephensMD , ButlerAG . Comparison of labetalol and propranolol in hypertension. British Journal of Clinical Pharmacology1980;9(3):233‐7. ">Nicholls 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spontaneous reports.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0021" title="O'ConnellK , DavisAR , KernsJ . Oral contraceptives: side effects and depression in adolescent girls. Contraception2007;75(4):299‐304. ">O'Connell 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asked to list any side effects or changes experienced.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spontaneous reports.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0023" title="Perez‐LloretS , ReyMV , FabreN , OryF , SpampinatoU , MontastrucJL , et al. Do Parkinson's disease patients disclose their adverse events spontaneously?. European Journal of Clinical Pharmacology2012;68(5):857‐65. ">Perez‐Lloret 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have you noticed any unpleasant effects of your medications during the previous week?"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have you had any physical or health problems during the past week (or specified assessment interval)? Have you noticed any changes in your physical appearance during the past week (or specified assessment interval)? Have you cut down on the things you usually do because of not feeling well physically during the past week (or specified assessment interval)?" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal structured interview</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAFTEE developed by the National Institute of Mental Health. Additional 11 items research team's own choice. Severity subjectively graded and action taken noted. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0025" title="ReillyMC , ZbrozekAS . Assessing the responsiveness of a quality‐of‐life instrument and the measurement of symptom severity in essential hypertension. Pharmacoeconomics1992;2(1):54‐66. ">Reilly 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asked about any health‐related symptoms or problems.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0026" title="RosenthalJ , BahrmannH , BenkertK , BaumgartP , BönnerG , KleinG , et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta‐blocker. Cardiology1996;87(5):409‐14. ">Rosenthal 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physician interview concerning general status of symptoms, development of signs (e.g. rash, swelling, bruises). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0029" title="TörökE , KósaE , SzontaghM , JuvanczP , EggenhoferJ , BorvendégJ . Comparison of methods to detect side‐effect on clinical application of chloranolol, a beta‐adrenergic receptor inhibitor. European Journal of Clinical Pharmacology1984;26(5):555‐62. ">Török 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spontaneous reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0030" title="WallanderMA , DimenäsE , SvärdsuddK , WiklundI . Evaluation of three methods of symptom reporting in a clinical trial of felodipine. European Journal of Clinical Pharmacology1991;41(3):187‐96. ">Wallander 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have you had any health problems since we first met?"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0031" title="WallinJ , SjövallJ . Detection of adverse drug reactions in a clinical trial using two types of questioning. Clinical Therapeutics1981;3(6):450‐2. ">Wallin 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have you had any troubles from the drug?"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0032" title="WernickeJF , FariesD , MiltonD , WeyrauchK . Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Safety2005;28(11):1057‐63. ">Wernicke 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asked to report experiences in own words.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0033" title="YeoWW , MacleanD , RichardsonPJ , RamsayLE . Cough and enalapril: assessment by spontaneous reporting and visual analogue scale under double‐blind conditions. British Journal Clinical Pharmacology1991;31(3):356‐9. ">Yeo 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have the tablets upset you in any way?"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Blank forms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0006" title="BorghiC , PallaviniG , ComiD , GrilloM , LombardoM , ManteroO , et al. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy. International Journal of Clinical Pharmacology, Therapy and Toxicology1984;22(6):324‐8. ">Borghi 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blank card to report signs and symptoms experienced.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐completed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open‐ended questionnaire with 3 entry lines.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open‐ended questionnaire with 10 entry lines.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0028" title="SpilkerAV , KesslerJM . Comparison of symptoms elicited by checklist and fill‐in‐the‐blank questionnaires. Pharmacoepidemiology News1987;22:272‐7. ">Spilker 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Questionnaire with 15 blank spaces to complete about demographics, tobacco, and alcohol use, symptoms experienced, treatments used. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐completed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0027" title="SheftellFD , FeleppaM , TepperSJ , RapoportAM , CiannellaL , BigalM . Assessment of adverse events associated with triptans ‐ methods of assessment influence the results. Headache2004;44(10):978‐82. ">Sheftell 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asked if they had AEs when using drug. If yes, asked to list and grade severity.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Checklists</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potential health issues and medicines by10 body systems, 28 symptoms, 17 medicines in total for both trials together. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal enquiry. Answers probed according to common clinical practice in eliciting a medical and treatment history. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A majority of fields were common between the 2 trials, although they could not be harmonised fully. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible drug side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>National Institute of Mental Health study checklist (NB assumed not all were asked).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0003" title="BarberBL , SantanelloNC . Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. International Journal of Clinical Pharmacology and Therapeutics1995;33(11):598‐604. ">Barber 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Common side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interviewer‐administered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Validated questionnaire for capturing frequency and bother of ocular and other local effects, effects on visual function of topical therapy for lowering intraocular pressure. Also, extent to which side effects and associated limitations in routine living activities interfere with health‐related quality of life, medication compliance, and participant satisfaction with the medication. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0004" title="BarrowmanJA , HerxheimerA , KitsTP . Unwanted effects of pentagastrin. Clinical Pharmacology and Therapeutics1970;11(6):862‐8. ">Barrowman 1970</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal enquiry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symptoms known or suspected to occur after pentagastrin, and some control items (headache, dryness of mouth, increased salivation). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0005" title="BentS , PadulaA , AvinsAL . Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Annals of Internal Medicine2006;144(4):257‐61. ">Bent 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>“Since the last visit, have you experienced any of the following?”: 53 symptoms, grouped by anatomical region. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐administered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Developed after a unpublished review of checklists used in earlier trials at same institution. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0006" title="BorghiC , PallaviniG , ComiD , GrilloM , LombardoM , ManteroO , et al. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy. International Journal of Clinical Pharmacology, Therapy and Toxicology1984;22(6):324‐8. ">Borghi 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49 items requiring yes/no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐completed (sequence changed each visit)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharmacological unwanted effects linked to the most common antihypertensive drugs, mainly ß‐blockers and diuretics. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 items</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0009" title="DeVriesST , MolPG , DeZeeuwD , Haaijer‐RuskampFM , DenigP . Development and initial validation of a patient‐reported adverse drug event questionnaire. Drug Safety2013;36(9):765‐77. ">De Vries 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse drug events (ADEs) categorised in 16 body categories</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Email invite for Internet‐based self‐administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Content validation of common ADEs drafted in layman terms with reference to CTCAE v 4.0, existing symptom and ADE checklists, then coded, categorised into body categories using MedDRA® classifications. Open‐ended option for 'other', questions relating to duration, frequency, seriousness, and causality based on literature. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0009" title="DeVriesST , MolPG , DeZeeuwD , Haaijer‐RuskampFM , DenigP . Development and initial validation of a patient‐reported adverse drug event questionnaire. Drug Safety2013;36(9):765‐77. ">De Vries 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse drug events not categorised in body categories</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Email invite for Internet‐based self‐administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Content validation of common ADEs drafted in layman terms with reference to CTCAE v 4.0, existing symptom and ADE checklists, then coded, categorised into body categories using MedDRA® classifications. Open‐ended option for 'other', questions relating to duration, frequency, seriousness, and causality based on literature. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0010" title="DeVriesST , Haaijer‐RuskampFM , DeZeeuwD , DenigP . The validity of a patient‐reported adverse drug event questionnaire using different recall periods. Quality of Life Research2014;23(9):2439‐45. ">De Vries 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse drug events (symptoms in lay terms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Email invite for Internet‐based self‐administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Content validation of common ADEs drafted in layman terms with reference to CTCAE v 4.0, existing symptom and ADE checklists, then coded, categorised into body categories using MedDRA® classifications. Open‐ended option for 'other', questions relating to duration, frequency, seriousness, and causality based on literature. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0011" title="DowningRW , RickelsK , MeyersF . Side reactions in neurotics. I. A comparison of two methods of assessment. Journal of Clinical Pharmacology and the Journal of New Drugs1970;10(5):289‐97. ">Downing 1970</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28‐item questionnaire. If AE reported, participant asked to estimate intensity, discomfort, and whether symptom was felt due to study medicine. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Structured interview using a coding sheet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 common medication effects, and 5 highly unlikely to be related captured as miscellaneous.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drug‐specific inquiry ‐ 18 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal enquiry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Constructed from an existing instrument (SAFTEE) as a scripted interview, with instructions, demographic queries, and a glossary of preferred AE terms. Clinically important AEs for various medicines. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Body system review ‐ 24 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal enquiry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Constructed from an existing instrument (SAFTEE) as a scripted interview, with instructions, demographic queries, and a glossary of preferred AE terms. Clinically important AEs for various medicines. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0013" title="HermansL , DeblanderA , DeKeyserP , ScheysI , LesaffreE , WestelinckKJ . At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild‐to‐moderate hypertension: a double‐blind, randomized, parallel‐group study. British Journal of Clinical Pharmacology1994;38(4):335‐40. ">Hermans 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐completed written questionnaire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticipated side effects of dihydropyridine calcium antagonists (swollen ankles, headache, flushing, palpitations, dizziness, or nausea). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 possible side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tinnitus, deafness, gastrointestinal complaints, and others with no obvious relevance.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0015" title="JacobsonAF , GoldsteinBJ , DominguezRA , SteinbookRM . Interrater agreement and reliability measures of SAFTEE: general inquiry vs. systematic inquiry. Psychopharmacology Bulletin1987;23(1):97‐101. ">Jacobson 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Review of 23 body systems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal structured interview</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAFTEE developed by the National Institute of Mental Health. This study part of validation exercise. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0016" title="KruftB , NelsonLA , StewartJA , StewartWC . Adverse event reporting. Ophthalmology2007;114(7):1420. ">Kruft 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ophthalmic symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0018" title="LundbergPK . Assessment of drugs' side effects: Visual Analogue Scale versus check‐list format. Perceptual and Motor Skills1980;50(3):1067‐73. ">Lundberg 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somesthetic Inventory: 54 body feelings (NB 9 fillers assessed through a visual analogue scale). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐completed ‐ participants asked to 'attune to inner stimuli', close eyes and determine how body felt. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Compilation and organisation of data on side effects of antihistamines</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0019" title="MonteiroWO , NoshirvaniHF , MarksIM , LelliottPT . Anorgasmia from clomipramine in obsessive‐compulsive disorder. A controlled trial. British Journal of Psychiatry1987;151:107‐12. ">Monteiro 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐rated physical symptom questionnaire (including sexual function items)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0020" title="NichollsDP , HusainiMH , BulpittCJ , StephensMD , ButlerAG . Comparison of labetalol and propranolol in hypertension. British Journal of Clinical Pharmacology1980;9(3):233‐7. ">Nicholls 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐administered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0021" title="O'ConnellK , DavisAR , KernsJ . Oral contraceptives: side effects and depression in adolescent girls. Contraception2007;75(4):299‐304. ">O'Connell 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 specific side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs commonly attributed to oral contraceptives, including headache, nausea, acne, abdominal pain, back pain, vomiting, breast tenderness, breast enlargement, mood swings, weight gain, premenstrual syndrome, and irregular bleeding. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 symptomatic side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Direct questioning to be answered 'yes' or 'no'.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Part of the ASPECT Scale ‐ a tool for evaluation of 34 commonly experienced symptomatic side effects of cardiovascular drugs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0023" title="Perez‐LloretS , ReyMV , FabreN , OryF , SpampinatoU , MontastrucJL , et al. Do Parkinson's disease patients disclose their adverse events spontaneously?. European Journal of Clinical Pharmacology2012;68(5):857‐65. ">Perez‐Lloret 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Predefined list of AEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal structured enquiry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pre‐defined list of most common ADRs to various anti‐Parkinson's Disease drugs from a literature search critically reviewed by a group of PD and pharmacovigilance specialists for consensus: general, GI, urinary, neuropsychiatric, dermatologic. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 body systems plus additional 11 items to represent side effects of MAOIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal structured interview</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAFTEE developed by the National Institute of Mental Health. Additional 11 items research team's own choice. Severity subjectively graded, and action taken noted. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0025" title="ReillyMC , ZbrozekAS . Assessing the responsiveness of a quality‐of‐life instrument and the measurement of symptom severity in essential hypertension. Pharmacoeconomics1992;2(1):54‐66. ">Reilly 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 symptoms associated with hypertension and anti‐hypertensive therapy (previously used). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0026" title="RosenthalJ , BahrmannH , BenkertK , BaumgartP , BönnerG , KleinG , et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta‐blocker. Cardiology1996;87(5):409‐14. ">Rosenthal 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Signs and symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐administered written questionnaire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formulated to elicit information concerning the appearance of signs and symptoms that could be related to ACE inhibitors or a beta‐blocker, and any other symptoms that may reflect well‐being. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0027" title="SheftellFD , FeleppaM , TepperSJ , RapoportAM , CiannellaL , BigalM . Assessment of adverse events associated with triptans ‐ methods of assessment influence the results. Headache2004;44(10):978‐82. ">Sheftell 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49 possible AEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mostly known Triptan side effects and some confounders (side effects not expected to be related with triptans). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0028" title="SpilkerAV , KesslerJM . Comparison of symptoms elicited by checklist and fill‐in‐the‐blank questionnaires. Pharmacoepidemiology News1987;22:272‐7. ">Spilker 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐completed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0029" title="TörökE , KósaE , SzontaghM , JuvanczP , EggenhoferJ , BorvendégJ . Comparison of methods to detect side‐effect on clinical application of chloranolol, a beta‐adrenergic receptor inhibitor. European Journal of Clinical Pharmacology1984;26(5):555‐62. ">Török 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 anticipated and other side effects</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0030" title="WallanderMA , DimenäsE , SvärdsuddK , WiklundI . Evaluation of three methods of symptom reporting in a clinical trial of felodipine. European Journal of Clinical Pharmacology1991;41(3):187‐96. ">Wallander 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have you had any of the following symptoms in the past month?"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Used in previous population studies, includes depression, tension, head, heart, lung, metabolism, musculoskeletal system, GI, and urinary tracts. Participants placed in an envelope and advised the physician would not have access. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0031" title="WallinJ , SjövallJ . Detection of adverse drug reactions in a clinical trial using two types of questioning. Clinical Therapeutics1981;3(6):450‐2. ">Wallin 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have you noticed any of the following reactions: diarrhoea, nausea, vomiting, other gastrointestinal disturbances, skin eruptions, or other troubles?" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0032" title="WernickeJF , FariesD , MiltonD , WeyrauchK . Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Safety2005;28(11):1057‐63. ">Wernicke 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Side Effects Checklist (child trial), BBAEQ‐M (child/adolescent trial), AMDP‐5 (adult trial). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Side Effects Checklist is based on the Subjective Treatment Emergent Symtpoms Scale (US National Institute of Mental Health) ‐ 30 items including general symptoms such as trouble sleeping, diarrhoea, headache, trouble eating. BBAEQ‐M: 24 items rated 0 to 9, AMDP‐5: 47 items rated 0 to ‐3. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Rating scales</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brief Suicide Severity Rating Scale: rating of suicidal ideation 0 to 5 and rating of suicidal behavior 0 to 5 using Columbia Classification Algorithm of Suicide Assessment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Published validated instruments</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0016" title="KruftB , NelsonLA , StewartJA , StewartWC . Adverse event reporting. Ophthalmology2007;114(7):1420. ">Kruft 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Visual analogue scales (VAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some VAS were validated instruments, details unknown</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0017" title="LandénM , HögbergP , ThaseME . Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Journal of Clinical Psychiatry2005;66(1):100‐6. ">Landén 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UKU side effect rating scale (none, mild, moderate, severe) for 3 symptoms of sexual dysfunction </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UKU is a validated instrument</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0018" title="LundbergPK . Assessment of drugs' side effects: Visual Analogue Scale versus check‐list format. Perceptual and Motor Skills1980;50(3):1067‐73. ">Lundberg 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Side Effects Report of 24 terms assessed with VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐completed ‐ definitions provided to participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arbitrarily selected terms</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Completed by participant and spouse independently</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0030" title="WallanderMA , DimenäsE , SvärdsuddK , WiklundI . Evaluation of three methods of symptom reporting in a clinical trial of felodipine. European Journal of Clinical Pharmacology1991;41(3):187‐96. ">Wallander 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41‐item VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Validated instrument, highly correlated items in 6 domains, rest single items</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0033" title="YeoWW , MacleanD , RichardsonPJ , RamsayLE . Cough and enalapril: assessment by spontaneous reporting and visual analogue scale under double‐blind conditions. British Journal Clinical Pharmacology1991;31(3):356‐9. ">Yeo 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS (cough)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Diary</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0010" title="DeVriesST , Haaijer‐RuskampFM , DeZeeuwD , DenigP . The validity of a patient‐reported adverse drug event questionnaire using different recall periods. Quality of Life Research2014;23(9):2439‐45. ">De Vries 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open‐ended question asking for symptoms experienced and closed‐ended question about attribution to any drug taken. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paper‐based</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>In‐depth interview</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prompted narrative of participant’s trial experience, reflection on previous ill health, and medicines used and photographs of typical over‐the‐counter and traditional medicines available to the study populations. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal interview</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0019" title="MonteiroWO , NoshirvaniHF , MarksIM , LelliottPT . Anorgasmia from clomipramine in obsessive‐compulsive disorder. A controlled trial. British Journal of Psychiatry1987;151:107‐12. ">Monteiro 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stuctured interview</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal interview</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>ADE: adverse drug event<br/> ADR: adverse drug reaction<br/> AE: adverse event<br/> AMDP‐5: Assessment and documentation of psychopathology<br/> ASPECT: Assessment of symptoms and psychological effects in cardiovascular therapy<br/> BBAEQ‐M: Barkley behavior and adverse events questionnaire‐modified<br/> CTCAE: Common terminology ceriteria for adverse events<br/> GI: general inquiry<br/> MAOI: monoamine oxidase inhibitor<br/> MedDRA: Medical dictionary for regulatory activities<br/> SAFTEE: Systematic assessment for treatment emergent events<br/> UKU: dvalg for Kliniske Undersøgelser<br/> VAS: visual analogue scale</sup> </p> </div> </div> <p>Due to the variety of indications and interventions/treatments, and whether comparisons were within clinical trials or not, the timeline over which the elicitation methods were applied and how often they were applied were diverse. Some studies compared data elicited on one visit occasion only, while other studies used data from multiple visit occasions, which were combined or reported separately. </p> </section> <section id="MR000039-sec-0067"> <h6 class="title">Outcomes</h6> <p>In addition to differences in participants, therapeutic areas, comparisons, data and follow‐up period, the disparate approaches to measuring and reporting outcomes supported our decision not to pool results. </p> <section id="MR000039-sec-0068"> <p><b>Number of AEs reported</b></p> <p>Several studies reported the number or proportion of AEs, or both, elicited by method at, or by, a particular time‐point. These were either given as a sum total of all AEs, by type of AE or the raw data were listed by method. However, three studies only gave the number (%) of participants reporting no versus at least one or two AEs (<a href="./references#MR000039-bbs2-0011" title="DowningRW , RickelsK , MeyersF . Side reactions in neurotics. I. A comparison of two methods of assessment. Journal of Clinical Pharmacology and the Journal of New Drugs1970;10(5):289‐97. ">Downing 1970</a>, <a href="./references#MR000039-bbs2-0017" title="LandénM , HögbergP , ThaseME . Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Journal of Clinical Psychiatry2005;66(1):100‐6. ">Landén 2005</a>) or the mean/median (range, standard deviation) number of AEs per participant (<a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a>, <a href="./references#MR000039-bbs2-0011" title="DowningRW , RickelsK , MeyersF . Side reactions in neurotics. I. A comparison of two methods of assessment. Journal of Clinical Pharmacology and the Journal of New Drugs1970;10(5):289‐97. ">Downing 1970</a>). Other variations included <a href="./references#MR000039-bbs2-0004" title="BarrowmanJA , HerxheimerA , KitsTP . Unwanted effects of pentagastrin. Clinical Pharmacology and Therapeutics1970;11(6):862‐8. ">Barrowman 1970</a> and <a href="./references#MR000039-bbs2-0003" title="BarberBL , SantanelloNC . Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. International Journal of Clinical Pharmacology and Therapeutics1995;33(11):598‐604. ">Barber 1995</a>, who calculated an average frequency of a particular domain for participants who did not report any AEs spontaneously (O) but indicated an AE by CL, and <a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a>, who presented AEs only as a score calculated from a severity rating scale. <a href="./references#MR000039-bbs2-0016" title="KruftB , NelsonLA , StewartJA , StewartWC . Adverse event reporting. Ophthalmology2007;114(7):1420. ">Kruft 2007</a> performed a meta‐analysis of four studies where the outcome was presented as the number and proportion of participants reporting AEs. <a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a> presented frequencies of AEs for two of the three methods compared, but presented the third method (R) as a change in VAS measurement. </p> <p>Three of the within‐participant comparison studies only gave the number of additional AEs obtained through the second or third method (i.e. capturing AEs only when they were first elicited), rather than absolute numbers of AEs obtained by each method (<a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a>, <a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a>, <a href="./references#MR000039-bbs2-0031" title="WallinJ , SjövallJ . Detection of adverse drug reactions in a clinical trial using two types of questioning. Clinical Therapeutics1981;3(6):450‐2. ">Wallin 1981</a>). <a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a> combined all AEs that were not auditory or gastrointestinal in nature as 'irrelevant' and reported them as a combined frequency/severity score. <a href="./references#MR000039-bbs2-0019" title="MonteiroWO , NoshirvaniHF , MarksIM , LelliottPT . Anorgasmia from clomipramine in obsessive‐compulsive disorder. A controlled trial. British Journal of Psychiatry1987;151:107‐12. ">Monteiro 1987</a> limited the comparison to participants who had not reported an AE by CL but had reported at least one AE either spontaneously (by O) or by INT. </p> <p>Statistical tests of effect by elicitation method, where used, mostly included Chi<sup>2</sup> and Mann‐Whitney U tests. However, <a href="./references#MR000039-bbs2-0009" title="DeVriesST , MolPG , DeZeeuwD , Haaijer‐RuskampFM , DenigP . Development and initial validation of a patient‐reported adverse drug event questionnaire. Drug Safety2013;36(9):765‐77. ">De Vries 2013</a> also used normal curve deviate statistics (Z value) for the measure of agreement between methods, and <a href="./references#MR000039-bbs2-0010" title="DeVriesST , Haaijer‐RuskampFM , DeZeeuwD , DenigP . The validity of a patient‐reported adverse drug event questionnaire using different recall periods. Quality of Life Research2014;23(9):2439‐45. ">De Vries 2014</a> calculated the sensitivity and positive predictive value at different MedDRA® reporting levels. <a href="./references#MR000039-bbs2-0030" title="WallanderMA , DimenäsE , SvärdsuddK , WiklundI . Evaluation of three methods of symptom reporting in a clinical trial of felodipine. European Journal of Clinical Pharmacology1991;41(3):187‐96. ">Wallander 1991</a> investigated the ability of each method to detect symptoms that changed over time and sensitivity to change, while <a href="./references#MR000039-bbs2-0023" title="Perez‐LloretS , ReyMV , FabreN , OryF , SpampinatoU , MontastrucJL , et al. Do Parkinson's disease patients disclose their adverse events spontaneously?. European Journal of Clinical Pharmacology2012;68(5):857‐65. ">Perez‐Lloret 2012</a> analysed factors related to spontaneous reporting of AEs. </p> <p>Seventeen studies presented comparative data by study group, either descriptively or through measures of effect (<a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a>, <a href="./references#MR000039-bbs2-0004" title="BarrowmanJA , HerxheimerA , KitsTP . Unwanted effects of pentagastrin. Clinical Pharmacology and Therapeutics1970;11(6):862‐8. ">Barrowman 1970</a>, <a href="./references#MR000039-bbs2-0006" title="BorghiC , PallaviniG , ComiD , GrilloM , LombardoM , ManteroO , et al. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy. International Journal of Clinical Pharmacology, Therapy and Toxicology1984;22(6):324‐8. ">Borghi 1984</a>, <a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a>, <a href="./references#MR000039-bbs2-0011" title="DowningRW , RickelsK , MeyersF . Side reactions in neurotics. I. A comparison of two methods of assessment. Journal of Clinical Pharmacology and the Journal of New Drugs1970;10(5):289‐97. ">Downing 1970</a>, <a href="./references#MR000039-bbs2-0013" title="HermansL , DeblanderA , DeKeyserP , ScheysI , LesaffreE , WestelinckKJ . At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild‐to‐moderate hypertension: a double‐blind, randomized, parallel‐group study. British Journal of Clinical Pharmacology1994;38(4):335‐40. ">Hermans 1994</a>, <a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a>, <a href="./references#MR000039-bbs2-0017" title="LandénM , HögbergP , ThaseME . Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Journal of Clinical Psychiatry2005;66(1):100‐6. ">Landén 2005</a>, <a href="./references#MR000039-bbs2-0018" title="LundbergPK . Assessment of drugs' side effects: Visual Analogue Scale versus check‐list format. Perceptual and Motor Skills1980;50(3):1067‐73. ">Lundberg 1980</a>, <a href="./references#MR000039-bbs2-0019" title="MonteiroWO , NoshirvaniHF , MarksIM , LelliottPT . Anorgasmia from clomipramine in obsessive‐compulsive disorder. A controlled trial. British Journal of Psychiatry1987;151:107‐12. ">Monteiro 1987</a>, <a href="./references#MR000039-bbs2-0020" title="NichollsDP , HusainiMH , BulpittCJ , StephensMD , ButlerAG . Comparison of labetalol and propranolol in hypertension. British Journal of Clinical Pharmacology1980;9(3):233‐7. ">Nicholls 1980</a>, <a href="./references#MR000039-bbs2-0021" title="O'ConnellK , DavisAR , KernsJ . Oral contraceptives: side effects and depression in adolescent girls. Contraception2007;75(4):299‐304. ">O'Connell 2007</a>, <a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a>, <a href="./references#MR000039-bbs2-0025" title="ReillyMC , ZbrozekAS . Assessing the responsiveness of a quality‐of‐life instrument and the measurement of symptom severity in essential hypertension. Pharmacoeconomics1992;2(1):54‐66. ">Reilly 1992</a>, <a href="./references#MR000039-bbs2-0026" title="RosenthalJ , BahrmannH , BenkertK , BaumgartP , BönnerG , KleinG , et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta‐blocker. Cardiology1996;87(5):409‐14. ">Rosenthal 1996</a>, <a href="./references#MR000039-bbs2-0030" title="WallanderMA , DimenäsE , SvärdsuddK , WiklundI . Evaluation of three methods of symptom reporting in a clinical trial of felodipine. European Journal of Clinical Pharmacology1991;41(3):187‐96. ">Wallander 1991</a>, <a href="./references#MR000039-bbs2-0032" title="WernickeJF , FariesD , MiltonD , WeyrauchK . Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Safety2005;28(11):1057‐63. ">Wernicke 2005</a>). However, the data in <a href="./references#MR000039-bbs2-0019" title="MonteiroWO , NoshirvaniHF , MarksIM , LelliottPT . Anorgasmia from clomipramine in obsessive‐compulsive disorder. A controlled trial. British Journal of Psychiatry1987;151:107‐12. ">Monteiro 1987</a> could not be extracted for both study groups. <a href="./references#MR000039-bbs2-0032" title="WernickeJF , FariesD , MiltonD , WeyrauchK . Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Safety2005;28(11):1057‐63. ">Wernicke 2005</a> used the ratio between the rate of AEs reported by drug versus placebo (D/P) plotted for solicited AEs on an x‐axis against spontaneous AEs on a y‐axis, and the ratio of D/P ratios. <a href="./references#MR000039-bbs2-0018" title="LundbergPK . Assessment of drugs' side effects: Visual Analogue Scale versus check‐list format. Perceptual and Motor Skills1980;50(3):1067‐73. ">Lundberg 1980</a> used an analysis of variance for data in each method arm reported by at least 50% of the sample, however, only summary descriptions were available for the between‐method comparison results. <a href="./references#MR000039-bbs2-0017" title="LandénM , HögbergP , ThaseME . Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Journal of Clinical Psychiatry2005;66(1):100‐6. ">Landén 2005</a> and <a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a> also reported AEs by drug and gender for the elicitation methods that they compared. </p> </section> <section id="MR000039-sec-0069"> <p><b>Nature of AEs reported, including quality of life, clinical relevance, and action taken</b></p> <p>The way studies analysed and presented the effect of elicitation method on the nature of AEs reported by participants also varied. <a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a> compared mean severity score on each visit occasion (weighting symptoms by a factor derived from the degree of subjective discomfort reported by the participant). <a href="./references#MR000039-bbs2-0003" title="BarberBL , SantanelloNC . Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. International Journal of Clinical Pharmacology and Therapeutics1995;33(11):598‐604. ">Barber 1995</a> reported the average bother, level of activity limitation, satisfaction with medication, compliance, and global quality of life domain scores for those participants who did not report any spontaneous AEs (O) but did indicate on the questionnaire (CL) that they had the AE. <a href="./references#MR000039-bbs2-0011" title="DowningRW , RickelsK , MeyersF . Side reactions in neurotics. I. A comparison of two methods of assessment. Journal of Clinical Pharmacology and the Journal of New Drugs1970;10(5):289‐97. ">Downing 1970</a> compared the levels of intensity of AEs identified by CL but not O, with those detected by both methods. <a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a> reported the frequency and proportion of AEs by discomfort level, and by elicitation method; <a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a> and <a href="./references#MR000039-bbs2-0013" title="HermansL , DeblanderA , DeKeyserP , ScheysI , LesaffreE , WestelinckKJ . At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild‐to‐moderate hypertension: a double‐blind, randomized, parallel‐group study. British Journal of Clinical Pharmacology1994;38(4):335‐40. ">Hermans 1994</a> reported the number (%) of AEs by severity. <a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a> assigned a score based on whether an AE was absent, slight, moderate, or severe, thus combining frequency and severity as the only outcome. <a href="./references#MR000039-bbs2-0015" title="JacobsonAF , GoldsteinBJ , DominguezRA , SteinbookRM . Interrater agreement and reliability measures of SAFTEE: general inquiry vs. systematic inquiry. Psychopharmacology Bulletin1987;23(1):97‐101. ">Jacobson 1987</a> and <a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a> reported mean AE severity and impairment by elicitation method. <a href="./references#MR000039-bbs2-0025" title="ReillyMC , ZbrozekAS . Assessing the responsiveness of a quality‐of‐life instrument and the measurement of symptom severity in essential hypertension. Pharmacoeconomics1992;2(1):54‐66. ">Reilly 1992</a> presented the proportion bothered, the mean degree of bother per participant, and calculated a severity index score. <a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a> and <a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a> both considered the impact of elicitation method on the number of participants for whom clinical action was taken and the number (%) of AEs deemed clinically relevant. </p> <p>Two studies looked at the duration of AEs detected by different elicitation methods (<a href="./references#MR000039-bbs2-0013" title="HermansL , DeblanderA , DeKeyserP , ScheysI , LesaffreE , WestelinckKJ . At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild‐to‐moderate hypertension: a double‐blind, randomized, parallel‐group study. British Journal of Clinical Pharmacology1994;38(4):335‐40. ">Hermans 1994</a>, <a href="./references#MR000039-bbs2-0025" title="ReillyMC , ZbrozekAS . Assessing the responsiveness of a quality‐of‐life instrument and the measurement of symptom severity in essential hypertension. Pharmacoeconomics1992;2(1):54‐66. ">Reilly 1992</a>), while <a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a> measured time to onset of self‐harm AEs by elicitation method. <a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a> and <a href="./references#MR000039-bbs2-0028" title="SpilkerAV , KesslerJM . Comparison of symptoms elicited by checklist and fill‐in‐the‐blank questionnaires. Pharmacoepidemiology News1987;22:272‐7. ">Spilker 1987</a> described the most commonly reported AEs by elicitation method, while <a href="./references#MR000039-bbs2-0015" title="JacobsonAF , GoldsteinBJ , DominguezRA , SteinbookRM . Interrater agreement and reliability measures of SAFTEE: general inquiry vs. systematic inquiry. Psychopharmacology Bulletin1987;23(1):97‐101. ">Jacobson 1987</a> and <a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a> investigated categories of AEs that were reported by participants through use of different questioning methods; <a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a> specifically looked at whether certain AEs were underreported through O (e.g. sexual dysfunction) by highlighting AEs that were reported more than five times as often by CL compared to O. </p> </section> <section id="MR000039-sec-0070"> <p><b>Other relevant outcome variables</b></p> <p>Other outcomes reported for some studies related to tool validation; <a href="./references#MR000039-bbs2-0009" title="DeVriesST , MolPG , DeZeeuwD , Haaijer‐RuskampFM , DenigP . Development and initial validation of a patient‐reported adverse drug event questionnaire. Drug Safety2013;36(9):765‐77. ">De Vries 2013</a> investigated content validity through cognitive debriefing, while <a href="./references#MR000039-bbs2-0010" title="DeVriesST , Haaijer‐RuskampFM , DeZeeuwD , DenigP . The validity of a patient‐reported adverse drug event questionnaire using different recall periods. Quality of Life Research2014;23(9):2439‐45. ">De Vries 2014</a> compared four‐week versus three‐month recall periods and <a href="./references#MR000039-bbs2-0015" title="JacobsonAF , GoldsteinBJ , DominguezRA , SteinbookRM . Interrater agreement and reliability measures of SAFTEE: general inquiry vs. systematic inquiry. Psychopharmacology Bulletin1987;23(1):97‐101. ">Jacobson 1987</a> investigated interrater reliability between different trial staff. <a href="./references#MR000039-bbs2-0009" title="DeVriesST , MolPG , DeZeeuwD , Haaijer‐RuskampFM , DenigP . Development and initial validation of a patient‐reported adverse drug event questionnaire. Drug Safety2013;36(9):765‐77. ">De Vries 2013</a> also examined the feasibility and acceptability of the different elicitation methods by time to complete the CLs and asking about ease of use. <a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a> determined the proportion of clinicians and parents rating satisfaction with the elicitation methods using several domains. </p> <p><a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a> performed a thematic qualitative data analysis in terms of explanations given for differential reporting of AEs, medical history, and the use of non‐study medications, and how participants expressed themselves, exploring the emerging themes in relation to broader theories. </p> </section> </section> </section> </section> <section id="MR000039-sec-0071"> <h4 class="title">Excluded studies</h4> <p>As our search was broad out of necessity, we listed only those studies which a reader might reasonably expect to see among the included studies in the <a href="./references#MR000039-sec-0114" title="">Characteristics of excluded studies</a> table. As indicted in the <a href="#MR000039-sec-0060">Results of the search</a> above, studies were excluded if they were not relevant to the topic of the review (e.g. non‐drug studies), if only abstracts were available where there was not enough information for an assessment of eligibility (and no relevant paper was found), if there was no relevance to clinical trials, if there was no comparison of elicitation methods, or data were not presented in a way that could be extracted. For the latter, some studies at first glance appeared to make a comparison but had to be excluded because the data collected through the different elicitation methods were categorised differently. </p> </section> </section> <section id="MR000039-sec-0072"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#MR000039-tbl-0002">Table 2</a>, <a href="#MR000039-tbl-0003">Table 3</a>, <a href="#MR000039-tbl-0004">Table 4</a> and <a href="#MR000039-tbl-0005">Table 5</a>. </p> <div class="table" id="MR000039-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias (selection, performance and detection, and attrition) of included studies for within‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Selection bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Performance and detection bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Attrition bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Random sequence generation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Allocation concealment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Blinding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Incomplete outcome data assessed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allen 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. 'Possible 'priming'' by earlier method, however cumulative data was part of the study. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared all participants completed all methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barber 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. 'Possible 'priming'' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A few dropouts, unlikely related to methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barrowman 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. 'Possible 'priming'' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared all participants completed all methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>De Vries 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence by two groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. 'Possible 'priming'' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A few dropouts, unlikely related to methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>De Vries 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. 'Possible 'priming'' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear whether attrition was related to method.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downing 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. 'Possible 'priming'' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared all participants completed all method.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greenhill 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. 'Priming' by earlier method, however cumulative data was part of the study. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared all participants completed all method.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hermans 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A few dropouts, unlikely related to methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jacobson 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence order of questions received by two groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kruft 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Landen 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared all participants completed all methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lundberg 1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared all participants completed all methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Montiero 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A few dropouts, unlikely related to methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nicholls 1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear why different numbers of participants for 2 methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O'Connell 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared that all participants completed all methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Os 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some dropouts but unlikely related to method.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perez‐Lloret 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared that all participants completed all methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rabkin 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared that all participants completed all methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reilly 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some dropouts but unlikely related to method.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rosenthal 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear why fewer participants for method 2; could be related to matching of symptoms between methods. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sheftell 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared that all participants completed all methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallander 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method, especially as participants took forms for both questioning methods home to complete. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant number of dropouts (45/236), potentially related to method (participants took forms for both questioning methods home to complete). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallin 1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wernicke 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yeo 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some dropouts (3 more in method 2) but unlikely related to method.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>AE: adverse event<br/> N/A: not applicable<br/> O: open question</sup> </p> </div> </div> <div class="table" id="MR000039-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Risk of bias (reporting and other) of included studies for within‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Reporting bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Other biases</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>No selective reporting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Explicit application</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allen 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Possible variations in phraseology between participants.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barber 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Possible variations in phraseology between participants..</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Queried if methods applied in same order for all participants.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barrowman 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Explicit instructions for staff to use.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>De Vries 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed explicit instructions for self‐administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>De Vries 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed explicit instructions for self‐administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downing 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only presented data that participants related to medication.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Explicit instructions for staff to use.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greenhill 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Explicit instructions for staff to use.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hermans 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed explicit instructions, particularly for self‐administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jacobson 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some overlap between data presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Explicit instructions for staff to use.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kruft 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Difficult to ascertain as short report.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meta‐analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Landen 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary data presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed explicit instructions, particularly for self‐administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lundberg 1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary data presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Explicit instructions for staff to use.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Montiero 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary data presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nicholls 1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O'Connell 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Os 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear order</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perez‐Lloret 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Explicit instructions for staff to use.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rabkin 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Explicit instructions for staff to use.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reilly 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rosenthal 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not all data presented ‐ those spontaneously‐elicited were only presented if they matched questions on the questionnaire. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sheftell 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed explicit instructions for self‐administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallander 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Although could assume explicit instructions for self‐administration of methods 2 and 3, they were completed at home so it was outside of the control of the clinic as to completion, including order. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallin 1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>May have been variations in phraseology between participants in method 2.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wernicke 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not all data presented. AEs reflecting same symptom in spontaneous and solicited methods were selected for the comparison. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>May have been variations in phraseology between participants in method 1.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meta‐analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yeo 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard O and assumed explicit instructions for self‐administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>AE: adverse event<br/> N/A: not applicable<br/> O: open question</sup> </p> </div> </div> <div class="table" id="MR000039-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Risk of bias (selection, performance and detection, and attrition) of included studies for between‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Selection bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Performance and detection bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Attrition bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Random sequence generation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Allocation concealment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Blinding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Incomplete outcome data assessed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Avery 1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information other than "arbitrarily assigned".</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided, however participants and assessors unlikely to be blinded due to the nature of study. The group who were exposed to both questioning methods may have been 'primed' by the first method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dropsouts were indicated but appeared similar between groups.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bent 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Computer‐generated prior to study. Baseline characteristics were similar between groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study personnel were blinded to the allocation.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Although participants were not informed of their group and analysts were blinded, study staff were aware of groups and were involved in completing some data. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed the study and outcome assessment.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Borghi 1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Little information provided, however the investigator was neither informed of the results of the self‐reporting, nor did they help participants fill in the forms. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Although group allocation of dropouts unclear, there were only a few.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brent 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐random allocation by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open allocation by enrolment period and nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants and assessors unlikely to be blinded due to the nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chiccolunghi 1975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Predetermined randomisation list. Baseline characteristics were similar between groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants and assessors unlikely to be blinded due to the nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant missing data, potentially related to the method as forms were distributed in the internal mail and it was left to staff to decide whether to complete and return them, although similar numbers were returned for each elicitation type (57% versus 44%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Huskisson 1974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐random allocation by study centre.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants and assessors unlikely to be blinded due to the nature of study; although groups were at different sites there may still have been room for biased assessments based on the method of questioning, and different staff may have elicited /recorded AEs differently. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spilker 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Table of random numbers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants and assessors unlikely to be blinded due to the nature of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Although group allocation of dropouts unclear, there were only a few.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Torok 1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐random allocation by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants and assessors unlikely to be blinded due to the nature of study; although groups were at different sites/in different studies, there may still have been room for biased assessments based on the method of questioning. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>AE: adverse event<br/> CL: checklist<br/> O: open question</sup> </p> </div> </div> <div class="table" id="MR000039-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Risk of bias (reporting and other) of included studies for between‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Reporting bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Other biases</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>No selective reporting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Explicit application</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Avery 1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary data presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Explicit phraseology for O. CL had specific items but not all was presented in laymans language so may have had inconsistent phraseology. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bent 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed explicit instructions for self‐administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Borghi 1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brent 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brief summary data presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Little information provided, although method 2 involved validated scales so assumed had explicit instructions on application. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear whether method 1 was used in both groups.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chiccolunghi 1975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed explicit instructions for self‐administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Large numbers of non‐responders to invitation which could be related to methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Huskisson 1974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Raw data transformed by scoring and some data grouped.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear whether method 1 used in both groups.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spilker 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed explicit instructions for self‐administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It was not stated how many were invited.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Torok 1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relevant AE data only presented for participants taking chloranolol.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>AE: adverse event<br/> CL: checklist<br/> O: open question</sup> </p> </div> </div> <section id="MR000039-sec-0073"> <h4 class="title">Allocation</h4> <p>For all 25 within‐participant comparison studies, there was a technically high risk of bias as neither random sequence generation and allocation concealment is feasible to implement in this design. However, this potential for bias was unlikely to have impacted the results substantially because all participants were exposed to all methods. For two studies, the order that participants received the questions were randomly assigned (<a href="./references#MR000039-bbs2-0009" title="DeVriesST , MolPG , DeZeeuwD , Haaijer‐RuskampFM , DenigP . Development and initial validation of a patient‐reported adverse drug event questionnaire. Drug Safety2013;36(9):765‐77. ">De Vries 2013</a>, <a href="./references#MR000039-bbs2-0015" title="JacobsonAF , GoldsteinBJ , DominguezRA , SteinbookRM . Interrater agreement and reliability measures of SAFTEE: general inquiry vs. systematic inquiry. Psychopharmacology Bulletin1987;23(1):97‐101. ">Jacobson 1987</a>). For the eight between‐participant comparisons, <a href="./references#MR000039-bbs2-0005" title="BentS , PadulaA , AvinsAL . Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Annals of Internal Medicine2006;144(4):257‐61. ">Bent 2006</a> used a computer‐generated method and blinded personnel to the allocation and therefore had a low risk of bias. <a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a> used a predetermined allocation list and <a href="./references#MR000039-bbs2-0028" title="SpilkerAV , KesslerJM . Comparison of symptoms elicited by checklist and fill‐in‐the‐blank questionnaires. Pharmacoepidemiology News1987;22:272‐7. ">Spilker 1987</a> used a table of random numbers which also reduced the risk of bias. We judged the remaining five studies as either at high risk of bias because it was clear that the allocation was not random (<a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a>, <a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a>, <a href="./references#MR000039-bbs2-0029" title="TörökE , KósaE , SzontaghM , JuvanczP , EggenhoferJ , BorvendégJ . Comparison of methods to detect side‐effect on clinical application of chloranolol, a beta‐adrenergic receptor inhibitor. European Journal of Clinical Pharmacology1984;26(5):555‐62. ">Török 1984</a>), or the allocation method was unclear (<a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a>, <a href="./references#MR000039-bbs2-0006" title="BorghiC , PallaviniG , ComiD , GrilloM , LombardoM , ManteroO , et al. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy. International Journal of Clinical Pharmacology, Therapy and Toxicology1984;22(6):324‐8. ">Borghi 1984</a>). However, where groups were determined by site (<a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a>), it may be that there was a lower risk of bias as different staff were involved. However, the latter, in itself, raises the possibility of inconsistent recording of AEs. <a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a> had a large proportion of non‐responders to the invitation to take part in their study, which may have increased the risk of bias because there may have been a selective non‐response related to a particular question method. </p> </section> <section id="MR000039-sec-0074"> <h4 class="title">Blinding</h4> <p>Of the 33 studies included in this review, only one stated that the investigator was blinded to the AE data reports being compared in the study; <a href="./references#MR000039-bbs2-0006" title="BorghiC , PallaviniG , ComiD , GrilloM , LombardoM , ManteroO , et al. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy. International Journal of Clinical Pharmacology, Therapy and Toxicology1984;22(6):324‐8. ">Borghi 1984</a> reported that the investigator was neither informed of the results of the self‐reported AEs by either the self‐completed checklist or blank form, nor did they help participants fill in the forms. It is not feasible to blind participants when they are reporting AEs, but for those taking part in studies where the comparison was between‐participants, there may have been less risk of bias from knowing which questioning method was used, as it was less likely that participants were made aware of different methods being used in different groups/sites. For the within‐participant comparisons, it was highly likely that participants were 'primed' by the first method ‐ i.e. they would be more likely to report that same AE when the second method was applied. As such, these were not independent comparisons. This was acknowledged by some study authors (<a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a>, <a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a>). The risk of bias for <a href="./references#MR000039-bbs2-0030" title="WallanderMA , DimenäsE , SvärdsuddK , WiklundI . Evaluation of three methods of symptom reporting in a clinical trial of felodipine. European Journal of Clinical Pharmacology1991;41(3):187‐96. ">Wallander 1991</a> may have been the highest because participants took forms for both questioning methods home to complete on their own (there were no details in the paper as to instructions for their order of completion so one may have prompted what to report in the other). </p> </section> <section id="MR000039-sec-0075"> <h4 class="title">Incomplete outcome data</h4> <p>Most studies had a low risk of attrition bias. However, the risk of bias in this domain was unclear in nine studies and two were considered of higher risk as they had high dropout rates and we could not be sure that these were not related to the questioning method (<a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a>, <a href="./references#MR000039-bbs2-0030" title="WallanderMA , DimenäsE , SvärdsuddK , WiklundI . Evaluation of three methods of symptom reporting in a clinical trial of felodipine. European Journal of Clinical Pharmacology1991;41(3):187‐96. ">Wallander 1991</a>). For <a href="./references#MR000039-bbs2-0030" title="WallanderMA , DimenäsE , SvärdsuddK , WiklundI . Evaluation of three methods of symptom reporting in a clinical trial of felodipine. European Journal of Clinical Pharmacology1991;41(3):187‐96. ">Wallander 1991</a>, there was a significant number of dropouts, which could potentially relate to a questioning method as participants took forms for both questioning methods home to complete and they may have decided not to bring one of the forms back due to the nature of its questions. For <a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a>, there was also a significant amount of missing data, which could potentially be related to the method of questioning as the forms were distributed by internal mail and staff decided whether or not they had completed the forms. It is possible that the decision not to complete and return a form was affected by the type of questioning (e.g. a longer form might be less likely to be completed than a shorter one). </p> </section> <section id="MR000039-sec-0076"> <h4 class="title">Selective reporting</h4> <p>Twenty studies had a low risk of selective reporting and the risk of bias in this domain was unclear in 11. Two studies were deemed high risk as they presented only a selection of data; <a href="./references#MR000039-bbs2-0026" title="RosenthalJ , BahrmannH , BenkertK , BaumgartP , BönnerG , KleinG , et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta‐blocker. Cardiology1996;87(5):409‐14. ">Rosenthal 1996</a> presented only spontaneously‐elicited AEs if they matched questions on the questionnaire that they were being compared to, and <a href="./references#MR000039-bbs2-0032" title="WernickeJF , FariesD , MiltonD , WeyrauchK . Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Safety2005;28(11):1057‐63. ">Wernicke 2005</a> selected for comparison those AEs reflecting the same symptom in the spontaneous and solicited methods (in order to calculate ratios of the rate reported for drug versus placebo). While there were clear reasons for these selections of data, it is possible that data not selected may have been informative. </p> </section> <section id="MR000039-sec-0077"> <h4 class="title">Other potential sources of bias</h4> <p>For <a href="./references#MR000039-bbs2-0003" title="BarberBL , SantanelloNC . Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. International Journal of Clinical Pharmacology and Therapeutics1995;33(11):598‐604. ">Barber 1995</a>, we were unclear whether the elicitation methods were applied in the same order for all participants, while for <a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a>, we were unclear as to how questioning methods were applied, making it impossible to assess whether the application could have biased these studies in some way. The application of elicitation methods was unclear for <a href="./references#MR000039-bbs2-0006" title="BorghiC , PallaviniG , ComiD , GrilloM , LombardoM , ManteroO , et al. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy. International Journal of Clinical Pharmacology, Therapy and Toxicology1984;22(6):324‐8. ">Borghi 1984</a>, <a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a>, <a href="./references#MR000039-bbs2-0019" title="MonteiroWO , NoshirvaniHF , MarksIM , LelliottPT . Anorgasmia from clomipramine in obsessive‐compulsive disorder. A controlled trial. British Journal of Psychiatry1987;151:107‐12. ">Monteiro 1987</a>, <a href="./references#MR000039-bbs2-0021" title="O'ConnellK , DavisAR , KernsJ . Oral contraceptives: side effects and depression in adolescent girls. Contraception2007;75(4):299‐304. ">O'Connell 2007</a>, <a href="./references#MR000039-bbs2-0020" title="NichollsDP , HusainiMH , BulpittCJ , StephensMD , ButlerAG . Comparison of labetalol and propranolol in hypertension. British Journal of Clinical Pharmacology1980;9(3):233‐7. ">Nicholls 1980</a>, <a href="./references#MR000039-bbs2-0025" title="ReillyMC , ZbrozekAS . Assessing the responsiveness of a quality‐of‐life instrument and the measurement of symptom severity in essential hypertension. Pharmacoeconomics1992;2(1):54‐66. ">Reilly 1992</a>, <a href="./references#MR000039-bbs2-0026" title="RosenthalJ , BahrmannH , BenkertK , BaumgartP , BönnerG , KleinG , et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta‐blocker. Cardiology1996;87(5):409‐14. ">Rosenthal 1996</a> and <a href="./references#MR000039-bbs2-0029" title="TörökE , KósaE , SzontaghM , JuvanczP , EggenhoferJ , BorvendégJ . Comparison of methods to detect side‐effect on clinical application of chloranolol, a beta‐adrenergic receptor inhibitor. European Journal of Clinical Pharmacology1984;26(5):555‐62. ">Török 1984</a>. Furthermore, there may have been differences in the phrasing of open questioning in <a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a> and <a href="./references#MR000039-bbs2-0003" title="BarberBL , SantanelloNC . Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. International Journal of Clinical Pharmacology and Therapeutics1995;33(11):598‐604. ">Barber 1995</a>. For the between‐participant comparisons used in <a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a> and <a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a>, it was not clear whether one group of participants were exposed to both questioning methods. <a href="./references#MR000039-bbs2-0016" title="KruftB , NelsonLA , StewartJA , StewartWC . Adverse event reporting. Ophthalmology2007;114(7):1420. ">Kruft 2007</a> and <a href="./references#MR000039-bbs2-0032" title="WernickeJF , FariesD , MiltonD , WeyrauchK . Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Safety2005;28(11):1057‐63. ">Wernicke 2005</a> were meta‐analyses where there was little information about the parent studies, so it was unclear whether there may have been some other inherent biases. Finally, all studies were limited by a lack of a true gold standard against which to assess the data reported by participants. </p> </section> </section> <section id="MR000039-sec-0078"> <h3 class="title" id="MR000039-sec-0078">Effect of methods</h3> <section id="MR000039-sec-0079"> <h4 class="title">The impact of different elicitation methods on the number of AEs reported</h4> <p>See <a href="#MR000039-tbl-0006">Table 6</a> and <a href="#MR000039-tbl-0007">Table 7</a> for details on the effects of the methods on the number of AEs reported for between‐participant comparisons; and <a href="#MR000039-tbl-0008">Table 8</a> and <a href="#MR000039-tbl-0009">Table 9</a> for details on the effects of the methods on the number of AEs reported for within‐participant comparisons. </p> <div class="table" id="MR000039-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Elicitation of the number of AEs reported for between‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Therapy area</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>AEs elicited</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Number participants</p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Number of AEs (total)</p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Number (%) participants with ≥1 AE</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Avery 1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Huskisson 1974**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rheumatology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Torok 1984***</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Various</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>537, 929</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75, 365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bent 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatic hyperplasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1 ‐ 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9(13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Borghi 1984*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxprenolol 48 (45), chlorthalidone 60 (57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxprenolol 76 (65), chlorthalidone 81 (69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spilker 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No indication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106 (80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154 (93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciccolunghi 1975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No indication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 (36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 (89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brent 2009**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐harm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicidal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (8.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (20.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐suicidal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (2.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (17.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicide attempts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (3.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (6.5)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>AE: adverse event</sup><br/> <sup>CL: checklist</sup><br/> <sup>N/A: not applicable</sup><br/> <sup>O: open question</sup><br/> <sup>vs: versus</sup><br/> <sup>R: rating scale</sup> </p> <p><sup>* All participants asked AEs by an open question (O), but as this process possibly involved 'filtering' of reports by the doctor, the data were not included in the review</sup> </p> <p><sup>** Huskisson used a composite measure of frequency and severity</sup> </p> <p><sup>*** A selection of the total AEs are presented in the review as those objectively measured were excluded</sup> </p> <p><sup>† 2‐sample test of proportions</sup> </p> <p><sup>†† 2‐sample t test</sup> </p> </div> </div> <div class="table" id="MR000039-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Effects of methods on the number of AEs reported for between‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Therapy area</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Effect (number of AEs)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By drug arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion with ≥ 1 AE†</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description (including of other effect measure if different)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Avery 1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant higher mean number of AEs at each visit by CL. See paper for details. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant higher mean number of AEs at 5 of 6 study visits by CL in the active drug arm. See paper for details. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Huskisson 1974**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rheumatology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear scoring; appears higher total score for AEs by CL than O (540 versus 409). AEs listed on CL were more frequently reported by CL than when not listed. AEs not listed on CL more frequently reported by O. See paper for details. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fenoprofen auditory, gastrointestinal I and all other ('irrelevant') AE scores 2‐3 x more frequently reported by CL than O, aspirin AE scores ranged from no difference (auditory), approx.. 1.5 x less gastrointestinal and 0.60 x more ('irrelevant') using O compared to CL. See paper for details. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Torok 1984***</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Various</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower number of AEs per 100 participants by O compared to CL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bent 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatic hyperplasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1 ‐ 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OvsO 0.14 (‐0.10; 0.12) P = 0.805, OvsCL ‐0.63 (‐0.75; ‐0.50) P = 0.000, OvsCL ‐0.64 (‐0.77; ‐0.52) P = 0.000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group assigned to CL reported significantly greater number of AEs than either O. No difference between O methods. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Borghi 1984*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only available by drug arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% ≥ 1 AE for Oxprenolol 0.20 (0.07; 0.33) P = 0.0031, Chlorthalidone 0.13 (0.00; 0.25) P = 0.05 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spilker 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No indication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.12 (‐0.20; ‐0.05) P = 0.013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group assigned to CL reported significantly greater number of AEs than O.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciccolunghi 1975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No indication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OvsO 0.05 (‐0.06; 0.16) P = 0.3676, OvsCL ‐0.48 (‐0.57; ‐0.38) P = 0.000, OvsCL ‐0.53 (‐0.63; ‐0.43) P = 0.000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group assigned to CL reported significantly greater number of AEs than either O. No difference between O methods. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% ≥ 1 AE for nonmed: OvsO 0.19 (‐0.09; 0.13) P = 0.7331, OvsCL ‐0.66 (‐0.77; ‐0.54) P = 0.0000, OvsCL ‐0.68 (‐0.79; ‐0.56) P = 0.0000. Med: OvsO 0.05 (‐0.12; 0.22) P = 0.5816, OvsCL ‐0.26 (‐0.38; ‐0.14) P = 0.001, Ovs CL ‐0.31 (‐0.44; ‐0.17) P = 0.0000 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brent 2009**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐harm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicidal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.12 (‐0.22; 0.09) P = 0.0017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group assigned to R reported significantly greater number of suicidal‐related AEs than O. NB no completed suicides. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐suicidal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.15 (‐0.22; ‐0.90) P = 0.0000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group assigned to R reported significantly greater number of non‐suicidal AEs than O. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicide attempts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.03 (‐0.07; 0.02) P = 0.2689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference between R and O for reporting of suicide attempts.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>AE: adverse event</sup><br/> <sup>CL: checklist</sup><br/> <sup>N/A: not applicable</sup><br/> <sup>O: open question</sup><br/> <sup>vs: versus</sup><br/> <sup>R: rating scale</sup> </p> <p><sup>* All participants asked AEs by an open question (O), but as this process possibly involved 'filtering' of reports by the doctor, the data were not included in the review</sup> </p> <p><sup>** Huskisson used a composite measure of frequency and severity</sup> </p> <p><sup>*** A selection of the total AEs are presented in the review as those objectively measured were excluded</sup> </p> <p><sup>† 2‐sample test of proportions</sup> </p> <p><sup>†† 2‐sample t test</sup> </p> </div> </div> <div class="table" id="MR000039-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Elicitiation of the number of AEs reported for within‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Therapy area</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="13" rowspan="1" valign="top"> <p><b>AEs elicited</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Number of AEs (total)</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Number (%) of participants with ≥1 AE</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>INT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>INT</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barber 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ophthalmology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barrowman 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downing 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hermans 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W2: 11 W4: 49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W2: 58 W4: 105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W2: 21(10) W8: 53 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W2: 39(19) W8: 61 (31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jacobson 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1871</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nicholls 1980*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O'Connell 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dysmenorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perez 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parkinson's Disease (PD) and post‐stroke controls (PSC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203 PD, 52 PSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113 + 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PD 1573, PSC 167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PD 85 (42), PSC 5 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PD 203 (100), PSC 47 (90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rabkin 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180/226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reilly 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W0 37 W12 46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W0 340 W12 96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W0 27 (29.5) W12 33 (35.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WO 84 (90.9) W12 74 (80.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rosenthal 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>705 (12.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2753 (50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallin 1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wernicke 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not known</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>de Vries 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sheftell 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Migraine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 (28.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248 (59.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Landen 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 (41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yeo 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (3.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kruft 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ophthalmology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Occular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Montiero 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>de Vries 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lundberg 1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antihistamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallander 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191/251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>926</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allen 2013*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Malaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3‐7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18, 80 (sites' data cannot be combined)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+1, +20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+0, +1**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greenhill 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Os 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185 (22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>ADE: adverse drug event<br/> AE: adverse event<br/> BSR: body system reviewCL: checklist<br/> D: drug<br/> DSI: drug‐specific inquiry<br/> INT: interview<br/> N/A: not applicable<br/> NK: not known<br/> O: open question<br/> O(B): blank page</sup> </p> <p><sup>PD: Parkinson's Disease<br/> PPV: positive predictive value<br/> PSC: post‐stroke control<br/> R: rating scaleSD: standard deviation<br/> SOC: system organ class<br/> Sp‐So: spontaneous‐solicited index<br/> VAS: visual analogue scale<br/> W0, W2, W4, W8, W12:<br/> χ²: chi‐squared<br/> Z: zeta (standard score)</sup> </p> <p><sup>*Two sites/groups reported separately as different participant populations</sup> </p> <p><sup>**subset of participants from C versus CL comparison then interviewed</sup> </p> <p><sup>† McNemar's test of proportions, †† 2‐sample t test</sup> </p> </div> </div> <div class="table" id="MR000039-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Effects of methods on the number of AEs reported for within‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Therapy area</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Effect (number of AEs)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By drug arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Test of proportions with ≥ 1 AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description (including of other effect measure if different).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barber 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ophthalmology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average frequency of domain scores (number (%) mean (SD)) for those not reporting AEs by O but indicating AE by CL: occular symptoms 41 (89.1), 1.18 (0.91); taste 3 (6.4), 2.5 (2.18); vision difficulties 33 (70.2), 2.8 (1.84); accommodation difficulties 20 (42.6), 3.68 (2.27); browache 12 (25.5), 2.75 (1.86). Scores ranged from participants experiencing AEs rarely to usually. Average domain scores increased as AEs reported by O and therapy discontinued ‐ participants reporting AEs to O reported more AEs by CL. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barrowman 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL elicited 1.8 x the number of AEs than O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of AEs for pentagastrin: O 2.1 CL 3.2 (range 1‐5). For placebo: O 0 CL 1 (range 0‐3). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downing 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 3.22 (1.49; 7.74) P = 0.0017†</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>While methods agreed for 85 (69%) of participants, CL elicited a significantly greater number of AEs than O. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>More AEs reported with amplodipine versus isradipine when either O or CL used. No drug‐placebo difference found when O used, however, for CL, a statistically significant difference found in proportion of participants with ≥ 1 AE (χ² 5.76, P &lt; 0.025). In those AEs deemed medication‐related, CL resulted in higher frequency of AEs in active arm and produced a larger drug‐placebo difference in frequency of AEs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hermans 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W0: ‐0.10 (‐0.17; ‐0.03) P = 0.0063, W8: ‐0.05 (‐0.14; 0.03) P = 0.2293††</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL elicited 2 x as many AEs as O and % of participants with ≥ 1AE significantly greater with CL at W0, however proportions similar at W8 between methods. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Between‐drug difference in AEs overall (and for frequency of ankle oedema) statistically significant (P = 0.02, 95% CI 3.1 to 26.7) for O, not for CL. No difference between methods for other specific AEs or for severity of ankle oedema. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jacobson 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL elicited 6.7 x the number of AEs than O. Mean number of AEs per assessment 5 more by CL compared to O. In overlapping group of 88 exposed to O, mean number of AEs per assessment was 1.6 x higher than when O was part of combined tool. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nicholls 1980*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See data by drug arm.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant difference in mean number of AEs between drugs by CL (5.4 labetolol, 3.6 propranolol P &lt; 0.05) but not by O (1.6 labetolol, 1.5 propranolol). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O'Connell 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dysmenorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL elicited 2.7 x the number of AEs than O.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median number of AEs for contraceptive and placebo by O was 1. By CL, median for both was 2. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perez 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parkinson's Disease (PD) and post‐stroke controls (PSC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significantly more participants reporting ≥ 1 AE on CL compared to O (P &lt; 0.01) in both groups. Only factor found related to reporting of ≥ 1 AE by participants in response to O, was if participant reported &gt; 2 AEs by CL (OR 1.2 (1.1 to 3.2). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rabkin 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL elicited 5 x mean number of AEs than O.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reilly 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W0: 0‐.65 (‐0.75; ‐0.54), P = 0.0000, W12: ‐0.47 (‐0.59; ‐0.34), P = 0.0000 ††</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% participants with ≥ 1 AE was significantly greater with CL at W0 and W12. Only 6% of symptoms reported on CL were reported on O. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rosenthal 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.38 (‐0.39; ‐0.36) P = 0.0000††</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% of participants with ≥ 1AE was significantly greater with CL.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Between‐drug difference in AEs overall was statistically significant (‐0.03 (‐0.07; ‐0.001), P = 0.0266) for O, not for CL.(‐0.04 ‐0.09; 0.004), P = 0.0776. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallin 1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64% increase in number of AEs elicited by CL after O.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wernicke 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not known</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See data by drug arm.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sp‐So index &gt; 1.0 for 22/29 (75.9%) AEs but not significant for most: O more effective in detecting difference between treatments. More statistically significant differences between treatments by CL (9 AEs) than O (5 AEs): differences in % of AEs between drug and placebo (rather than ratios of AE rates) more often greater with CL. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>de Vries 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivities, PPV of CL compared with O (D) at primary SOC (95% CI): 4‐weeks 33% (4‐78) and 10% (1‐30); 3‐months 33% (21‐47) and 51% (34‐69). Sensitivities at specific ADE level (95% CI): 4‐weeks 43% (10‐92); 3‐months 41% (30‐54). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sheftell 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Migraine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.31 (‐0.38; ‐0.25) P = 0.0000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significantly more AEs reported through CL for those reporting 1, 2, 3 or more AEs.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Landen 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 11 (5;26) χ² 45, P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R elicited significantly greater number of AEs than O. 2 women versus 5 men reported AE by O (χ² 6.7, P = 0.01) and 29 women versus 20 men by R (χ²3.7, P = 0.06). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between drugs by either method.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yeo 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.08 (‐0.15; ‐0.01) P = 0.0374.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% participants with ≥ 1AE significantly greater with R compared to O. Increase in cough by R less consistent in men than women. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kruft 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ophthalmology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Occular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For 13 of 14 questions, there was a statistically greater positive response to CL or R than O. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Montiero 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Of 10 participants (all active) who did not report AE by CL, 3 reported AE by O and 8 by INT. 36% of those with drug‐induced AE at interview did not report at CL despite concern with it and even if they were secretly reducing dose of drug to overcome it. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No AEs in placebo arm by any method</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>de Vries 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of AEs similar between the CLs (Z = ‐0.049, P = 0.961).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lundberg 1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antihistamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two‐factor repeated measure of variance for AEs reported by ≥ 50% sample showed significant effects of drug for 6 symptoms by CL but no difference by R. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallander 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher mean number AEs through R versus CL (overall and sex/age groups). In addition to measuring frequency, R also quantified degree of change in symptoms. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allen 2013*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Malaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3‐7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% increase in number of AEs: Site 1: 16.7% O to CL, no change with INT. Site 2: 87.0% O to CL, 2.3% CL to INT (subset). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greenhill 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative % increase in number of AEs: 33% O to first CL (drug‐specific inquiry, DSI) followed by 202% to next CL (body system review, BSR). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Os 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.17 (‐0.20; ‐0.13) P = 0.0000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% participants with ≥ 1 AE significantly greater with CL compared to O. Not possible to compare frequency overall with R. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cough more frequent with lisinopril than nifedipine (8.5 versus 3.1%, P = 0.0009) by O. Similar change in frequency with R. Not possible to present same data for CL. </p> <p>O: AE 3 x more frequent in female versus male with lisinopril (12.6 versus 4.4%, P = 0.0027), no difference for nifedipine. 3 fold difference with CL. By VAS, participant and spouse assessed frequency of lisinopril‐associated AE similarly. With O, similar number of AEs independent of smoking, with CL a statistically significant difference between non‐smokers and smokers (16 versus 7%, P = 0.0018). </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>ADE: adverse drug event<br/> AE: adverse event<br/> BSR: body system reviewCL: checklist<br/> D: drug<br/> DSI: drug‐specific inquiry<br/> INT: interview<br/> N/A: not applicable<br/> NK: not known<br/> O: open question<br/> O(B): blank page</sup> </p> <p><sup>PD: Parkinson's Disease<br/> PPV: positive predictive value<br/> PSC: post‐stroke control<br/> R: rating scaleSD: standard deviation<br/> SOC: system organ class<br/> Sp‐So: spontaneous‐solicited index<br/> VAS: visual analogue scale<br/> W0, W2, W4, W8, W12:<br/> χ²: chi‐squared<br/> Z: zeta (standard score)</sup> </p> <p><sup>*Two sites/groups reported separately as different participant populations</sup> </p> <p><sup>**subset of participants from C versus CL comparison then interviewed</sup> </p> <p><sup>† McNemar's test of proportions, †† 2‐sample t test</sup> </p> </div> </div> <section id="MR000039-sec-0080"> <h5 class="title">Between‐participant comparisons</h5> <section id="MR000039-sec-0081"> <h6 class="title">‐ Overall</h6> <p>For the eight studies comparing elicitation methods between groups of participants, 12 different comparisons involving an open enquiry (O) could be derived (one of which had three different endpoints), resulting in 14 comparisons in total (<a href="#MR000039-tbl-0006">Table 6</a> and <a href="#MR000039-tbl-0007">Table 7</a>). There was no common statistical rubric, but we were able to represent some effect measures as a risk ratio of the proportion of participants with at least one AE. This showed a lower level of reporting for O compared to CL, with a range for the risk ratios of 0.12 to 0.64. Using O as the reference, there was an increase in the absolute or mean number of AEs elicited, or the number of participants reporting at least one AE, whenever CL or R was used (except for suicide attempts in <a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a>, which were more often reported by O than CL). This increased sensitivity of CL/R was observed regardless of the study location, therapy area, whether the study was conducted within or outside of a clinical trial or with patient or healthy volunteers, the duration of follow‐up and whether the outcome variable could be considered as a treatment‐emergent AE or not. The two studies that compared different types of O (<a href="./references#MR000039-bbs2-0005" title="BentS , PadulaA , AvinsAL . Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Annals of Internal Medicine2006;144(4):257‐61. ">Bent 2006</a> and <a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a>) found no difference in the number of AEs detected. </p> </section> <section id="MR000039-sec-0082"> <h6 class="title">‐ Between study groups</h6> <p>Four studies presented data by study group (<a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a>, <a href="./references#MR000039-bbs2-0006" title="BorghiC , PallaviniG , ComiD , GrilloM , LombardoM , ManteroO , et al. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy. International Journal of Clinical Pharmacology, Therapy and Toxicology1984;22(6):324‐8. ">Borghi 1984</a>, and <a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a> within a clinical trial and <a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a> outside of a clinical trial). <a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a> found that the trend for more AEs through CL was sustained when the active treatment group was examined while removing the placebo participants. <a href="./references#MR000039-bbs2-0006" title="BorghiC , PallaviniG , ComiD , GrilloM , LombardoM , ManteroO , et al. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy. International Journal of Clinical Pharmacology, Therapy and Toxicology1984;22(6):324‐8. ">Borghi 1984</a> found that there did not appear to be a difference between the methods for detecting AEs. <a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a> had predetermined that only auditory and GI AEs would be termed drug‐related and all other AEs were deemed as irrelevant 'noise'. Using this classification system, they showed that the reporting of all three types of AEs increased for fenoprofen by two to three times, although the aspirin scores were inconsistent. While in a different context, for <a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a>, there was no difference in the detection of AEs between participants taking medication and those not taking medication when comparing the two types of O. There was a statistically significantly greater number of AEs detected by CL compared to O in participants taking medications, but no such difference was seen in those not taking medications. </p> </section> </section> <section id="MR000039-sec-0083"> <h5 class="title">Within‐participant comparisons</h5> <section id="MR000039-sec-0084"> <h6 class="title">‐ Overall</h6> <p>For the 25 studies comparing elicitation methods between groups of participants, 19 comparisons involved an open enquiry (O/B/D) and a checklist‐type method (CL) (although for <a href="./references#MR000039-bbs2-0016" title="KruftB , NelsonLA , StewartJA , StewartWC . Adverse event reporting. Ophthalmology2007;114(7):1420. ">Kruft 2007</a> the data for CL and R could not be distinguished). See <a href="#MR000039-tbl-0008">Table 8</a> for details on the elicitation of the number of AEs and <a href="#MR000039-tbl-0009">Table 9</a> for a summary of the results. The direction of the effect of the method on the number of AEs was in favour of the CL in all studies except <a href="./references#MR000039-bbs2-0013" title="HermansL , DeblanderA , DeKeyserP , ScheysI , LesaffreE , WestelinckKJ . At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild‐to‐moderate hypertension: a double‐blind, randomized, parallel‐group study. British Journal of Clinical Pharmacology1994;38(4):335‐40. ">Hermans 1994</a> and <a href="./references#MR000039-bbs2-0010" title="DeVriesST , Haaijer‐RuskampFM , DeZeeuwD , DenigP . The validity of a patient‐reported adverse drug event questionnaire using different recall periods. Quality of Life Research2014;23(9):2439‐45. ">De Vries 2014</a>. The former, despite finding an increase in absolute numbers of AEs with the CL, found no increase when looking at the percentage of participants with at least one AE. <a href="./references#MR000039-bbs2-0010" title="DeVriesST , Haaijer‐RuskampFM , DeZeeuwD , DenigP . The validity of a patient‐reported adverse drug event questionnaire using different recall periods. Quality of Life Research2014;23(9):2439‐45. ">De Vries 2014</a> had performed their study to validate a CL and found low sensitivity (33%) and positive prediction values (10 to 51%) compared to their open question diary. The fact that the diary was completed daily is likely to have influenced this finding. </p> <p>Two studies compared different types of CL: <a href="./references#MR000039-bbs2-0009" title="DeVriesST , MolPG , DeZeeuwD , Haaijer‐RuskampFM , DenigP . Development and initial validation of a patient‐reported adverse drug event questionnaire. Drug Safety2013;36(9):765‐77. ">De Vries 2013</a> and <a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a>. The former found that adding body categories did not affect the frequency of AE data reports, while <a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a> found that using a body system review resulted in a greater increase in AE reports compared to a drug‐specific inquiry. </p> <p>Several studies incorporated scales (R); <a href="./references#MR000039-bbs2-0017" title="LandénM , HögbergP , ThaseME . Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Journal of Clinical Psychiatry2005;66(1):100‐6. ">Landén 2005</a>, <a href="./references#MR000039-bbs2-0016" title="KruftB , NelsonLA , StewartJA , StewartWC . Adverse event reporting. Ophthalmology2007;114(7):1420. ">Kruft 2007</a>, <a href="./references#MR000039-bbs2-0033" title="YeoWW , MacleanD , RichardsonPJ , RamsayLE . Cough and enalapril: assessment by spontaneous reporting and visual analogue scale under double‐blind conditions. British Journal Clinical Pharmacology1991;31(3):356‐9. ">Yeo 1991</a> and <a href="./references#MR000039-bbs2-0030" title="WallanderMA , DimenäsE , SvärdsuddK , WiklundI . Evaluation of three methods of symptom reporting in a clinical trial of felodipine. European Journal of Clinical Pharmacology1991;41(3):187‐96. ">Wallander 1991</a> found that the use of R resulted in increased AE reports. <a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a> observed that the increase in cough reported by R was less consistent in men compared to women. <a href="./references#MR000039-bbs2-0017" title="LandénM , HögbergP , ThaseME . Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Journal of Clinical Psychiatry2005;66(1):100‐6. ">Landén 2005</a> found fewer women than men reporting AEs by O but more women than men reporting AEs by R (the latter was not statistically significant). </p> <p><a href="./references#MR000039-bbs2-0019" title="MonteiroWO , NoshirvaniHF , MarksIM , LelliottPT . Anorgasmia from clomipramine in obsessive‐compulsive disorder. A controlled trial. British Journal of Psychiatry1987;151:107‐12. ">Monteiro 1987</a> found 36% of those with drug‐induced sexual dysfunction at INT did not report this at the previous CL, despite their concern about this AE, even if they were secretly reducing dose of drug to overcome it. </p> <p><a href="./references#MR000039-bbs2-0023" title="Perez‐LloretS , ReyMV , FabreN , OryF , SpampinatoU , MontastrucJL , et al. Do Parkinson's disease patients disclose their adverse events spontaneously?. European Journal of Clinical Pharmacology2012;68(5):857‐65. ">Perez‐Lloret 2012</a> explored the relationship of various demographic and disease‐related factors with reporting at least one AE in response to O, and the only association found was with participants who reported more than two AEs by CL. </p> </section> <section id="MR000039-sec-0085"> <h6 class="title">‐ Between study groups</h6> <p>Common findings were identified when considering if the question method influenced the ability to detect differences between study groups. <a href="./references#MR000039-bbs2-0020" title="NichollsDP , HusainiMH , BulpittCJ , StephensMD , ButlerAG . Comparison of labetalol and propranolol in hypertension. British Journal of Clinical Pharmacology1980;9(3):233‐7. ">Nicholls 1980</a> and <a href="./references#MR000039-bbs2-0026" title="RosenthalJ , BahrmannH , BenkertK , BaumgartP , BönnerG , KleinG , et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta‐blocker. Cardiology1996;87(5):409‐14. ">Rosenthal 1996</a> (drug‐drug comparisons) and <a href="./references#MR000039-bbs2-0011" title="DowningRW , RickelsK , MeyersF . Side reactions in neurotics. I. A comparison of two methods of assessment. Journal of Clinical Pharmacology and the Journal of New Drugs1970;10(5):289‐97. ">Downing 1970</a> (drug‐placebo comparisons) showed a statistically significant difference between groups when using CL, and no such effect when using O. <a href="./references#MR000039-bbs2-0013" title="HermansL , DeblanderA , DeKeyserP , ScheysI , LesaffreE , WestelinckKJ . At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild‐to‐moderate hypertension: a double‐blind, randomized, parallel‐group study. British Journal of Clinical Pharmacology1994;38(4):335‐40. ">Hermans 1994</a> found the opposite; the between‐drug difference in AEs overall (and for frequency of ankle oedema) was statistically significant for O, not for CL. <a href="./references#MR000039-bbs2-0032" title="WernickeJF , FariesD , MiltonD , WeyrauchK . Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Safety2005;28(11):1057‐63. ">Wernicke 2005</a>'s use of drug/placebo ratios for reported AEs suggested that O is more effective in distinguishing a difference between trial groups. However, they also found that there were more statistically significant differences between trial groups by CL compared to O (nine versus five AEs). <a href="./references#MR000039-bbs2-0017" title="LandénM , HögbergP , ThaseME . Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Journal of Clinical Psychiatry2005;66(1):100‐6. ">Landén 2005</a> (drug‐drug) and <a href="./references#MR000039-bbs2-0021" title="O'ConnellK , DavisAR , KernsJ . Oral contraceptives: side effects and depression in adolescent girls. Contraception2007;75(4):299‐304. ">O'Connell 2007</a> (drug‐placebo) showed no difference between groups. The two studies that compared a CL with an R also had conflicting results: <a href="./references#MR000039-bbs2-0018" title="LundbergPK . Assessment of drugs' side effects: Visual Analogue Scale versus check‐list format. Perceptual and Motor Skills1980;50(3):1067‐73. ">Lundberg 1980</a> found a difference between drugs by their CL but not by their R, while <a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a> found no difference between these types of tools. </p> </section> </section> </section> <section id="MR000039-sec-0086"> <h4 class="title">The impact of different elicitation methods on the nature of AEs reported</h4> <p>See <a href="#MR000039-tbl-0010">Table 10</a> and <a href="#MR000039-tbl-0011">Table 11</a> for details on the effects of the methods on the nature of AEs reported for between‐ and within‐participant comparisons. </p> <div class="table" id="MR000039-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Effects of methods on the nature of AEs reported for between‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Location</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Within/outside trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Therapy area</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment‐emergent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect (nature of AEs)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Avery 1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A statistically significant higher mean severity AEs at each visit by CL overall and in just the active arm. See paper for details. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Huskisson 1974**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rheumatology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severity was included as a composite measure with frequency so presented under effect (number of AEs). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Torok 1984***</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not necessarily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Various</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bent 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatic hyperplasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1 ‐ 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Borghi 1984*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spilker 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthy volunteers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No indication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not necessarily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most common symptoms by CL were fatigue, headache, and nasal congestion and by O were headache, back or muscle pain, and nasal congestion. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciccolunghi 1975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthy volunteers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No indication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not necessarily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O was associated with a greater severity of symptoms than CL. The type of symptoms reported did depend to some extent on the method. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brent 2009**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐harm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicidal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>There was no difference between R and O for reporting of serious suicidal or non‐suicidal AEs (8.4% versus 7.3%, χ² = 0.03, df = 1, P = 0.87). Time to onset for suicidal and non‐suicidal AEs earlier for CL than O: median 2 versus 5 weeks (χ² = 9.41, df = 1, P = 0.004). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐suicidal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicide attempts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>AE: adverse event<br/> CL: checklist<br/> df: degrees of freedom<br/> N/A: not applicable<br/> O: open question<br/> R: rating scale<br/> χ²: chi‐squared</sup> </p> <p><sup>* All participants asked AEs by open question (O), but as this process possibly involved 'filtering' of reports by the doctor data not included in the review.</sup> </p> <p><sup>** Huskisson used a composite measure of frequency and severity</sup> </p> <p><sup>*** A selection of the total AEs are presented in review as those objectively measured were excluded</sup> </p> </div> </div> <div class="table" id="MR000039-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Effects of methods on the nature of AEs reported for within‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Location</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Within / outside trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Therapy area</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment‐emergent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect (nature of AEs)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barber 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ophthalmology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants reporting AEs by O and discontinuing therapy reported more bother and activity limitation compared to those who did not report by O but did by CL. Average global QoL scores increased as participants reported AEs by O and discontinued therapy; participants who reported AEs by O indicated more negative impact of side effects and activity limitations on QoL, more dissatisfaction with medication, and more noncompliance versus those not reporting by O. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barrowman 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointenstinal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downing 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greater proportion of participants reporting an AE by both O and CL (26, 90%) had high mean intensity scores compared to those only reporting by CL (12, 50% ‐ predominantly those taking tranquillizers) P &lt; 0.01. The former participants more often reported AEs at a high discomfort level compared to the latter, P &lt; 0.05. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hermans 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no apparent difference between the methods for severity and duration of AEs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jacobson 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL detected a greater variety of AEs than O while AEs reported by O had a higher mean severity compared to those reported by CL. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nicholls 1980*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O'Connell 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dysmenorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perez 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parkinson's Disease, post‐stroke controls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No relationship between AE severity and the O questioning method.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rabkin 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs reported to O significantly more distressing, more often interfered with daily functioning and elicited more changes in clinical management versus CL (NB for latter additional 46 participants assessed). No medically serious AEs elicited by O alone. Overall, and for participants on active drug (but not placebo), mean severity of AEs reported by O significantly greater versus CL. However, 61% of AEs rated severe/very severe elicited by CL, 65% AEs causing severe/very severe dysfunction detected by CL versus 35% by O. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reilly 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not necessarily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptoms reported by O more bothersome than CL. no change in mean degree of distress caused by AEs using CL, but increase in distress associated with AEs by O. Duration of AEs similar for O and CL but a higher symptom severity score by O versus CL. Significant relationship between degree of bother (P &lt; 0.0001), duration (P = 0.02), severity (P = 0.0003) and reporting of AEs by O. Only 18% of symptoms bothering participants a lot/extremely were first reported by CL. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rosenthal 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallin 1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conclusions severity not supported by the data.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wernicke 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not known</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not known</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>de Vries 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sheftell 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multinational</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Migraine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference between O and CL for severity. However 31 (7.5%) participants who rated AE as severe in CL did not report the AE in O. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Landen 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yeo 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kruft 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multinational</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ophthalmology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Occular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Montiero 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>de Vries 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lundberg 1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antihistamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallander 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allen 2013*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients, healthy volunteers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Malaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3‐7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All additional AEs were mild and unlikely related to trial drug.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greenhill 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54% of AEs elicited by O were moderate to severe compared to 75% of those elicited by DSI and 37% for BSR. Of the 17 severe AEs, 6 (37%) were elicited by BSR. 31% of the AEs elicited by O were clinically relevant compared with 12% for the DSI and 15% for the BSR. Of the clinically relevant AEs (N = 37), 19 (53%) were elicited by BSR. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Os 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>AE: adverse event<br/> BSR: body system review<br/> CL: checklist<br/> DSI: drug‐specific inquiry<br/> INT: interview<br/> N/A: not applicable<br/> NB: nota bene<br/> NK: not known<br/> O: open question/spontaneous<br/> QoL: quality of life<br/> R: rating scale</sup> </p> <p><sup>*Two sites/groups reported separately as different participant populations</sup> </p> </div> </div> <section id="MR000039-sec-0087"> <h5 class="title">Between‐participant comparisons</h5> <p><a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a> found a statistically significant higher mean severity at each visit by CL, both overall and when removing placebo data, in contrast to <a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a> who found that O was associated with a greater severity of symptoms than CL (<a href="#MR000039-tbl-0010">Table 10</a>). <a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a> found no difference between O and R for reporting of serious suicidal or nonsuicidal ideation AEs, but the time to onset for both was earlier for data elicited by R compared to O. In terms of the individual types of AEs reported, <a href="./references#MR000039-bbs2-0028" title="SpilkerAV , KesslerJM . Comparison of symptoms elicited by checklist and fill‐in‐the‐blank questionnaires. Pharmacoepidemiology News1987;22:272‐7. ">Spilker 1987</a> found that the most common symptoms elicited by CL were fatigue, headache, and nasal congestion, compared to headache, back or muscle pain, and nasal congestion by O, so there appeared to be some overlap. <a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a> had used a composite measure for frequency and severity so is reported under the number of AEs section above. </p> </section> <section id="MR000039-sec-0088"> <h5 class="title">Within‐participant comparisons</h5> <p>Of the 10 studies investigating the nature of AEs reported through questioning method, six found O more likely to detect more severe or intense AEs, or AEs causing more bother, distress, or limiting activity (<a href="./references#MR000039-bbs2-0003" title="BarberBL , SantanelloNC . Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. International Journal of Clinical Pharmacology and Therapeutics1995;33(11):598‐604. ">Barber 1995</a>, <a href="./references#MR000039-bbs2-0011" title="DowningRW , RickelsK , MeyersF . Side reactions in neurotics. I. A comparison of two methods of assessment. Journal of Clinical Pharmacology and the Journal of New Drugs1970;10(5):289‐97. ">Downing 1970</a>; <a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a>, <a href="./references#MR000039-bbs2-0015" title="JacobsonAF , GoldsteinBJ , DominguezRA , SteinbookRM . Interrater agreement and reliability measures of SAFTEE: general inquiry vs. systematic inquiry. Psychopharmacology Bulletin1987;23(1):97‐101. ">Jacobson 1987</a>; <a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a>; <a href="./references#MR000039-bbs2-0025" title="ReillyMC , ZbrozekAS . Assessing the responsiveness of a quality‐of‐life instrument and the measurement of symptom severity in essential hypertension. Pharmacoeconomics1992;2(1):54‐66. ">Reilly 1992</a>), although <a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a> showed that their drug‐specific review CL detected more moderate AEs compared to O (<a href="#MR000039-tbl-0011">Table 11</a>). Meanwhile, the paper by <a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a> revealed that 61% of AEs rated severe or very severe were elicited by the CL and 65% of AEs causing severe or very severe dysfunction were detected by CL compared to 35% by O. <a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a> reported that additional AEs detected thorough CL or INT were rated as mild, but the severity of AEs detected by O was not given. <a href="./references#MR000039-bbs2-0013" title="HermansL , DeblanderA , DeKeyserP , ScheysI , LesaffreE , WestelinckKJ . At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild‐to‐moderate hypertension: a double‐blind, randomized, parallel‐group study. British Journal of Clinical Pharmacology1994;38(4):335‐40. ">Hermans 1994</a> and <a href="./references#MR000039-bbs2-0023" title="Perez‐LloretS , ReyMV , FabreN , OryF , SpampinatoU , MontastrucJL , et al. Do Parkinson's disease patients disclose their adverse events spontaneously?. European Journal of Clinical Pharmacology2012;68(5):857‐65. ">Perez‐Lloret 2012</a> found no difference between the elicitation methods in the severity of AEs detected, as did <a href="./references#MR000039-bbs2-0027" title="SheftellFD , FeleppaM , TepperSJ , RapoportAM , CiannellaL , BigalM . Assessment of adverse events associated with triptans ‐ methods of assessment influence the results. Headache2004;44(10):978‐82. ">Sheftell 2004</a>. However, the latter also found that 31 (7.5%) of participants who rated their AE as severe in the CL had not reported it when previously asked by O. </p> <p><a href="./references#MR000039-bbs2-0003" title="BarberBL , SantanelloNC . Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. International Journal of Clinical Pharmacology and Therapeutics1995;33(11):598‐604. ">Barber 1995</a> found that participants who spontaneously reported AEs indicated a more negative impact of side effects and activity imitations on quality of life, more dissatisfaction with their medication, and more noncompliance compared to those not reporting spontaneously; the average global quality of life scores increased as participants reported AEs spontaneously and discontinued therapy. The two studies that looked at the duration of AEs detected by questioning method (<a href="./references#MR000039-bbs2-0013" title="HermansL , DeblanderA , DeKeyserP , ScheysI , LesaffreE , WestelinckKJ . At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild‐to‐moderate hypertension: a double‐blind, randomized, parallel‐group study. British Journal of Clinical Pharmacology1994;38(4):335‐40. ">Hermans 1994</a>, <a href="./references#MR000039-bbs2-0025" title="ReillyMC , ZbrozekAS . Assessing the responsiveness of a quality‐of‐life instrument and the measurement of symptom severity in essential hypertension. Pharmacoeconomics1992;2(1):54‐66. ">Reilly 1992</a>) showed no difference. </p> <p><a href="./references#MR000039-bbs2-0015" title="JacobsonAF , GoldsteinBJ , DominguezRA , SteinbookRM . Interrater agreement and reliability measures of SAFTEE: general inquiry vs. systematic inquiry. Psychopharmacology Bulletin1987;23(1):97‐101. ">Jacobson 1987</a> observed that their CL detected a greater variety of AEs compared to O. <a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a>, using essentially the same tool, observed that the 23 AEs that were reported more than five times as often by CL compared to O included no reports of sexual dysfunction. The authors concluded that there was therefore no evidence of selective underreporting of sexual dysfunction by O compared to other AEs, such as cognitive and affective symptoms. They suggested that the phrase used to introduce the questioning may have inadvertently suggested to participants that the latter were not the topic of the enquiry. </p> </section> </section> <section id="MR000039-sec-0089"> <h4 class="title">The impact of different elicitation methods on other relevant outcome variables</h4> <section id="MR000039-sec-0090"> <h5 class="title">Clinical action/relevance</h5> <p><a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a> found that both their O and CL methods contributed equally to the elicitation of AEs that, in the clinician's opinion, required some change in management (13% and 11%, respectively). However, those AEs elicited by O required more extensive changes (dose suspension or discontinuation compared with increased surveillance or change in dose) and all of these AEs were in the trials' drug groups, not placebo. <a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a> also found that a higher proportion of AEs elicited through O led to some clinical action (31%) compared with those identified with the CLs (12% when using a drug‐specific CL and 15% a body‐system review). Of the clinically relevant AEs (N = 37), 19 (53%) were elicited by a body system review. </p> </section> <section id="MR000039-sec-0091"> <h5 class="title">Validity, feasibility, acceptability and satisfaction</h5> <p><a href="./references#MR000039-bbs2-0009" title="DeVriesST , MolPG , DeZeeuwD , Haaijer‐RuskampFM , DenigP . Development and initial validation of a patient‐reported adverse drug event questionnaire. Drug Safety2013;36(9):765‐77. ">De Vries 2013</a> found significant problems during content validation that needed to be resolved while designing their self‐reported questionnaire (CL), such as making it clearer to participants which questions related to their underlying disease symptoms and which to AEs. The final tool was a questionnaire of 252 items and approximately 50% of respondents found a body‐category structure to be helpful, while most found the tool easy to use and took less than 60 minutes to complete. <a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a> found that while 80% of parents found their body‐system review CL method 'just right' (71% specifically finding the duration of the process 'just right'), 70% of clinicians considered it to be too detailed and 74% found it took too long. Of note, however, is that satisfaction ratings for the more detailed enquiry were significantly higher in parents who received reimbursement fees compared to those who did not. Overall, the body‐system review was deemed very useful by 66% of parents but only 28% of clinicians in that study. <a href="./references#MR000039-bbs2-0010" title="DeVriesST , Haaijer‐RuskampFM , DeZeeuwD , DenigP . The validity of a patient‐reported adverse drug event questionnaire using different recall periods. Quality of Life Research2014;23(9):2439‐45. ">De Vries 2014</a> found that a recall period of either four weeks or three months did not impact the sensitivity of identifying participants who experienced an AE through their CL tool at either a MedDRA® organ class or specific level. The positive predictive value was especially low for a four‐week recall period. <a href="./references#MR000039-bbs2-0015" title="JacobsonAF , GoldsteinBJ , DominguezRA , SteinbookRM . Interrater agreement and reliability measures of SAFTEE: general inquiry vs. systematic inquiry. Psychopharmacology Bulletin1987;23(1):97‐101. ">Jacobson 1987</a> found good overall interrater reliability for detecting AEs using both their O and CL methods (best when raters were both present for the same participant consultation) but low interrater reliability for individual AEs and measures such as duration, severity, and functional impairment. </p> </section> <section id="MR000039-sec-0092"> <h5 class="title">Qualitative</h5> <p>The one study (which we had conducted) that incorporated a qualitative analysis (<a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a>) found that the CL and INT facilitated participants' recognition of health issues and treatments, and consideration of what to report. Information about AEs, medical history or non‐study medicine use or both was sometimes not reported because participants forgot, it was considered irrelevant or insignificant, or they feared the consequences of reporting this. Some medicine names were not known, and answers to questions were sometimes considered inferior to the information that could be obtained from blood tests for detecting ill health. There were some differences between the two trial sites in this study that had an impact on reporting: South African inpatient HIV‐infected, but otherwise healthy volunteers, exhibited a 'trial citizenship', working to achieve the researchers' goals, while Tanzanian HIV‐positive or ‐negative outpatients with malaria symptoms sometimes deferred responsibility for identifying items to report to the trial's clinicians. </p> </section> <section id="MR000039-sec-0093"> <h5 class="title">Non‐study medicines and medical histories</h5> <p><a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a> also found that using the CL and INT (the latter in a subset of participants) after O resulted in an additional 23 and four non‐study medication reports respectively in one site, two, and nine in the other site. The same pattern was found for past medical history reports; an additional eight and four reports for CL and INT respectively in one site, 245 and 15 in the other site. These quantitative data could not, however, be pooled due to different numbers and types of participants in each site. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="MR000039-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="MR000039-sec-0094"></div> <p>Our Cochrane methodology review shows that the question of how different elicitation methods impact the reporting of subjective AE data by drug trial participants has been considered since at least the 1960s, and yet is still being debated nearly 50 years later. This situation probably reflects the complexity of the topic: namely, how to accurately represent the often unknown adverse effects of a drug on a myriad subjective endpoints. The review itself was complicated by the diversity in the participant populations, designs, and elicitation methods used in the included studies. It is also difficult to ensure quality in this type of methodology research and in differentiating AE reports from disease‐related symptoms. For instance, there may have been publication biases whereby studies that did not find any major differences between methods may have chosen not to report this. However, our review did provide reasonable evidence of an increase, often substantial, in the number of AEs elicited when using more comprehensive (specific, detailed and/or lengthy) questioning, whether a checklist‐type tool or rating scale, compared to a more open general enquiry, whether a verbal question or blank form for self‐report, in a wide variety of indications and contexts. This finding is, of course, intuitive. </p> <p>Importantly, some of the included studies took their research beyond the quantitative effects and investigated the nature of the AEs reported in response to different questioning methods. Of the 10 studies comparing elicitation methods within participants, six found that participants reported more severe or bothersome AEs to an open enquiry. While the studies used disparate methods to assess these endpoints (including the detail of the questioning itself and whether the nature of the AE was assessed by participants or investigators), these findings are supported by the qualitative data from <a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a>, whereby participants described this process in action; the checklist had reminded them of a mild or intermittent AE, or of the need to consider or report it, or both. However, some studies had different findings: <a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a> showed that even quite severe AEs were missed by the open enquiry and only detected by a checklist. Moreover, <a href="./references#MR000039-bbs2-0019" title="MonteiroWO , NoshirvaniHF , MarksIM , LelliottPT . Anorgasmia from clomipramine in obsessive‐compulsive disorder. A controlled trial. British Journal of Psychiatry1987;151:107‐12. ">Monteiro 1987</a> found that some debilitating sexual dysfunction AEs were not reported spontaneously or in response to a specific checklist and were only revealed at an in‐depth interview. <a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a> also suggested that the way the instructions to participants had been phrased in their general enquiry may have resulted in under‐reporting of cognitive and affective AEs. This signals the care required when phrasing questions. It is, therefore, difficult to draw firm conclusions about the impact of questioning method on the nature of AEs detected without further research. </p> <p>The research that was nested within comparative drug trials also had mixed results when considering if the questioning method influenced the ability to detect differences in harm between trial groups. <a href="./references#MR000039-bbs2-0020" title="NichollsDP , HusainiMH , BulpittCJ , StephensMD , ButlerAG . Comparison of labetalol and propranolol in hypertension. British Journal of Clinical Pharmacology1980;9(3):233‐7. ">Nicholls 1980</a> and <a href="./references#MR000039-bbs2-0026" title="RosenthalJ , BahrmannH , BenkertK , BaumgartP , BönnerG , KleinG , et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta‐blocker. Cardiology1996;87(5):409‐14. ">Rosenthal 1996</a> (drug‐drug comparisons) and <a href="./references#MR000039-bbs2-0011" title="DowningRW , RickelsK , MeyersF . Side reactions in neurotics. I. A comparison of two methods of assessment. Journal of Clinical Pharmacology and the Journal of New Drugs1970;10(5):289‐97. ">Downing 1970</a> (drug‐placebo comparisons) showed a statistically significant difference between groups when using a checklist‐type tool, and no such effect when using an open enquiry. In contrast, <a href="./references#MR000039-bbs2-0013" title="HermansL , DeblanderA , DeKeyserP , ScheysI , LesaffreE , WestelinckKJ . At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild‐to‐moderate hypertension: a double‐blind, randomized, parallel‐group study. British Journal of Clinical Pharmacology1994;38(4):335‐40. ">Hermans 1994</a> found the opposite: the open enquiry appeared to detect a difference while the checklist did not. <a href="./references#MR000039-bbs2-0032" title="WernickeJF , FariesD , MiltonD , WeyrauchK . Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Safety2005;28(11):1057‐63. ">Wernicke 2005</a> used a drug/placebo ratio for reported AE, which suggested that the open enquiry is more effective in distinguishing a difference between groups. However, they also found that there were more statistically significant differences between trial groups by a checklist approach compared to an open enquiry (nine versus five AEs). <a href="./references#MR000039-bbs2-0006" title="BorghiC , PallaviniG , ComiD , GrilloM , LombardoM , ManteroO , et al. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy. International Journal of Clinical Pharmacology, Therapy and Toxicology1984;22(6):324‐8. ">Borghi 1984</a> and <a href="./references#MR000039-bbs2-0017" title="LandénM , HögbergP , ThaseME . Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Journal of Clinical Psychiatry2005;66(1):100‐6. ">Landén 2005</a> (drug‐drug) and <a href="./references#MR000039-bbs2-0021" title="O'ConnellK , DavisAR , KernsJ . Oral contraceptives: side effects and depression in adolescent girls. Contraception2007;75(4):299‐304. ">O'Connell 2007</a> (drug‐placebo) all showed no difference between questioning methods, so no conclusions could be drawn for those studies comparing checklist‐type tools with rating scales. These mixed results may reflect several issues: problems with the host trials relating to their power to detect a difference in the safety outcome by drug, that a particular questioning method is no better than another at being able to detect a difference between study groups, or that the study groups being compared have similar safety profiles. </p> <p>One response to our findings would be to suggest that all studies use comprehensive specific enquiries in addition to an open enquiry, as they appear to be complementary. This would fit with the tenet of many clinical trials, especially preregistration trials, which aim to collect all AEs (i.e. high sensitivity with no provision for specificity relating to AE severity, bother from AEs, or the clinical outcome or association between the drug and the AE). However, more comprehensive enquiries are time‐consuming and, while <a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a> found that parents of children generally found the more detailed questioning useful, a majority of clinicians found using a body system review too detailed and took too long. It is also unclear as to how much questioning is comprehensive enough, bearing in mind that tools may range from a short checklist to the 252 items developed by <a href="./references#MR000039-bbs2-0009" title="DeVriesST , MolPG , DeZeeuwD , Haaijer‐RuskampFM , DenigP . Development and initial validation of a patient‐reported adverse drug event questionnaire. Drug Safety2013;36(9):765‐77. ">De Vries 2013</a>. More research is therefore needed to explore the practicalities of using tools of different lengths and designs and to achieve a balance between sensitivity and feasibility. For instance, <a href="./references#MR000039-bbs2-0010" title="DeVriesST , Haaijer‐RuskampFM , DeZeeuwD , DenigP . The validity of a patient‐reported adverse drug event questionnaire using different recall periods. Quality of Life Research2014;23(9):2439‐45. ">De Vries 2014</a> found that adding body categories which filtered and therefore limited the questions did not affect the outcome. </p> <p>Another option would be to use different types of questioning depending on what is known about the safety profile of the drug, which may itself be a factor in the phase of development; with more comprehensive questioning early in the process and less comprehensive questioning as data builds about a favourable benefit:harm profile. Provision for this is made by the US Food and Drug Administration (FDA): manufacturers are allowed to make a case for limiting the safety data to serious AEs, for instance (<a href="./references#MR000039-bbs2-0086" title="USFood , DrugAdministration . Draft guidance for Industry: determining the extent of safety data collection needed in late stage premarket and postapproval clinical investigations. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291158.pdf (accessed prior to 14 September 2017). ">FDA 2012</a>). In addition, for the treatment of life‐threatening illness, there may be a case for using less a sensitive enquiry and focusing on the more serious AEs. However, while it is unlikely that there is a perfect questioning tool, it is difficult to recommend that researchers use an enquiry method that may miss some clinically relevant data or effects that are important to participants, especially those that could impact on adherence when a drug is eventually distributed on a large scale, post‐registration. Despite what researchers and regulatory authorities may feel is known about important ADRs, there may be long‐term or persistent mild effects that do not influence clinical action but nevertheless impact on the quality of life of even severely ill patients. An example is persistent nausea in oncology patients that is considered less clinically relevant by clinicians but a debilitating disorder by patients (<a href="./references#MR000039-bbs2-0083" title="EdgerlyM , FojoT . Is there room for improvement in adverse event reporting in the era of targeted therapies?. Journal of the National Cancer Institute.2008;100(4):240‐2. ">Edgerly 2008</a>). Similarly, while there is guidance about the need to enquire specifically for potential ADRs that are embarrassing for participants to talk about (such as sexual dysfunction), other drugs with the potential for such effects may not have been identified as yet and this ADR will only be detected after many participants have been exposed to the drug (<a href="./references#MR000039-bbs2-0081" title="Council for International Organizations of Medical Sciences. Management of Safety Information from Clinical Trials. Report of CIOMS Working Group VI. Geneva: CIOMS, 2005. ">CIOMS 2005</a>). </p> <section id="MR000039-sec-0095"> <h3 class="title" id="MR000039-sec-0095">Summary of main results</h3> <p>Despite different study designs, populations and details of questioning methods, the review showed that more specific questioning of study participants leads to more AEs being reported compared to a more general enquiry. A subset of six studies suggested that more severe, bothersome, or otherwise clinically relevant AEs were reported when an initial open enquiry was used; while some less severe, bothersome, or clinically relevant AEs were only reported with a subsequent specific enquiry. However, two studies showed that quite severe or debilitating AEs were only detected by an interview, while other studies did not find a difference in the nature of AEs between elicitation methods. No conclusions could be made regarding the impact of questioning method on the ability to detect a statistically significant difference between study groups, because the findings of the research we reviewed were inconsistent. </p> </section> <section id="MR000039-sec-0096"> <h3 class="title" id="MR000039-sec-0096">Overall completeness and applicability of evidence</h3> <p>Our review shows that, for a wide variety of populations, more AEs will be reported when participants are asked more comprehensive questions about their health. Some of the authors of the included studies hypothesised that such intensive questioning is suggestive, the implication being that participants will be made to report an AE that is not actually real. However, we did not uncover any evidence for these concerns as there was no gold standard applied in the studies against which to measure the 'truth', although a diary may be the closest to this (<a href="./references#MR000039-bbs2-0010" title="DeVriesST , Haaijer‐RuskampFM , DeZeeuwD , DenigP . The validity of a patient‐reported adverse drug event questionnaire using different recall periods. Quality of Life Research2014;23(9):2439‐45. ">De Vries 2014</a>). More research could be done to harness the techniques used in patient‐reported outcome (PRO) methods to understand and validate AE context‐specific question tools, as is being done for oncology (<a href="./references#MR000039-bbs2-0037" title="BaschE , ReeveBB , MitchellSA , ClauserSB , MinasianLM , DueckAC , et al. Development of the National Cancer Institute's patient‐reported outcomes version of the common terminology criteria for adverse events (PRO‐CTCAE). Journal of National Cancer Institute2014;106(9):244. [DOI: doi.org/10.1093/jnci/dju244] ">Basch 2014</a>). As a minimum, there is a need for more studies using interviews to understand reporting behaviour in a variety of contexts. </p> <p>Another observation from our findings is that few tools other than checklists and scales were used, aside from one study that tested a diary. This could be an issue of our methodology, resulting in studies comparing such tools being missed. Alternatively, it could be that there are trials that use such tools but without any related methodology research, or that they are seldom used to elicit AEs. While there has been significant technological growth in innovative ways to engage with trial participants about a range of experiences and endpoints, including health‐related quality of life measures, the methods for eliciting AEs are lagging behind. Until there is progress, authors should be encouraged to be clear within their teams as to the rationale for, and application of, the questioning method used, which will contribute to consistency in trial conduct. As important is the need to provide sufficient detail of the elicitation method when reporting results, so as to lead to a better understanding by readers about how this may have influenced individual results and help in the conduct of systematic reviews and meta‐analyses. </p> <p>Few studies considered the impact of the elicitation method on other variables such as previous or concomitant medications and medical histories. These are important for determining whether AEs are ADRs (and may impact on eligibility criteria). This finding may be because the primary outcome of this review focused on AEs and we did not identify other studies that focused exclusively on those other variables. </p> </section> <section id="MR000039-sec-0097"> <h3 class="title" id="MR000039-sec-0097">Quality of the evidence</h3> <p>We did not use the Grading Recommendations, Assessment, Development and Evaluation (GRADE) approach in this review because it was not possible to conduct any meta‐analysis. The quality of evidence was limited by the heterogeneity of studies included, the design limitations inherent for this kind of methodology research and also limitations in the application of study methods and incomplete reporting in individual studies. Aside from differences in therapeutic areas, drug interventions and the actual questioning methods applied, some studies were conducted with students or staff (<a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a> and <a href="./references#MR000039-bbs2-0028" title="SpilkerAV , KesslerJM . Comparison of symptoms elicited by checklist and fill‐in‐the‐blank questionnaires. Pharmacoepidemiology News1987;22:272‐7. ">Spilker 1987</a>) as opposed to trial participants or patients. While there was merit in our being inclusive in anticipation that the number of eligible studies may be low, these differences did limit our ability to make recommendations about specific elicitation methods or contexts. Sequence generation and allocation concealment are not necessarily relevant for within‐participant comparison studies but are relevant for between‐participant comparisons, particularly for studies with non‐random allocation of elicitation method to participants enrolled at the same site (<a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a>, <a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a>). Where elicitation methods were allocated by site or study (as for <a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a> and <a href="./references#MR000039-bbs2-0029" title="TörökE , KósaE , SzontaghM , JuvanczP , EggenhoferJ , BorvendégJ . Comparison of methods to detect side‐effect on clinical application of chloranolol, a beta‐adrenergic receptor inhibitor. European Journal of Clinical Pharmacology1984;26(5):555‐62. ">Török 1984</a>), it is more likely that there was inconsistent recording of AEs, which could also impact the quality of the comparisons. It is not feasible to blind participants to a questioning method and this is likely to have affected the reporting of AEs when elicitation methods were used in sequence, since the data reports were not independent. There may have been a particular risk of bias for <a href="./references#MR000039-bbs2-0030" title="WallanderMA , DimenäsE , SvärdsuddK , WiklundI . Evaluation of three methods of symptom reporting in a clinical trial of felodipine. European Journal of Clinical Pharmacology1991;41(3):187‐96. ">Wallander 1991</a> as participants took forms for both questioning methods home to complete on their own. However, for the other studies, if the data were applied consistently and recorded accurately, then these cumulative comparisons are still useful, as they reflected the impact of using more than one method together, compared to one of the methods being used alone. All studies were limited by a lack of a true gold standard against which to assess the data reported by participants. Most studies had a low or unclear risk of attrition bias, but two could be considered of higher risk because it was not clear if dropouts were related to the questioning method that they used (<a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a>, <a href="./references#MR000039-bbs2-0030" title="WallanderMA , DimenäsE , SvärdsuddK , WiklundI . Evaluation of three methods of symptom reporting in a clinical trial of felodipine. European Journal of Clinical Pharmacology1991;41(3):187‐96. ">Wallander 1991</a>). </p> </section> <section id="MR000039-sec-0098"> <h3 class="title" id="MR000039-sec-0098">Potential biases in the review process</h3> <p>There were practical reasons for limiting the search to studies published in English and reporting terms synonymous with AE three or more times in the title or abstract. However, the review could have been improved by extending the search to languages other than English. Our findings also suggested that the electronic search missed several publications identified by non‐electronic means. This highlights the importance of conducting a thorough review of reference lists of both included studies, and other articles that are relevant to the topic (as we did for this review). This raises the possibility that we may have missed other eligible studies, which may have weakened our overall conclusions. However, changes to the search strategy are unlikely to have overcome these issues without increasing the number of references to an unmanageable level and this issue could be explored in further research into the review methodology, such as those suggested within the Study Within A Review initiative (<a href="./references#MR000039-bbs2-0080" title="Anon . Education section – Studies within a review (SWAR). Journal of Evidence‐based Medicine2012;5:188‐9. [DOI: 10.1111/j.1756‐5391.2012.01193.x] ">Anon 2012</a>). </p> <p>While we excluded studies with objective measures of AEs if the subjective data could not be extracted separately, some included studies may have also included objectively measured AEs without reporting them as such. We included populations taking part in clinical trials and methods studies outside of a clinical trial, provided relevance to clinical trials was cited. These environments may be quite different, in that the trial context may shape behaviour, including how AEs are reported (<a href="./references#MR000039-bbs2-0079" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral interaction trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a>, <a href="./references#MR000039-bbs2-0088" title="HeavenB , MurtachM , RapleyT , MayC , GrahamR , KanerE , et al. Patients or research subjects? A qualitative study of participation in a randomised controlled trial of a complex intervention. Patient Education and Counseling2006;62:260‐70. ">Heaven 2006</a>, <a href="./references#MR000039-bbs2-0095" title='PatersonC , ZhengZ , XueC , WangY . "Playing their parts": the experiences of participants in a randomized sham‐controlled acupuncture trial. Journal of Alternative and Complementary Medicine2008;14(2):199‐208. '>Paterson 2008</a>, <a href="./references#MR000039-bbs2-0098" title="ScottC , WalkerJ , WhiteP , LewithG . Forging convictions: the effects of active participation in a clinical trial. Social Science and Medicine2011;72(12):2041‐8. ">Scott 2011</a>). This review focused on clinical trials and methods studies relevant for trials. However, as trials are not the only valuable source of information of harms, and in fact have inherent limitations on the detection of harms, they may not always be the best method to evaluate different elicitation methods. Other types of studies should be also ideally be explored in this regard. Separating the three‐way comparisons of within‐participant studies into two‐way comparisons may have distorted results due to the possible effects of priming of one method on a subsequent one. In addition, the number of AEs or ADRs in a particular study or population may have impacted the ability to detect a difference between questioning methods and the types of items selected for a checklist may also influence this. We chose to include studies regardless of whether they prospectively or retrospectively addressed the comparison of AE elicitation methods (and this was not always clear from the reports of studies), although in general it is less optimal to retrospectively report outcomes. Lastly, we were not always able to confirm the calculations of the original authors. </p> </section> <section id="MR000039-sec-0099"> <h3 class="title" id="MR000039-sec-0099">Agreements and disagreements with other studies or reviews</h3> <p>No similar reviews were identified.</p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="MR000039-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/media/CDSR/MR000039/urn:x-wiley:14651858:media:MR000039:MR000039-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/media/CDSR/MR000039/image_t/tMR000039-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="MR000039-fig-0001" src="/cdsr/doi/10.1002/14651858.MR000039.pub2/media/CDSR/MR000039/image_n/nMR000039-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/media/CDSR/MR000039/image_n/nMR000039-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="MR000039-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of questioning methods</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Description</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Development</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Open questions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Questions about health and medicine use without reference to particular conditions, body systems, or treatments. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal. Answers probed according to common clinical practice in eliciting a medical and treatment history. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have you noticed any change in bodily function or had any physical complaints in the past week?". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0003" title="BarberBL , SantanelloNC . Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. International Journal of Clinical Pharmacology and Therapeutics1995;33(11):598‐604. ">Barber 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants instructed to call if they experienced AE and asked at visits if they had experienced AE. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Passive and verbal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0004" title="BarrowmanJA , HerxheimerA , KitsTP . Unwanted effects of pentagastrin. Clinical Pharmacology and Therapeutics1970;11(6):862‐8. ">Barrowman 1970</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asked to describe any unusual sensation.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0005" title="BentS , PadulaA , AvinsAL . Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Annals of Internal Medicine2006;144(4):257‐61. ">Bent 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>“Did you have any significant medical problem since the last study visit?”). If “yes”, asked to identify. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐administered, recorded by study assistant on checklist.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0005" title="BentS , PadulaA , AvinsAL . Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Annals of Internal Medicine2006;144(4):257‐61. ">Bent 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>“Since the last study visit, have you limited your usual daily activities for more than 1 day because of a medical problem?”). If “yes”, asked to identify. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐administered, recorded by study assistant on checklist.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0006" title="BorghiC , PallaviniG , ComiD , GrilloM , LombardoM , ManteroO , et al. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy. International Journal of Clinical Pharmacology, Therapy and Toxicology1984;22(6):324‐8. ">Borghi 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No detail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No detail</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spontaneous reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0011" title="DowningRW , RickelsK , MeyersF . Side reactions in neurotics. I. A comparison of two methods of assessment. Journal of Clinical Pharmacology and the Journal of New Drugs1970;10(5):289‐97. ">Downing 1970</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"How are you feeling?". If no reference to drug‐related symptomology: "How else are you feeling?" then "How does the drug make you feel?". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Has ____ had any physical or health problems since….? I'm talking about something that started to become a problem during this time or an old problem that got much worse.", "Have there been activities that ____ didn't do as often or that he/she didn't do at all because of not feeling well since _____?", "Since ____, has ____ said that his/her body feels funny... or that he/she has any aches or pains... or that some part of him/her hurts or doesn't feel well?" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Constructed from an existing instrument (SAFTEE) as a scripted interview, with instructions, demographic queries and a glossary of preferred AE terms. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0013" title="HermansL , DeblanderA , DeKeyserP , ScheysI , LesaffreE , WestelinckKJ . At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild‐to‐moderate hypertension: a double‐blind, randomized, parallel‐group study. British Journal of Clinical Pharmacology1994;38(4):335‐40. ">Hermans 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"How have you felt since your last visit?"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have you noticed any new symptoms which might be related to the treatment?"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0015" title="JacobsonAF , GoldsteinBJ , DominguezRA , SteinbookRM . Interrater agreement and reliability measures of SAFTEE: general inquiry vs. systematic inquiry. Psychopharmacology Bulletin1987;23(1):97‐101. ">Jacobson 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have you had any physical or health problems during the past week (or specified assessment interval)? Have you noticed any changes in your physical appearance during the past week (or specified assessment interval)? Have you cut down on the things you usually do because of not feeling well physically during the past week (or specified assessment interval)?" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal structured interview</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAFTEE developed by the National Institute of Mental Health. This study part of validation exercise. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0016" title="KruftB , NelsonLA , StewartJA , StewartWC . Adverse event reporting. Ophthalmology2007;114(7):1420. ">Kruft 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"How are you doing since your last visit?".</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0017" title="LandénM , HögbergP , ThaseME . Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Journal of Clinical Psychiatry2005;66(1):100‐6. ">Landén 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐leading question such as: "Have you felt different in any way since you started the new treatment?" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0019" title="MonteiroWO , NoshirvaniHF , MarksIM , LelliottPT . Anorgasmia from clomipramine in obsessive‐compulsive disorder. A controlled trial. British Journal of Psychiatry1987;151:107‐12. ">Monteiro 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spontaneous reports.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0020" title="NichollsDP , HusainiMH , BulpittCJ , StephensMD , ButlerAG . Comparison of labetalol and propranolol in hypertension. British Journal of Clinical Pharmacology1980;9(3):233‐7. ">Nicholls 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spontaneous reports.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0021" title="O'ConnellK , DavisAR , KernsJ . Oral contraceptives: side effects and depression in adolescent girls. Contraception2007;75(4):299‐304. ">O'Connell 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asked to list any side effects or changes experienced.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spontaneous reports.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0023" title="Perez‐LloretS , ReyMV , FabreN , OryF , SpampinatoU , MontastrucJL , et al. Do Parkinson's disease patients disclose their adverse events spontaneously?. European Journal of Clinical Pharmacology2012;68(5):857‐65. ">Perez‐Lloret 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have you noticed any unpleasant effects of your medications during the previous week?"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have you had any physical or health problems during the past week (or specified assessment interval)? Have you noticed any changes in your physical appearance during the past week (or specified assessment interval)? Have you cut down on the things you usually do because of not feeling well physically during the past week (or specified assessment interval)?" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal structured interview</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAFTEE developed by the National Institute of Mental Health. Additional 11 items research team's own choice. Severity subjectively graded and action taken noted. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0025" title="ReillyMC , ZbrozekAS . Assessing the responsiveness of a quality‐of‐life instrument and the measurement of symptom severity in essential hypertension. Pharmacoeconomics1992;2(1):54‐66. ">Reilly 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asked about any health‐related symptoms or problems.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0026" title="RosenthalJ , BahrmannH , BenkertK , BaumgartP , BönnerG , KleinG , et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta‐blocker. Cardiology1996;87(5):409‐14. ">Rosenthal 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physician interview concerning general status of symptoms, development of signs (e.g. rash, swelling, bruises). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0029" title="TörökE , KósaE , SzontaghM , JuvanczP , EggenhoferJ , BorvendégJ . Comparison of methods to detect side‐effect on clinical application of chloranolol, a beta‐adrenergic receptor inhibitor. European Journal of Clinical Pharmacology1984;26(5):555‐62. ">Török 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spontaneous reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0030" title="WallanderMA , DimenäsE , SvärdsuddK , WiklundI . Evaluation of three methods of symptom reporting in a clinical trial of felodipine. European Journal of Clinical Pharmacology1991;41(3):187‐96. ">Wallander 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have you had any health problems since we first met?"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0031" title="WallinJ , SjövallJ . Detection of adverse drug reactions in a clinical trial using two types of questioning. Clinical Therapeutics1981;3(6):450‐2. ">Wallin 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have you had any troubles from the drug?"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0032" title="WernickeJF , FariesD , MiltonD , WeyrauchK . Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Safety2005;28(11):1057‐63. ">Wernicke 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asked to report experiences in own words.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0033" title="YeoWW , MacleanD , RichardsonPJ , RamsayLE . Cough and enalapril: assessment by spontaneous reporting and visual analogue scale under double‐blind conditions. British Journal Clinical Pharmacology1991;31(3):356‐9. ">Yeo 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have the tablets upset you in any way?"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Blank forms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0006" title="BorghiC , PallaviniG , ComiD , GrilloM , LombardoM , ManteroO , et al. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy. International Journal of Clinical Pharmacology, Therapy and Toxicology1984;22(6):324‐8. ">Borghi 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blank card to report signs and symptoms experienced.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐completed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open‐ended questionnaire with 3 entry lines.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open‐ended questionnaire with 10 entry lines.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0028" title="SpilkerAV , KesslerJM . Comparison of symptoms elicited by checklist and fill‐in‐the‐blank questionnaires. Pharmacoepidemiology News1987;22:272‐7. ">Spilker 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Questionnaire with 15 blank spaces to complete about demographics, tobacco, and alcohol use, symptoms experienced, treatments used. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐completed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0027" title="SheftellFD , FeleppaM , TepperSJ , RapoportAM , CiannellaL , BigalM . Assessment of adverse events associated with triptans ‐ methods of assessment influence the results. Headache2004;44(10):978‐82. ">Sheftell 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asked if they had AEs when using drug. If yes, asked to list and grade severity.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Checklists</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potential health issues and medicines by10 body systems, 28 symptoms, 17 medicines in total for both trials together. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal enquiry. Answers probed according to common clinical practice in eliciting a medical and treatment history. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A majority of fields were common between the 2 trials, although they could not be harmonised fully. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0002" title="AveryCW , IbelleBP , AllisonB , MandellN . Systematic errors in the evaluation of side effects. American Journal of Psychiatry1967;123(7):875‐8. ">Avery 1967</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible drug side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>National Institute of Mental Health study checklist (NB assumed not all were asked).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0003" title="BarberBL , SantanelloNC . Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. International Journal of Clinical Pharmacology and Therapeutics1995;33(11):598‐604. ">Barber 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Common side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interviewer‐administered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Validated questionnaire for capturing frequency and bother of ocular and other local effects, effects on visual function of topical therapy for lowering intraocular pressure. Also, extent to which side effects and associated limitations in routine living activities interfere with health‐related quality of life, medication compliance, and participant satisfaction with the medication. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0004" title="BarrowmanJA , HerxheimerA , KitsTP . Unwanted effects of pentagastrin. Clinical Pharmacology and Therapeutics1970;11(6):862‐8. ">Barrowman 1970</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal enquiry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symptoms known or suspected to occur after pentagastrin, and some control items (headache, dryness of mouth, increased salivation). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0005" title="BentS , PadulaA , AvinsAL . Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Annals of Internal Medicine2006;144(4):257‐61. ">Bent 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>“Since the last visit, have you experienced any of the following?”: 53 symptoms, grouped by anatomical region. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐administered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Developed after a unpublished review of checklists used in earlier trials at same institution. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0006" title="BorghiC , PallaviniG , ComiD , GrilloM , LombardoM , ManteroO , et al. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy. International Journal of Clinical Pharmacology, Therapy and Toxicology1984;22(6):324‐8. ">Borghi 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49 items requiring yes/no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐completed (sequence changed each visit)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharmacological unwanted effects linked to the most common antihypertensive drugs, mainly ß‐blockers and diuretics. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0008" title="CiccolunghiSN , ChaudriHA . A methodological study of some factors influencing the reporting of symptoms. Journal of Clinical Pharmacology1975;15(7):496‐505. ">Ciccolunghi 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 items</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0009" title="DeVriesST , MolPG , DeZeeuwD , Haaijer‐RuskampFM , DenigP . Development and initial validation of a patient‐reported adverse drug event questionnaire. Drug Safety2013;36(9):765‐77. ">De Vries 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse drug events (ADEs) categorised in 16 body categories</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Email invite for Internet‐based self‐administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Content validation of common ADEs drafted in layman terms with reference to CTCAE v 4.0, existing symptom and ADE checklists, then coded, categorised into body categories using MedDRA® classifications. Open‐ended option for 'other', questions relating to duration, frequency, seriousness, and causality based on literature. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0009" title="DeVriesST , MolPG , DeZeeuwD , Haaijer‐RuskampFM , DenigP . Development and initial validation of a patient‐reported adverse drug event questionnaire. Drug Safety2013;36(9):765‐77. ">De Vries 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse drug events not categorised in body categories</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Email invite for Internet‐based self‐administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Content validation of common ADEs drafted in layman terms with reference to CTCAE v 4.0, existing symptom and ADE checklists, then coded, categorised into body categories using MedDRA® classifications. Open‐ended option for 'other', questions relating to duration, frequency, seriousness, and causality based on literature. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0010" title="DeVriesST , Haaijer‐RuskampFM , DeZeeuwD , DenigP . The validity of a patient‐reported adverse drug event questionnaire using different recall periods. Quality of Life Research2014;23(9):2439‐45. ">De Vries 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse drug events (symptoms in lay terms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Email invite for Internet‐based self‐administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Content validation of common ADEs drafted in layman terms with reference to CTCAE v 4.0, existing symptom and ADE checklists, then coded, categorised into body categories using MedDRA® classifications. Open‐ended option for 'other', questions relating to duration, frequency, seriousness, and causality based on literature. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0011" title="DowningRW , RickelsK , MeyersF . Side reactions in neurotics. I. A comparison of two methods of assessment. Journal of Clinical Pharmacology and the Journal of New Drugs1970;10(5):289‐97. ">Downing 1970</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28‐item questionnaire. If AE reported, participant asked to estimate intensity, discomfort, and whether symptom was felt due to study medicine. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Structured interview using a coding sheet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 common medication effects, and 5 highly unlikely to be related captured as miscellaneous.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drug‐specific inquiry ‐ 18 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal enquiry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Constructed from an existing instrument (SAFTEE) as a scripted interview, with instructions, demographic queries, and a glossary of preferred AE terms. Clinically important AEs for various medicines. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0012" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(12):1488‐96. ">Greenhill 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Body system review ‐ 24 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal enquiry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Constructed from an existing instrument (SAFTEE) as a scripted interview, with instructions, demographic queries, and a glossary of preferred AE terms. Clinically important AEs for various medicines. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0013" title="HermansL , DeblanderA , DeKeyserP , ScheysI , LesaffreE , WestelinckKJ . At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild‐to‐moderate hypertension: a double‐blind, randomized, parallel‐group study. British Journal of Clinical Pharmacology1994;38(4):335‐40. ">Hermans 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐completed written questionnaire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticipated side effects of dihydropyridine calcium antagonists (swollen ankles, headache, flushing, palpitations, dizziness, or nausea). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0014" title="HuskissonEC , WojtulewskiJA . Measurement of side effects of drugs. British Medical Journal1974;2(5921):698‐9. ">Huskisson 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 possible side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tinnitus, deafness, gastrointestinal complaints, and others with no obvious relevance.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0015" title="JacobsonAF , GoldsteinBJ , DominguezRA , SteinbookRM . Interrater agreement and reliability measures of SAFTEE: general inquiry vs. systematic inquiry. Psychopharmacology Bulletin1987;23(1):97‐101. ">Jacobson 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Review of 23 body systems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal structured interview</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAFTEE developed by the National Institute of Mental Health. This study part of validation exercise. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0016" title="KruftB , NelsonLA , StewartJA , StewartWC . Adverse event reporting. Ophthalmology2007;114(7):1420. ">Kruft 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ophthalmic symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0018" title="LundbergPK . Assessment of drugs' side effects: Visual Analogue Scale versus check‐list format. Perceptual and Motor Skills1980;50(3):1067‐73. ">Lundberg 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somesthetic Inventory: 54 body feelings (NB 9 fillers assessed through a visual analogue scale). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐completed ‐ participants asked to 'attune to inner stimuli', close eyes and determine how body felt. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Compilation and organisation of data on side effects of antihistamines</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0019" title="MonteiroWO , NoshirvaniHF , MarksIM , LelliottPT . Anorgasmia from clomipramine in obsessive‐compulsive disorder. A controlled trial. British Journal of Psychiatry1987;151:107‐12. ">Monteiro 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐rated physical symptom questionnaire (including sexual function items)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0020" title="NichollsDP , HusainiMH , BulpittCJ , StephensMD , ButlerAG . Comparison of labetalol and propranolol in hypertension. British Journal of Clinical Pharmacology1980;9(3):233‐7. ">Nicholls 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐administered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0021" title="O'ConnellK , DavisAR , KernsJ . Oral contraceptives: side effects and depression in adolescent girls. Contraception2007;75(4):299‐304. ">O'Connell 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 specific side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs commonly attributed to oral contraceptives, including headache, nausea, acne, abdominal pain, back pain, vomiting, breast tenderness, breast enlargement, mood swings, weight gain, premenstrual syndrome, and irregular bleeding. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 symptomatic side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Direct questioning to be answered 'yes' or 'no'.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Part of the ASPECT Scale ‐ a tool for evaluation of 34 commonly experienced symptomatic side effects of cardiovascular drugs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0023" title="Perez‐LloretS , ReyMV , FabreN , OryF , SpampinatoU , MontastrucJL , et al. Do Parkinson's disease patients disclose their adverse events spontaneously?. European Journal of Clinical Pharmacology2012;68(5):857‐65. ">Perez‐Lloret 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Predefined list of AEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal structured enquiry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pre‐defined list of most common ADRs to various anti‐Parkinson's Disease drugs from a literature search critically reviewed by a group of PD and pharmacovigilance specialists for consensus: general, GI, urinary, neuropsychiatric, dermatologic. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0024" title="RabkinJG , MarkowitzJS , Ocepek‐WeliksonK , WagerSS . General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. Journal of Clinical Psychopharmacology1992;12(1):3‐10. ">Rabkin 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 body systems plus additional 11 items to represent side effects of MAOIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal structured interview</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAFTEE developed by the National Institute of Mental Health. Additional 11 items research team's own choice. Severity subjectively graded, and action taken noted. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0025" title="ReillyMC , ZbrozekAS . Assessing the responsiveness of a quality‐of‐life instrument and the measurement of symptom severity in essential hypertension. Pharmacoeconomics1992;2(1):54‐66. ">Reilly 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 symptoms associated with hypertension and anti‐hypertensive therapy (previously used). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0026" title="RosenthalJ , BahrmannH , BenkertK , BaumgartP , BönnerG , KleinG , et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta‐blocker. Cardiology1996;87(5):409‐14. ">Rosenthal 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Signs and symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐administered written questionnaire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formulated to elicit information concerning the appearance of signs and symptoms that could be related to ACE inhibitors or a beta‐blocker, and any other symptoms that may reflect well‐being. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0027" title="SheftellFD , FeleppaM , TepperSJ , RapoportAM , CiannellaL , BigalM . Assessment of adverse events associated with triptans ‐ methods of assessment influence the results. Headache2004;44(10):978‐82. ">Sheftell 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49 possible AEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mostly known Triptan side effects and some confounders (side effects not expected to be related with triptans). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0028" title="SpilkerAV , KesslerJM . Comparison of symptoms elicited by checklist and fill‐in‐the‐blank questionnaires. Pharmacoepidemiology News1987;22:272‐7. ">Spilker 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐completed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0029" title="TörökE , KósaE , SzontaghM , JuvanczP , EggenhoferJ , BorvendégJ . Comparison of methods to detect side‐effect on clinical application of chloranolol, a beta‐adrenergic receptor inhibitor. European Journal of Clinical Pharmacology1984;26(5):555‐62. ">Török 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 anticipated and other side effects</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0030" title="WallanderMA , DimenäsE , SvärdsuddK , WiklundI . Evaluation of three methods of symptom reporting in a clinical trial of felodipine. European Journal of Clinical Pharmacology1991;41(3):187‐96. ">Wallander 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have you had any of the following symptoms in the past month?"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Used in previous population studies, includes depression, tension, head, heart, lung, metabolism, musculoskeletal system, GI, and urinary tracts. Participants placed in an envelope and advised the physician would not have access. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0031" title="WallinJ , SjövallJ . Detection of adverse drug reactions in a clinical trial using two types of questioning. Clinical Therapeutics1981;3(6):450‐2. ">Wallin 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Have you noticed any of the following reactions: diarrhoea, nausea, vomiting, other gastrointestinal disturbances, skin eruptions, or other troubles?" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0032" title="WernickeJF , FariesD , MiltonD , WeyrauchK . Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Safety2005;28(11):1057‐63. ">Wernicke 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Side Effects Checklist (child trial), BBAEQ‐M (child/adolescent trial), AMDP‐5 (adult trial). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Side Effects Checklist is based on the Subjective Treatment Emergent Symtpoms Scale (US National Institute of Mental Health) ‐ 30 items including general symptoms such as trouble sleeping, diarrhoea, headache, trouble eating. BBAEQ‐M: 24 items rated 0 to 9, AMDP‐5: 47 items rated 0 to ‐3. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Rating scales</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0007" title="BrentDA , EmslieGJ , ClarkeGN , AsarnowJ , SpiritoA , RitzL , et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI‐resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry2009;166(4):418‐26. ">Brent 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brief Suicide Severity Rating Scale: rating of suicidal ideation 0 to 5 and rating of suicidal behavior 0 to 5 using Columbia Classification Algorithm of Suicide Assessment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Published validated instruments</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0016" title="KruftB , NelsonLA , StewartJA , StewartWC . Adverse event reporting. Ophthalmology2007;114(7):1420. ">Kruft 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Visual analogue scales (VAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some VAS were validated instruments, details unknown</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0017" title="LandénM , HögbergP , ThaseME . Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Journal of Clinical Psychiatry2005;66(1):100‐6. ">Landén 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UKU side effect rating scale (none, mild, moderate, severe) for 3 symptoms of sexual dysfunction </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UKU is a validated instrument</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0018" title="LundbergPK . Assessment of drugs' side effects: Visual Analogue Scale versus check‐list format. Perceptual and Motor Skills1980;50(3):1067‐73. ">Lundberg 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Side Effects Report of 24 terms assessed with VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐completed ‐ definitions provided to participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arbitrarily selected terms</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0022" title="OsI , BratlandB , DahlöfB , GisholtK , SyvertsenJO , TretliS . Female preponderance for lisinopril‐induced cough in hypertension. American Journal of Hypertension1994;7(11):1012‐5. ">Os 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Completed by participant and spouse independently</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0030" title="WallanderMA , DimenäsE , SvärdsuddK , WiklundI . Evaluation of three methods of symptom reporting in a clinical trial of felodipine. European Journal of Clinical Pharmacology1991;41(3):187‐96. ">Wallander 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41‐item VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Validated instrument, highly correlated items in 6 domains, rest single items</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0033" title="YeoWW , MacleanD , RichardsonPJ , RamsayLE . Cough and enalapril: assessment by spontaneous reporting and visual analogue scale under double‐blind conditions. British Journal Clinical Pharmacology1991;31(3):356‐9. ">Yeo 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS (cough)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Diary</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0010" title="DeVriesST , Haaijer‐RuskampFM , DeZeeuwD , DenigP . The validity of a patient‐reported adverse drug event questionnaire using different recall periods. Quality of Life Research2014;23(9):2439‐45. ">De Vries 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open‐ended question asking for symptoms experienced and closed‐ended question about attribution to any drug taken. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paper‐based</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>In‐depth interview</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0001" title="AllenEN , MushiAK , MassaweIS , VestergaardLS , LemngeM , StaedkeSG , et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral trials. BMC Medical Research Methodology2013;13:140. ">Allen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prompted narrative of participant’s trial experience, reflection on previous ill health, and medicines used and photographs of typical over‐the‐counter and traditional medicines available to the study populations. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal interview</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#MR000039-bbs2-0019" title="MonteiroWO , NoshirvaniHF , MarksIM , LelliottPT . Anorgasmia from clomipramine in obsessive‐compulsive disorder. A controlled trial. British Journal of Psychiatry1987;151:107‐12. ">Monteiro 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stuctured interview</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verbal interview</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No details</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>ADE: adverse drug event<br/> ADR: adverse drug reaction<br/> AE: adverse event<br/> AMDP‐5: Assessment and documentation of psychopathology<br/> ASPECT: Assessment of symptoms and psychological effects in cardiovascular therapy<br/> BBAEQ‐M: Barkley behavior and adverse events questionnaire‐modified<br/> CTCAE: Common terminology ceriteria for adverse events<br/> GI: general inquiry<br/> MAOI: monoamine oxidase inhibitor<br/> MedDRA: Medical dictionary for regulatory activities<br/> SAFTEE: Systematic assessment for treatment emergent events<br/> UKU: dvalg for Kliniske Undersøgelser<br/> VAS: visual analogue scale</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of questioning methods</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="MR000039-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias (selection, performance and detection, and attrition) of included studies for within‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Selection bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Performance and detection bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Attrition bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Random sequence generation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Allocation concealment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Blinding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Incomplete outcome data assessed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allen 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. 'Possible 'priming'' by earlier method, however cumulative data was part of the study. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared all participants completed all methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barber 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. 'Possible 'priming'' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A few dropouts, unlikely related to methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barrowman 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. 'Possible 'priming'' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared all participants completed all methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>De Vries 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence by two groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. 'Possible 'priming'' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A few dropouts, unlikely related to methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>De Vries 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. 'Possible 'priming'' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear whether attrition was related to method.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downing 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. 'Possible 'priming'' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared all participants completed all method.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greenhill 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. 'Priming' by earlier method, however cumulative data was part of the study. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared all participants completed all method.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hermans 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A few dropouts, unlikely related to methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jacobson 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence order of questions received by two groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kruft 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Landen 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared all participants completed all methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lundberg 1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared all participants completed all methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Montiero 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A few dropouts, unlikely related to methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nicholls 1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear why different numbers of participants for 2 methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O'Connell 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared that all participants completed all methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Os 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some dropouts but unlikely related to method.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perez‐Lloret 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared that all participants completed all methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rabkin 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared that all participants completed all methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reilly 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some dropouts but unlikely related to method.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rosenthal 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear why fewer participants for method 2; could be related to matching of symptoms between methods. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sheftell 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appeared that all participants completed all methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallander 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method, especially as participants took forms for both questioning methods home to complete. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant number of dropouts (45/236), potentially related to method (participants took forms for both questioning methods home to complete). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallin 1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wernicke 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yeo 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants/assessors unlikely to be blinded due to the nature of study. Possible 'priming' by earlier method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some dropouts (3 more in method 2) but unlikely related to method.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>AE: adverse event<br/> N/A: not applicable<br/> O: open question</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias (selection, performance and detection, and attrition) of included studies for within‐participant comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="MR000039-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Risk of bias (reporting and other) of included studies for within‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Reporting bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Other biases</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>No selective reporting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Explicit application</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allen 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Possible variations in phraseology between participants.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barber 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Possible variations in phraseology between participants..</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Queried if methods applied in same order for all participants.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barrowman 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Explicit instructions for staff to use.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>De Vries 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed explicit instructions for self‐administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>De Vries 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed explicit instructions for self‐administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downing 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only presented data that participants related to medication.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Explicit instructions for staff to use.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greenhill 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Explicit instructions for staff to use.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hermans 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed explicit instructions, particularly for self‐administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jacobson 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some overlap between data presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Explicit instructions for staff to use.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kruft 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Difficult to ascertain as short report.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meta‐analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Landen 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary data presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed explicit instructions, particularly for self‐administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lundberg 1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary data presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Explicit instructions for staff to use.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Montiero 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary data presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nicholls 1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O'Connell 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Os 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear order</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perez‐Lloret 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Explicit instructions for staff to use.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rabkin 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Explicit instructions for staff to use.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reilly 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rosenthal 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not all data presented ‐ those spontaneously‐elicited were only presented if they matched questions on the questionnaire. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sheftell 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed explicit instructions for self‐administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallander 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Although could assume explicit instructions for self‐administration of methods 2 and 3, they were completed at home so it was outside of the control of the clinic as to completion, including order. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallin 1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>May have been variations in phraseology between participants in method 2.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wernicke 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not all data presented. AEs reflecting same symptom in spontaneous and solicited methods were selected for the comparison. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>May have been variations in phraseology between participants in method 1.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meta‐analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yeo 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard O and assumed explicit instructions for self‐administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>AE: adverse event<br/> N/A: not applicable<br/> O: open question</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Risk of bias (reporting and other) of included studies for within‐participant comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="MR000039-tbl-0004"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Risk of bias (selection, performance and detection, and attrition) of included studies for between‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Selection bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Performance and detection bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Attrition bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Random sequence generation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Allocation concealment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Blinding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Incomplete outcome data assessed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Avery 1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information other than "arbitrarily assigned".</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided, however participants and assessors unlikely to be blinded due to the nature of study. The group who were exposed to both questioning methods may have been 'primed' by the first method. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dropsouts were indicated but appeared similar between groups.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bent 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Computer‐generated prior to study. Baseline characteristics were similar between groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study personnel were blinded to the allocation.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Although participants were not informed of their group and analysts were blinded, study staff were aware of groups and were involved in completing some data. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed the study and outcome assessment.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Borghi 1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Little information provided, however the investigator was neither informed of the results of the self‐reporting, nor did they help participants fill in the forms. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Although group allocation of dropouts unclear, there were only a few.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brent 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐random allocation by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open allocation by enrolment period and nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants and assessors unlikely to be blinded due to the nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chiccolunghi 1975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Predetermined randomisation list. Baseline characteristics were similar between groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants and assessors unlikely to be blinded due to the nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant missing data, potentially related to the method as forms were distributed in the internal mail and it was left to staff to decide whether to complete and return them, although similar numbers were returned for each elicitation type (57% versus 44%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Huskisson 1974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐random allocation by study centre.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants and assessors unlikely to be blinded due to the nature of study; although groups were at different sites there may still have been room for biased assessments based on the method of questioning, and different staff may have elicited /recorded AEs differently. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spilker 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Table of random numbers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants and assessors unlikely to be blinded due to the nature of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Although group allocation of dropouts unclear, there were only a few.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Torok 1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐random allocation by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open by nature of study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants and assessors unlikely to be blinded due to the nature of study; although groups were at different sites/in different studies, there may still have been room for biased assessments based on the method of questioning. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>AE: adverse event<br/> CL: checklist<br/> O: open question</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Risk of bias (selection, performance and detection, and attrition) of included studies for between‐participant comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="MR000039-tbl-0005"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Risk of bias (reporting and other) of included studies for between‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Reporting bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Other biases</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>No selective reporting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Explicit application</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Avery 1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary data presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Explicit phraseology for O. CL had specific items but not all was presented in laymans language so may have had inconsistent phraseology. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bent 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed explicit instructions for self‐administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Borghi 1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brent 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brief summary data presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Little information provided, although method 2 involved validated scales so assumed had explicit instructions on application. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear whether method 1 was used in both groups.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chiccolunghi 1975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed explicit instructions for self‐administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Large numbers of non‐responders to invitation which could be related to methods.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Huskisson 1974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Raw data transformed by scoring and some data grouped.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear whether method 1 used in both groups.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spilker 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All data appeared presented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed explicit instructions for self‐administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It was not stated how many were invited.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Torok 1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relevant AE data only presented for participants taking chloranolol.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clear from information provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>AE: adverse event<br/> CL: checklist<br/> O: open question</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Risk of bias (reporting and other) of included studies for between‐participant comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="MR000039-tbl-0006"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Elicitation of the number of AEs reported for between‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Therapy area</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>AEs elicited</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Number participants</p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Number of AEs (total)</p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Number (%) participants with ≥1 AE</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Avery 1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Huskisson 1974**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rheumatology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Torok 1984***</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Various</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>537, 929</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75, 365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bent 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatic hyperplasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1 ‐ 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9(13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Borghi 1984*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxprenolol 48 (45), chlorthalidone 60 (57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxprenolol 76 (65), chlorthalidone 81 (69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spilker 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No indication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106 (80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154 (93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciccolunghi 1975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No indication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 (36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 (89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brent 2009**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐harm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicidal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (8.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (20.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐suicidal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (2.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (17.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicide attempts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (3.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (6.5)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="16"> <div class="table-footnote"> <p><sup>AE: adverse event</sup><br/> <sup>CL: checklist</sup><br/> <sup>N/A: not applicable</sup><br/> <sup>O: open question</sup><br/> <sup>vs: versus</sup><br/> <sup>R: rating scale</sup> </p> <p><sup>* All participants asked AEs by an open question (O), but as this process possibly involved 'filtering' of reports by the doctor, the data were not included in the review</sup> </p> <p><sup>** Huskisson used a composite measure of frequency and severity</sup> </p> <p><sup>*** A selection of the total AEs are presented in the review as those objectively measured were excluded</sup> </p> <p><sup>† 2‐sample test of proportions</sup> </p> <p><sup>†† 2‐sample t test</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Elicitation of the number of AEs reported for between‐participant comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="MR000039-tbl-0007"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Effects of methods on the number of AEs reported for between‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Therapy area</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Effect (number of AEs)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By drug arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion with ≥ 1 AE†</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description (including of other effect measure if different)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Avery 1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant higher mean number of AEs at each visit by CL. See paper for details. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant higher mean number of AEs at 5 of 6 study visits by CL in the active drug arm. See paper for details. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Huskisson 1974**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rheumatology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear scoring; appears higher total score for AEs by CL than O (540 versus 409). AEs listed on CL were more frequently reported by CL than when not listed. AEs not listed on CL more frequently reported by O. See paper for details. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fenoprofen auditory, gastrointestinal I and all other ('irrelevant') AE scores 2‐3 x more frequently reported by CL than O, aspirin AE scores ranged from no difference (auditory), approx.. 1.5 x less gastrointestinal and 0.60 x more ('irrelevant') using O compared to CL. See paper for details. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Torok 1984***</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Various</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower number of AEs per 100 participants by O compared to CL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bent 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatic hyperplasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1 ‐ 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OvsO 0.14 (‐0.10; 0.12) P = 0.805, OvsCL ‐0.63 (‐0.75; ‐0.50) P = 0.000, OvsCL ‐0.64 (‐0.77; ‐0.52) P = 0.000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group assigned to CL reported significantly greater number of AEs than either O. No difference between O methods. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Borghi 1984*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only available by drug arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% ≥ 1 AE for Oxprenolol 0.20 (0.07; 0.33) P = 0.0031, Chlorthalidone 0.13 (0.00; 0.25) P = 0.05 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spilker 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No indication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.12 (‐0.20; ‐0.05) P = 0.013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group assigned to CL reported significantly greater number of AEs than O.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciccolunghi 1975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No indication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OvsO 0.05 (‐0.06; 0.16) P = 0.3676, OvsCL ‐0.48 (‐0.57; ‐0.38) P = 0.000, OvsCL ‐0.53 (‐0.63; ‐0.43) P = 0.000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group assigned to CL reported significantly greater number of AEs than either O. No difference between O methods. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% ≥ 1 AE for nonmed: OvsO 0.19 (‐0.09; 0.13) P = 0.7331, OvsCL ‐0.66 (‐0.77; ‐0.54) P = 0.0000, OvsCL ‐0.68 (‐0.79; ‐0.56) P = 0.0000. Med: OvsO 0.05 (‐0.12; 0.22) P = 0.5816, OvsCL ‐0.26 (‐0.38; ‐0.14) P = 0.001, Ovs CL ‐0.31 (‐0.44; ‐0.17) P = 0.0000 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brent 2009**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐harm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicidal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.12 (‐0.22; 0.09) P = 0.0017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group assigned to R reported significantly greater number of suicidal‐related AEs than O. NB no completed suicides. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐suicidal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.15 (‐0.22; ‐0.90) P = 0.0000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group assigned to R reported significantly greater number of non‐suicidal AEs than O. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicide attempts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.03 (‐0.07; 0.02) P = 0.2689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference between R and O for reporting of suicide attempts.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>AE: adverse event</sup><br/> <sup>CL: checklist</sup><br/> <sup>N/A: not applicable</sup><br/> <sup>O: open question</sup><br/> <sup>vs: versus</sup><br/> <sup>R: rating scale</sup> </p> <p><sup>* All participants asked AEs by an open question (O), but as this process possibly involved 'filtering' of reports by the doctor, the data were not included in the review</sup> </p> <p><sup>** Huskisson used a composite measure of frequency and severity</sup> </p> <p><sup>*** A selection of the total AEs are presented in the review as those objectively measured were excluded</sup> </p> <p><sup>† 2‐sample test of proportions</sup> </p> <p><sup>†† 2‐sample t test</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Effects of methods on the number of AEs reported for between‐participant comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="MR000039-tbl-0008"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Elicitiation of the number of AEs reported for within‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Therapy area</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="13" rowspan="1" valign="top"> <p><b>AEs elicited</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Number of AEs (total)</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Number (%) of participants with ≥1 AE</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>INT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>INT</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barber 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ophthalmology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barrowman 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downing 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hermans 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W2: 11 W4: 49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W2: 58 W4: 105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W2: 21(10) W8: 53 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W2: 39(19) W8: 61 (31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jacobson 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1871</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nicholls 1980*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O'Connell 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dysmenorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perez 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parkinson's Disease (PD) and post‐stroke controls (PSC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203 PD, 52 PSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113 + 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PD 1573, PSC 167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PD 85 (42), PSC 5 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PD 203 (100), PSC 47 (90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rabkin 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180/226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reilly 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W0 37 W12 46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W0 340 W12 96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W0 27 (29.5) W12 33 (35.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WO 84 (90.9) W12 74 (80.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rosenthal 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>705 (12.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2753 (50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallin 1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wernicke 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not known</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>de Vries 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sheftell 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Migraine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 (28.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248 (59.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Landen 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 (41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yeo 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (3.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kruft 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ophthalmology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Occular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Montiero 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>de Vries 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lundberg 1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antihistamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallander 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191/251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>926</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allen 2013*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Malaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3‐7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18, 80 (sites' data cannot be combined)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+1, +20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+0, +1**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greenhill 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Os 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185 (22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="17"> <div class="table-footnote"> <p><sup>ADE: adverse drug event<br/> AE: adverse event<br/> BSR: body system reviewCL: checklist<br/> D: drug<br/> DSI: drug‐specific inquiry<br/> INT: interview<br/> N/A: not applicable<br/> NK: not known<br/> O: open question<br/> O(B): blank page</sup> </p> <p><sup>PD: Parkinson's Disease<br/> PPV: positive predictive value<br/> PSC: post‐stroke control<br/> R: rating scaleSD: standard deviation<br/> SOC: system organ class<br/> Sp‐So: spontaneous‐solicited index<br/> VAS: visual analogue scale<br/> W0, W2, W4, W8, W12:<br/> χ²: chi‐squared<br/> Z: zeta (standard score)</sup> </p> <p><sup>*Two sites/groups reported separately as different participant populations</sup> </p> <p><sup>**subset of participants from C versus CL comparison then interviewed</sup> </p> <p><sup>† McNemar's test of proportions, †† 2‐sample t test</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Elicitiation of the number of AEs reported for within‐participant comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="MR000039-tbl-0009"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Effects of methods on the number of AEs reported for within‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Therapy area</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Effect (number of AEs)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By drug arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Test of proportions with ≥ 1 AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description (including of other effect measure if different).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barber 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ophthalmology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average frequency of domain scores (number (%) mean (SD)) for those not reporting AEs by O but indicating AE by CL: occular symptoms 41 (89.1), 1.18 (0.91); taste 3 (6.4), 2.5 (2.18); vision difficulties 33 (70.2), 2.8 (1.84); accommodation difficulties 20 (42.6), 3.68 (2.27); browache 12 (25.5), 2.75 (1.86). Scores ranged from participants experiencing AEs rarely to usually. Average domain scores increased as AEs reported by O and therapy discontinued ‐ participants reporting AEs to O reported more AEs by CL. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barrowman 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL elicited 1.8 x the number of AEs than O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of AEs for pentagastrin: O 2.1 CL 3.2 (range 1‐5). For placebo: O 0 CL 1 (range 0‐3). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downing 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 3.22 (1.49; 7.74) P = 0.0017†</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>While methods agreed for 85 (69%) of participants, CL elicited a significantly greater number of AEs than O. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>More AEs reported with amplodipine versus isradipine when either O or CL used. No drug‐placebo difference found when O used, however, for CL, a statistically significant difference found in proportion of participants with ≥ 1 AE (χ² 5.76, P &lt; 0.025). In those AEs deemed medication‐related, CL resulted in higher frequency of AEs in active arm and produced a larger drug‐placebo difference in frequency of AEs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hermans 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W0: ‐0.10 (‐0.17; ‐0.03) P = 0.0063, W8: ‐0.05 (‐0.14; 0.03) P = 0.2293††</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL elicited 2 x as many AEs as O and % of participants with ≥ 1AE significantly greater with CL at W0, however proportions similar at W8 between methods. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Between‐drug difference in AEs overall (and for frequency of ankle oedema) statistically significant (P = 0.02, 95% CI 3.1 to 26.7) for O, not for CL. No difference between methods for other specific AEs or for severity of ankle oedema. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jacobson 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL elicited 6.7 x the number of AEs than O. Mean number of AEs per assessment 5 more by CL compared to O. In overlapping group of 88 exposed to O, mean number of AEs per assessment was 1.6 x higher than when O was part of combined tool. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nicholls 1980*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See data by drug arm.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant difference in mean number of AEs between drugs by CL (5.4 labetolol, 3.6 propranolol P &lt; 0.05) but not by O (1.6 labetolol, 1.5 propranolol). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O'Connell 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dysmenorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL elicited 2.7 x the number of AEs than O.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median number of AEs for contraceptive and placebo by O was 1. By CL, median for both was 2. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perez 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parkinson's Disease (PD) and post‐stroke controls (PSC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significantly more participants reporting ≥ 1 AE on CL compared to O (P &lt; 0.01) in both groups. Only factor found related to reporting of ≥ 1 AE by participants in response to O, was if participant reported &gt; 2 AEs by CL (OR 1.2 (1.1 to 3.2). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rabkin 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL elicited 5 x mean number of AEs than O.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reilly 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W0: 0‐.65 (‐0.75; ‐0.54), P = 0.0000, W12: ‐0.47 (‐0.59; ‐0.34), P = 0.0000 ††</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% participants with ≥ 1 AE was significantly greater with CL at W0 and W12. Only 6% of symptoms reported on CL were reported on O. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rosenthal 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.38 (‐0.39; ‐0.36) P = 0.0000††</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% of participants with ≥ 1AE was significantly greater with CL.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Between‐drug difference in AEs overall was statistically significant (‐0.03 (‐0.07; ‐0.001), P = 0.0266) for O, not for CL.(‐0.04 ‐0.09; 0.004), P = 0.0776. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallin 1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64% increase in number of AEs elicited by CL after O.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wernicke 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not known</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See data by drug arm.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sp‐So index &gt; 1.0 for 22/29 (75.9%) AEs but not significant for most: O more effective in detecting difference between treatments. More statistically significant differences between treatments by CL (9 AEs) than O (5 AEs): differences in % of AEs between drug and placebo (rather than ratios of AE rates) more often greater with CL. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>de Vries 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivities, PPV of CL compared with O (D) at primary SOC (95% CI): 4‐weeks 33% (4‐78) and 10% (1‐30); 3‐months 33% (21‐47) and 51% (34‐69). Sensitivities at specific ADE level (95% CI): 4‐weeks 43% (10‐92); 3‐months 41% (30‐54). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sheftell 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Migraine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.31 (‐0.38; ‐0.25) P = 0.0000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significantly more AEs reported through CL for those reporting 1, 2, 3 or more AEs.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Landen 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 11 (5;26) χ² 45, P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R elicited significantly greater number of AEs than O. 2 women versus 5 men reported AE by O (χ² 6.7, P = 0.01) and 29 women versus 20 men by R (χ²3.7, P = 0.06). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between drugs by either method.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yeo 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.08 (‐0.15; ‐0.01) P = 0.0374.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% participants with ≥ 1AE significantly greater with R compared to O. Increase in cough by R less consistent in men than women. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kruft 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ophthalmology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Occular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For 13 of 14 questions, there was a statistically greater positive response to CL or R than O. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Montiero 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Of 10 participants (all active) who did not report AE by CL, 3 reported AE by O and 8 by INT. 36% of those with drug‐induced AE at interview did not report at CL despite concern with it and even if they were secretly reducing dose of drug to overcome it. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No AEs in placebo arm by any method</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>de Vries 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of AEs similar between the CLs (Z = ‐0.049, P = 0.961).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lundberg 1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antihistamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two‐factor repeated measure of variance for AEs reported by ≥ 50% sample showed significant effects of drug for 6 symptoms by CL but no difference by R. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallander 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher mean number AEs through R versus CL (overall and sex/age groups). In addition to measuring frequency, R also quantified degree of change in symptoms. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allen 2013*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Malaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3‐7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% increase in number of AEs: Site 1: 16.7% O to CL, no change with INT. Site 2: 87.0% O to CL, 2.3% CL to INT (subset). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greenhill 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative % increase in number of AEs: 33% O to first CL (drug‐specific inquiry, DSI) followed by 202% to next CL (body system review, BSR). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Os 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.17 (‐0.20; ‐0.13) P = 0.0000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% participants with ≥ 1 AE significantly greater with CL compared to O. Not possible to compare frequency overall with R. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cough more frequent with lisinopril than nifedipine (8.5 versus 3.1%, P = 0.0009) by O. Similar change in frequency with R. Not possible to present same data for CL. </p> <p>O: AE 3 x more frequent in female versus male with lisinopril (12.6 versus 4.4%, P = 0.0027), no difference for nifedipine. 3 fold difference with CL. By VAS, participant and spouse assessed frequency of lisinopril‐associated AE similarly. With O, similar number of AEs independent of smoking, with CL a statistically significant difference between non‐smokers and smokers (16 versus 7%, P = 0.0018). </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>ADE: adverse drug event<br/> AE: adverse event<br/> BSR: body system reviewCL: checklist<br/> D: drug<br/> DSI: drug‐specific inquiry<br/> INT: interview<br/> N/A: not applicable<br/> NK: not known<br/> O: open question<br/> O(B): blank page</sup> </p> <p><sup>PD: Parkinson's Disease<br/> PPV: positive predictive value<br/> PSC: post‐stroke control<br/> R: rating scaleSD: standard deviation<br/> SOC: system organ class<br/> Sp‐So: spontaneous‐solicited index<br/> VAS: visual analogue scale<br/> W0, W2, W4, W8, W12:<br/> χ²: chi‐squared<br/> Z: zeta (standard score)</sup> </p> <p><sup>*Two sites/groups reported separately as different participant populations</sup> </p> <p><sup>**subset of participants from C versus CL comparison then interviewed</sup> </p> <p><sup>† McNemar's test of proportions, †† 2‐sample t test</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Effects of methods on the number of AEs reported for within‐participant comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="MR000039-tbl-0010"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Effects of methods on the nature of AEs reported for between‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Location</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Within/outside trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Therapy area</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment‐emergent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect (nature of AEs)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Avery 1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A statistically significant higher mean severity AEs at each visit by CL overall and in just the active arm. See paper for details. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Huskisson 1974**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rheumatology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severity was included as a composite measure with frequency so presented under effect (number of AEs). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Torok 1984***</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not necessarily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Various</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bent 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatic hyperplasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1 ‐ 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Borghi 1984*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spilker 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthy volunteers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No indication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not necessarily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most common symptoms by CL were fatigue, headache, and nasal congestion and by O were headache, back or muscle pain, and nasal congestion. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciccolunghi 1975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthy volunteers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No indication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not necessarily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O was associated with a greater severity of symptoms than CL. The type of symptoms reported did depend to some extent on the method. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brent 2009**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐harm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicidal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>There was no difference between R and O for reporting of serious suicidal or non‐suicidal AEs (8.4% versus 7.3%, χ² = 0.03, df = 1, P = 0.87). Time to onset for suicidal and non‐suicidal AEs earlier for CL than O: median 2 versus 5 weeks (χ² = 9.41, df = 1, P = 0.004). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐suicidal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicide attempts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>AE: adverse event<br/> CL: checklist<br/> df: degrees of freedom<br/> N/A: not applicable<br/> O: open question<br/> R: rating scale<br/> χ²: chi‐squared</sup> </p> <p><sup>* All participants asked AEs by open question (O), but as this process possibly involved 'filtering' of reports by the doctor data not included in the review.</sup> </p> <p><sup>** Huskisson used a composite measure of frequency and severity</sup> </p> <p><sup>*** A selection of the total AEs are presented in review as those objectively measured were excluded</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Effects of methods on the nature of AEs reported for between‐participant comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="MR000039-tbl-0011"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Effects of methods on the nature of AEs reported for within‐participant comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Location</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Within / outside trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Therapy area</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment‐emergent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect (nature of AEs)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barber 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ophthalmology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants reporting AEs by O and discontinuing therapy reported more bother and activity limitation compared to those who did not report by O but did by CL. Average global QoL scores increased as participants reported AEs by O and discontinued therapy; participants who reported AEs by O indicated more negative impact of side effects and activity limitations on QoL, more dissatisfaction with medication, and more noncompliance versus those not reporting by O. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barrowman 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointenstinal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downing 1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greater proportion of participants reporting an AE by both O and CL (26, 90%) had high mean intensity scores compared to those only reporting by CL (12, 50% ‐ predominantly those taking tranquillizers) P &lt; 0.01. The former participants more often reported AEs at a high discomfort level compared to the latter, P &lt; 0.05. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hermans 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no apparent difference between the methods for severity and duration of AEs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jacobson 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CL detected a greater variety of AEs than O while AEs reported by O had a higher mean severity compared to those reported by CL. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nicholls 1980*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O'Connell 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dysmenorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perez 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parkinson's Disease, post‐stroke controls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No relationship between AE severity and the O questioning method.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rabkin 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs reported to O significantly more distressing, more often interfered with daily functioning and elicited more changes in clinical management versus CL (NB for latter additional 46 participants assessed). No medically serious AEs elicited by O alone. Overall, and for participants on active drug (but not placebo), mean severity of AEs reported by O significantly greater versus CL. However, 61% of AEs rated severe/very severe elicited by CL, 65% AEs causing severe/very severe dysfunction detected by CL versus 35% by O. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reilly 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not necessarily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptoms reported by O more bothersome than CL. no change in mean degree of distress caused by AEs using CL, but increase in distress associated with AEs by O. Duration of AEs similar for O and CL but a higher symptom severity score by O versus CL. Significant relationship between degree of bother (P &lt; 0.0001), duration (P = 0.02), severity (P = 0.0003) and reporting of AEs by O. Only 18% of symptoms bothering participants a lot/extremely were first reported by CL. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rosenthal 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallin 1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conclusions severity not supported by the data.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wernicke 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not known</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not known</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>de Vries 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sheftell 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multinational</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Migraine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference between O and CL for severity. However 31 (7.5%) participants who rated AE as severe in CL did not report the AE in O. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Landen 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yeo 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kruft 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multinational</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ophthalmology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Occular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Montiero 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>de Vries 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lundberg 1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antihistamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallander 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allen 2013*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients, healthy volunteers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Malaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3‐7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All additional AEs were mild and unlikely related to trial drug.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greenhill 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychiatry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 occasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54% of AEs elicited by O were moderate to severe compared to 75% of those elicited by DSI and 37% for BSR. Of the 17 severe AEs, 6 (37%) were elicited by BSR. 31% of the AEs elicited by O were clinically relevant compared with 12% for the DSI and 15% for the BSR. Of the clinically relevant AEs (N = 37), 19 (53%) were elicited by BSR. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Os 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>AE: adverse event<br/> BSR: body system review<br/> CL: checklist<br/> DSI: drug‐specific inquiry<br/> INT: interview<br/> N/A: not applicable<br/> NB: nota bene<br/> NK: not known<br/> O: open question/spontaneous<br/> QoL: quality of life<br/> R: rating scale</sup> </p> <p><sup>*Two sites/groups reported separately as different participant populations</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Effects of methods on the nature of AEs reported for within‐participant comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.MR000039.pub2/full#MR000039-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.MR000039.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#MR000039-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#MR000039-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#MR000039-note-0001">日本語</a> </li> <li class="section-language"> <a class="" href="pt#MR000039-note-0002">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#MR000039-note-0018">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"/> </img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eMR000039\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eMR000039\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eMR000039\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eMR000039\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eMR000039\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eMR000039\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eMR000039\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eMR000039\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eMR000039\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eMR000039\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eMR000039\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eMR000039\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eMR000039\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eMR000039\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eMR000039\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eMR000039\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eMR000039\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eMR000039\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=JmNqPX1V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.MR000039.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.MR000039.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.MR000039.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.MR000039.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.MR000039.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716095700"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.MR000039.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716095703"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.MR000039.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d9724bc91f409',t:'MTc0MDcxNjA5Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 